Inflammation-Induced Plasticity of Micturition Reflex Pathways by Arms, Lauren
University of Vermont
ScholarWorks @ UVM
Graduate College Dissertations and Theses Dissertations and Theses
7-19-2011




Follow this and additional works at: http://scholarworks.uvm.edu/graddis
This Dissertation is brought to you for free and open access by the Dissertations and Theses at ScholarWorks @ UVM. It has been accepted for
inclusion in Graduate College Dissertations and Theses by an authorized administrator of ScholarWorks @ UVM. For more information, please contact
donna.omalley@uvm.edu.
Recommended Citation




















The Faculty of the Graduate College 
of 







In Partial Fulfillment of the Requirements 
for the Degree of Doctor of Philosophy 







Accepted by the Faculty ofthe Graduate College, The University ofVermont, in partial 
fulfillment ofthe requirements for the degree ofDoctor ofPhilosophy, specializing in 
Neuroscience. 




Deborah H. Damon, Ph.D. 
Chairperson 
Dean, Graduate College 
Date: December 7,2010 
 
 
                                                Abstract 
Although a seemingly basic and simple behavior, micturition necessitates precise 
integration and coordination of multiple divisions of the nervous system: visceral 
sensory, somatic motor, sympathetic, parasympathetic, as well as voluntary control from 
higher brain/ brainstem centers.  When coordination of this circuitry falters, the 
consequences can be devastating and include severely decreased quality of life and 
substantial economic burden.  This dissertation project investigates the potential role(s) of 
inflammatory mediators in bladder sensory physiology with the long term goal of 
elucidating potential targets for intervention.  The overall hypothesis is that 
inflammatory-induced changes in the urinary bladder or afferent projections ultimately 
lead to dysfunctional micturition symptoms. Using a rodent model of cyclophosphamide 
(CYP)-induced bladder inflammation, we examined the expression and function of the 
chemokine/ receptor pair, CXCL12/CXCR4, and the activated (phosphorylated) form of 
ubiquitous signaling molecule, AKT using a multidisciplinary approach that includes: 
immunohistochemistry, protein and transcript quantification techniques, and in vivo 
bladder physiology studies combined with pharmacological tools. 
Peripheral chemokine levels are elevated in patients with various chronic pelvic 
inflammatory/ pain syndromes including interstitial cystitis/bladder pain syndrome 
(IC/BPS) and are implicated in numerous inflammatory and mechanical pain models in 
rodents.  However studies had not previously shown a direct functional role for 
chemokine signaling in micturition.  We hypothesized that CXCL12 and CXCR4 would 
increase in the urinary bladder with CYP-induced bladder inflammation and that CXCR4 
receptor blockade with AMD3100 would reduce CYP-induced bladder hyperreflexia.  
ELISA, immunohistochemical and qRT-PCR experiments demonstrate duration-
dependent increases in CXCL12 and CXCR4 protein and transcript expression in specific 
tissue compartments of the urinary bladder, mainly the urothelium.  In vivo studies 
provide evidence of a role for chemokine signaling in the mediation of micturition 
function.  Intravesical infusion with AMD3100, a CXCR4 receptor antagonist, 
significantly reduced CYP-induced bladder hyperreflexia as evidenced by increased 
bladder capacity, intercontraction interval and decreased voiding frequency.    
 AKT is a putative cellular survival signal, however, recent studies also implicate 
the signaling molecule in the induction and maintenance of pain processes, development 
of long term plasticity (e.g. LTP and central sensitization) and visceral inflammation.  
Functional studies addressing the contribution of pAKT in micturition have not been 
performed. We hypothesized that increasing pAKT levels would contribute to CYP-
induced bladder hyperreflexia.  Western blot and immunohistochemical studies 
demonstrated that phosphorylation of AKT increases in the whole urinary bladder with 
CYP-induced bladder inflammation in a tissue compartment- and time-dependent 
manner.  Intravesical infusion with inhibitors of AKT phosphorylation, AKT Inhibitor IV 
and deguelin, significantly improved symptoms of CYP-induced bladder hyperreflexia 
suggesting a functional role for pAKT in bladder physiology. 
 These studies demonstrate the functional capacity of inflammatory mediators and 
inflammatory associated signaling pathways in micturition reflex pathways.  Chemokine 
signaling via the CXCR4 receptor and upstream activators of AKT may provide 
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Chapter 1: Comprehensive Literature Review 
 
I.  Introduction 
 
Micturition is a fundamental and necessary human behavior.  The essential role of 
the bladder is to store incoming urine from the kidneys and to execute periodic 
elimination.  Although bladder function appears relatively simple, micturition 
necessitates precise integration and coordination of multiple divisions of the nervous 
system: sympathetic, parasympathetic and somatic, as well as voluntary control from 
higher brain/ brainstem centers.  When changes in neuronal functions related to or within 
this circuitry occur, as in pathologic states (e.g. bladder outlet obstruction, overactive 
bladder, spinal cord injury, Parkinson’s Disease, multiple sclerosis or Interstitial Cystitis/ 
Bladder Pain Syndrome) consequences can be devastating and include severely decreased 
quality of life and substantial economic burden.  Injury or disease within micturition 
reflex circuitry can result in bladder hyperreflexia, hyporeflexia, incontinence, irritative 
voiding and associated pain. Little is known about the mechanisms underlying bladder 
dysfunction and therefore research investigating potential mechanisms and mediators is 
essential. 
One type of bladder dysfunction is Interstitial Cystitis/Bladder Pain Syndrome 
(IC/BPS), a chronic syndrome of unknown etiology with symptoms of urgency, 
frequency and nocturia; additionally, patients experience pain that is localized beyond the 
bladder in suprapubic and pelvic regions.  Theories as to the origin of IC/BPS include 
mast cell degeneration, infection, urothelial deficiency, autoimmune disorder, toxic 
urinary components and neurogenic causes, however no consensus has been reached.  
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Although each theory argues a different primary insult, common to each theory is an 
inflammatory component, either as a direct effector (e.g. mast cell degeneration, 
autoimmune disorder) or as a secondary result (e.g. urothelial deficiency, infection). 
Additionally, inflammatory cells and mediators are detected in the bladders and urine of 
patients with IC/BPS.  Numerous inflammatory mediators exhibit functional roles during 
bladder inflammation in rodents. 
Inflammation, especially chronic inflammation, may induce plasticity within the 
urinary bladder and/or its central and peripheral innervation leading to chronic bladder 
dysfunction.  Inflammatory mediators may contribute to bladder dysfunction via 
sensitization of second order bladder afferents in the spinal cord or primary afferents.  In 
the case of primary afferents, sensitization may occur either directly or indirectly via 
urothelium (the epithelial lining of the bladder) to neuron communication.  In any case, a 
sensitized afferent limb of the micturition reflex pathway may ultimately lead to 
hyperalgesia and allodynia that, in terms of bladder function, would translate into 
heightened bladder sensation, increased voiding frequency and/or pain.  The overall goal 
of this thesis dissertation is to further characterize the role of inflammation in bladder 
dysfunction.  Specifically, I examine expression and functional role(s) of a chemokine/ 
receptor pair, CXCL12/CXCR4, and a signaling molecule involved in inflammatory 







II. Anatomy and Function of the Lower Urinary Tract 
A. Anatomy of the Lower Urinary Tract  
 
Micturition necessitates precise integration and coordination of multiple divisions 
of the nervous system.  Lending to its complexity, the lower urinary tract (LUT), 
composed of the bladder, urethra and internal and external urethral sphincters, is 
composed of both striated and smooth muscle, and therefore under both voluntary 
(somatic) and involuntary (autonomic) influence (Figure 1) (Andersson and Arner, 2004).  
Based on regional differences in adrenergic innervation, the bladder is divided into two 
main parts: the body and the base (Elbadawi, 1996).  Sympathetic adrenergic innervation 
is more dense in the base region compared to the body (Klück, 1980; Elbadawi, 1996).  
The base occupies the inferior portion of the urinary bladder (i.e. below the ureteral 
orifices) and includes the trigone, urethrovesical junction (bladder neck) and anterior 
bladder wall.  As the name suggests, the trigone is the triangle-shaped area bounded by 
the ureteral orifices and the bladder neck along the posterior surface of the bladder wall 
(Elbadawi, 1996).   
             The urinary bladder wall has three layers: a urothelium on the luminal surface, a 
lamina propria just deep to the urothelium (a.k.a. the suburothelium), and an outer 
smooth muscle layer, named the detrusor (Andersson and Arner, 2004; Figure 1).  The 
urothelium is composed of at least three layers: an apical layer on the luminal surface, an 
intermediate layer (multiple intermediate layers are present in human and other species) 
and a basal layer attached to a basement membrane.  The highly specialized apical cells, 
also termed umbrella cells, are large, hexagonal shaped cells and have structural 
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characteristics that aid in the defense against toxic urine components (e.g. potassium) or 
bacterial adherence and infection.  Sulfated polysaccharides or glycosaminoglycans 
(GAGs) are large, negatively charged molecules that line the entire apical surface of the 
urothelium (Parsons, 2007).  Due to their negative charge, GAGs trap water molecules 
and solutes and thus create a mucous layer with anti-adherence properties along the 
luminal lining of the bladder (Parsons, 2007).   Surface expression of specialized 
membrane lipids, together with dense networks of uroplakin proteins, restrict the flow of 
toxic urinary components into the urothelium or underlying bladder tissue (e.g. 
suburothelial plexus of afferent nerve fibers) (Lewis, 2000; Birder, 2006).  Uroplakins are 
urothelium- specific crystalline proteins that assemble into hexagonal plaques and 
constitute the majority of apical urothelium protein content (Staehelin et al., 1972; Birder, 
2006).  Additionally, transmembrane proteins assist in cell-cell adhesion and tight 
junctions restrict the flow of water and ions between cells (Claude and Goodenough, 
1973; Birder, 2006).   
 Increased barrier permeability is thought to contribute to symptoms of bladder 
dysfunction in various bladder pathologies (Parsons et al., 1991; Hurst et al., 2007; 
Parsons, 2007).  Urinary potassium levels are decreased in bladders from patients with 
IC/BPS, a chronic bladder inflammation syndrome, suggesting transurothelial absorption 
into the bladder and underlying structures (i.e. suburothelial nerve plexus, interstitial 
cells, detrusor smooth muscle) (Parsons et al., 2005).    Treatment with heparin, an 
exogenous GAG, often relieves symptoms of IC/BPS probably by restoring the mucus 




                               
 
 
Figure 1.  Anatomy of the lower urinary tract.  The LUT is composed of the urinary 
bladder, internal and external urethral sphincters and the urethra.  The bladder consists of 
3 layers: a urothelium on the luminal surface, a lamina propria just deep to the urothelium 
that contains a suburothelial plexus of nerve fibers and vasculature, and an outer muscle 
layer, named the detrusor that contains both longitudinal and circular smooth muscle.  
The external urethral sphincter is composed of striated muscle and encircles the urethra 





Deep to the urothelium is a lamina propria termed the suburothelium.  Within the 
suburothelium are dense neuronal and vascular networks (Figure 1).  Sensory fibers 
within the lamina propria are most dense in the neck region of the bladder.  Populations 
of interstitial cells (a.k.a. myofibroblasts) also reside in the suburothelium.  Although the 
role of interstitial cells is uncertain, some suggest that they have a pace-making 
(McCloskey and Gurney, 2002) or intermediary role between neurons and detrusor 
smooth muscle cells (Sui et al., 2002; Andersson and Arner, 2004).  Expression of 
functional gap junctions supports the plausibility of this hypothesis (Sui et al., 2002).  
The detrusor muscle is composed of longitudinal and circular smooth muscle 
fibers.  Muscle cells are encased into bundles with collagen-rich connective tissue.  The 
bundles of smooth muscle cells weave amongst each other and do not follow a 
discernable pattern (Murakumo et al., 1995; Andersson and Arner, 2004).  Gap junctions 
between cells allow for rapid communication and for coordinated contraction of the entire 
bladder wall. 
The urethra and associated sphincters are the remaining components of the LUT.  
The urethra contains smooth muscle that is structurally and functionally different than 
bladder smooth muscle.  The internal urethral sphincter, a smooth muscle sphincter, is 
located just inferior to the bladder at the urethrovesical junction (Elbadawi, 1996; Fowler 
et al., 2008).  In contrast, the external urethral sphincter, located inferiorly to the prostate 
in males or at the inferior end of the urethra in females, is under voluntary control as it is 
a striated muscle sphincter (Elbadawi, 1996).  The external urethral sphincter encircles 
the urethra creating a diaphragm that contributes to continence.  
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 B.  Neural Control of Micturition 
 
The bladder is unique in that it requires constant central control.  Proper bladder 
function is biphasic and includes a storage mode, under sympathetic control, and an 
elimination mode, under parasympathetic control.  Local spinal reflexes, in conjunction 
with higher brain/brainstem centers, orchestrate the phasic or switch-like behavior in the 
bladder by via inhibition of pro-voiding centers during the storage mode and initiating the 
switch to elimination mode at the appropriate times (de Groat et al., 1982; de Groat et al., 
1998).   During storage mode sympathetic activation inhibits the detrusor muscle causing 
it to relax, and excites the bladder neck and urethra causing them to contract (Kingsley, 
1996; Holstege, 2005; Fowler et al., 2008).  The result is an elastic bladder able to 
accommodate incoming urine from the kidneys, as well as a constricted outflow to 
prevent involuntary loss of urine through the urethra.  In addition, contraction of the 
external urinary sphincter via somatic motor output closes the urethra to urinary flow, and 
in combination with sympathetic output, allows for urinary continence (Kingsley, 1996; 
Holstege, 2005; Fowler et al., 2008).  During elimination mode, parasympathetic 
activation sends excitatory signals to the detrusor causing it to contract, and thus creates 
enough pressure to void the bladder of urine entirely during micturition (Holstege et al., 
1986; Blok and Holstege 1997; Sasaki, 2005); at the same time, both sympathetic and 
somatic motor input to the bladder, urethra and sphincter muscles must be turned off 
(Kingsley, 1996; Blok et al., 1997; Sie et al., 2001; Holstege, 2005; Fowler et al., 2008).  
Micturition centers in the brainstem receive afferent information in regard to filling 
(Griffiths et al., 2005; Kuipers, 2006).  When a bladder threshold volume has been 
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reached, these centers initiate the change from storage to elimination mode (Holstege 
1986; Block et at., 1997; Blok et al., 1998; Sasaki, 2005 Holstege, 2005; Fowler et al., 
2008).  However, through learned behavior, higher brain centers quell the micturition 
reflex until it is socially appropriate to void (Block et al., 1997; Blok et al., 1998; 
Griffiths et al., 2005).  Therefore, complete and socially appropriate micturition requires 
the precise coordination of sympathetic, parasympathetic and somatic motor outflow, in 
conjunction with visceral sensory information and volitional control by the central 
nervous system. 
In humans, all peripheral control for micturition originates from the lower 
thoracic to the sacral spinal cord.  Specifically, sympathetic innervation originates from 
the intermediolateral grey matter (IML) of spinal segments T11-L2 (Holstege, 2005; 
Fowler et al., 2008).  Preganglionic sympathetic fibers travel through the sympathetic 
chain to synapse in the inferior mesenteric ganglion or major pelvic ganglion (Fowler et 
al., 2008; de Groat and Yoshimura, 2010).  Post-ganglionic sympathetic fibers travel in 
the hypogastric nerve and pass to both the bladder and urethra.  In the detrusor smooth 
muscle, they elicit inhibitory effects by releasing norepinephrine onto β3 adrenergic 
receptors thus causing the bladder to relax and allow for filling (de Groat and Suam, 
1972; Fowler et al., 2008).  In the urethra, however, postganglionic sympathetic fibers 
have an excitatory influence on urethral smooth muscle by releasing norepinephrine onto 
α1 adrenergic receptors resulting in contraction (Flood, 1990; Fowler et al., 2008).  
Somatic motor outflow aids the sympathetic division in maintaining urinary continence 
by exciting the external urethral sphincter via release of acetylcholine onto nicotinic 
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receptors (Fowler et al., 2008).  Because somatic motor innervation to the external 
urethral sphincter must synchronize with autonomic innervation of the LUT, the cell 
bodies of the motor neurons originate from a specialized nucleus, named Onuf’s nucleus, 
in the anterior horn (lamina IX) (Schrøder, 1981; Kingsley, 1996; Fowler et al., 2008) of 
sacral spinal cord segments S2-S4 (Fowler et al., 2008).  The somatic motor axons pass 
along the pudendal nerve to the urinary sphincter.  
 Sensory information from the bladder and urethra associated with bladder 
pressure is carried via A-δ fibers in the hypogastric (bladder body and bladder neck), 
pudendal (urethra) and pelvic nerves (bladder body) (de Groat et al., 1982; Fowler et al., 
2008).  Filling continues until the bladder reaches near capacity.  As the bladder 
approaches capacity, tension drastically increases, and stretch mechanoreceptors in the 
bladder wall elicit intense afferent firing (de Groat et al., 1982; Fowler et al., 2008).  Cell 
bodies of these afferent fibers originate in the dorsal root ganglia (DRG) of spinal levels 
T11-L2 and S2-S4 (Holstege, 2005; Fowler et al., 2008).  Central terminals of bladder 
primary afferents enter the spinal cord through Lissaur’s tract and terminate on 
interneurons and spinal tract neurons in the superficial dorsal horn (SDH; lamina I), 
dorsal commisure (DCM; lamina X) and sacral parasympathetic nucleus (SPN; lamina V- 
VII) (Morgan et al., 1981; Kingsley, 1996; de Groat and Yoshimura, 2010).  Ascending 
projections head rostrally to the periaqueductal gray matter (PAG) in the midbrain where 
bladder afferent information is integrated (Holstege, 2005; Fowler et al., 2008).  Bladder 
interneurons may assist in local spinal cord reflexes (Birder et al., 1999) that maintain 
functional homeostasis including inhibition of parasympathetic pre-ganglionic neurons 
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during storage mode (de Groat and Yoshimura, 2010).  This reflex is termed the guarding 
reflex and neurons involved in the communication between bladder primary afferents and 
parasympathetic motor output are located in the lateral collateral pathway (LCP) (Morgan 
et al., 1981; de Groat and Yoshimura, 2010).  
The medial PAG receives afferent information regarding bladder filling and 
volitional control from spinal cord tract neurons or cortical/subcortical structures (e.g. 
prefrontal cortex, insular cortex and limbic system) (Holstege, 2005; Fowler et al., 2008).  
Connections with these areas are robustly inhibitory and reflect the importance of 
emotion and executive function involved in choosing an appropriate time and place to 
void (Griffiths et al., 2005).   However, when environmental cues are favorable for 
micturition, and when sufficient bladder filling has occurred, cortical inhibitions are 
reduced and, together with volitional signals, cause the lateral PAG to activate 
projections to the pontine micturition center (PMC) located in the dorsolateral pontine 
tegmentum (Sasaki, 2005; Holstege, 2005).   The PMC, particularly on the right side in 
humans, is the main excitatory center that initiates voiding (Blok et al., 1998; Komiyama 
et al., 1998; Holstege, 2005).  Without endogenous or artificial activation of the PMC, 
micturition does not occur (Komiyama et al., 1998; Holstege, 2005).  Axons projecting 
from the PMC travel in the lateral and dorsolateral funiculus along the spinal cord before 
synapsing with bladder associated interneurons and preganglionic neurons in the 
thoracolumbar and sacral segments (Holstege, 2005).  PMC projections directly excite 
parasympathetic neurons in the SPN in the sacral spinal cord (human S2-S4) to initiate 
detrusor smooth muscle contraction while other projections assist in sympathetic and 
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somatic motor inhibition (Holstege et al., 1986; Blok and Holstege, 1997; Blok et al., 
1997; Sie et al., 2001; Fowler et al., 2008).     
Pre-ganglionic parasympathetic axons travel in pelvic nerves and head to and 
synapse in the pelvic ganglia. Post-ganglionic parasympathetics head to the detrusor 
smooth muscle where they will assert an excitatory influence by releasing acetylcholine 
onto muscarinic-3 (m3) receptors and, to a lesser extent, ATP onto P2X2, P2X3, P2X2/3  
purinergic receptors, thus causing the bladder to contract (Carpenter, 1977; Burnstock et 
al., 1978; Dean and Dowie 1978; Holt et al., 1985; Fowler et al., 2008).  For efficient 
urinary expulsion, the PMC must also inhibit sympathetic and somatic motor neurons in 
order to relax the bladder neck and external urinary sphincter muscle.  To do so, PMC 
neurons synapse on γ-aminobutyric acid (GABA)-ergic and glycinergic interneurons in 
the spinal cord that in turn inhibit neurons in the sympathetic and Onuf’s nuclei (Blok et 
al., 1997; Sie et al., 2001; Holstege, 2005).  It has also been suggested that nitric oxide 
released from parasympathetic post-ganglionics in the urethra causes relaxation of the 
urethral smooth muscle (Dokita et al., 1991; Persson and Andersson 1992; Persson and 
Andersson, 1994).  PMC activation results in bladder contraction and sphincter 





Figure 2.  Neural control of micturition.  Sympathetic innervation of the urinary 
bladder is responsible for relaxation of the bladder and contraction of bladder neck during 
filling.  Pre-ganglionic sympathetic cell bodies originate from T11-L2 spinal cord levels 
in humans and travel in the hypogastric nerve. Somatic motor control originates from S2-
S4 spinal cord levels, travels in the pudendal nerve and contracts the external urethral 
sphincter during filling to maintain continence.  Parasympathetic cell bodies are also 
located in spinal cord levels S2-S4.  Parasympathetic fibers travel in the pelvic nerve and 
are responsible for the intense bladder contraction during voiding.  Bladder afferents 
ascend to higher brain/brainstem centers such as the PAG, the main center responsible for 
receiving and integrating bladder afferent information.  The PMC initiates the switch 





C. Awakening of c-fiber Afferents 
 
A second type of afferent neuron, the unmyelinated, capsaicin- sensitive c-fiber 
afferent, also innervates the urinary bladder.  Although c-fiber afferents comprise 
approximately 70% of bladder afferents, c-fibers are quiescent and play no role during 
physiologic bladder filling and emptying (Fowler et al., 2008).  Bladder c-fibers do 
respond to noxious stimuli such as cooling, toxic urinary components, pathologically 
high intravesical pressure and inflammation (Fall et al., 1990; Häbler et al., 1990; Jänig 
and Koltenburg, 1990; Chai et al., 1998; Yoshimura et al., 2007; de Groat, 2010; Kanai 
and Andersson, 2010).    C-fiber activation is thought to contribute to plasticity of 
micturition reflex pathways.  For example, suprasacral spinal cord injury causes loss of 
brainstem and cortical input to micturition reflex pathways and this involves 
“awakening” of c-fiber afferents.  The micturition reflex partially recovers by adapting 
from a spinobulbospinal pathway into a local spinal cord reflex.  Changes in the reflex 
pathways include activation of primary afferent c-fibers during bladder filling.  Activated 
c-fiber-induced sensitization of the afferent limb of the micturition reflex is thought to 
mediate symptoms related to bladder dysfunction and pain in various types of bladder 
pathologies including IC/BPS, suprasacral spinal cord injury (de Groat et al., 1990; 
Cheng et al., 1999; de Groat and Yoshimura, 2006; Fowler et al., 2008) and bladder 
outlet obstruction (Häbler et al., 1990; Chai et al., 1998). 
D.  Cystometry: Evaluation of Bladder Function in Humans and Animals 
 
Cystometry is a technique commonly used to evaluate bladder function in both 
experimental animals and humans.  Cystometry entails continuous infusion of fluid (e.g. 
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saline) into the bladder while measuring bladder reflex parameters.  Typical 
measurements recorded during cystometry include filling pressure (the pressure during 
the filling phase of the micturition cycle), threshold pressure (pressure at the beginning of 
the void event), peak micturition pressure (the highest pressure reached during voiding), 
intercontraction interval (the time lapsed between the end of one void event and the end 
of the next), void volume, bladder capacity and presence/ frequency of non-voiding 
contractions (Maggi et al., 1986).   
In experimental rodent models of cystometry a urinary catheter is secured at one 
end in the dome, or most caudal region, of the bladder and the other end runs 
subcutaneously through the thorax before being externalized at the base of the neck.   
This externalization allows for easy access during saline and/or drug infusions during 
conscious cystometry.  Both conscious and anesthetized cystometry experimental models 
are utilized in the current literature; however, major urodynamic differences exist 
between the two models.  Importantly, bladder capacity is significantly increased under 
anesthesia (Ghoniem et al., 1996; Yokoyama et al., 1997).  General anesthesia may block 
glutamate transmission in the brain thus affecting the micturition reflex (Ghoniem et al., 
1996; Yokoyama et al., 1997).  Therefore, conscious cystometry more closely resembles 
physiologic bladder functions. However, the surgical implantation of the tubing into the 
bladder may affect bladder sensation or detrusor contractility, therefore a recovery period 
of at least several days is allotted before urodynamic testing. 
Urodynamic parameters are attributed to either the efferent or afferent limb of 
micturition pathways (Maggi et al., 1986).  Experiments involving blockade of nicotinic 
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signaling in micturition reflex pathways should ablate the efferent control of the urinary 
bladder.  In the presence of nicotinic blockade, peak amplitude of micturition decreased 
and voiding efficiency became problematic, thus leaving residual urine in the bladder.  
Presumably due to this increased residual urine, resting and threshold pressures 
increased, suggesting that neuronal pathways regulating resting and threshold pressures 
remained intact.  Additionally, as time progressed, intercontraction interval decreased in 
response to additive residual volume over repeated cyles of saline instillation suggesting 
that bladder capacity had not changed with nicotinic blockade (Maggi et al., 1986).  
Nicotinic blockade impaired the ability of the bladder to evacuate urine entirely, but not 
the ablity of the bladder to detect intraluminal volumes, therefore, peak amplitude of  
micturition and void volume are under efferent conrol while threshold pressure, resting 
pressure, intercontraction interval and bladder capacity are associated with the afferent 
limb of the reflex pathway (Maggi et al., 1986). 
The presence of non-voiding contractions (i.e. significant rises in bladder filling 
pressure that does not elicit expulsion of urine) is atypical in cystometric recordings from 
healthy humans or experimental animals.  However, various forms of bladder pathology 
(e.g. spinal cord injury, bladder outlet obstruction and bladder inflammation) are 
associated with the emergence of non-voiding contractions.  Neither the function nor the 
origin of these contractions is fully understood.  Both myogenic and neurogenic 
mechanisms have been proposed (Brading et al., 1997; Herrera et al., 2003; Comiter et 
al., 2010).  Experimental manipulations show the ability of isolated bladder smooth 
muscle strips to increase the number of spontaneous activity or phasic contractions in 
16 
 
response to stretch in the absence of urothelium or intact neuronal innervation, and 
therefore imply a myogenic mechanism for the induction of non-voiding contractions 
(Brading, 1997; Herrera et al., 2003).  Alternatively, neurogenic mechanisms may also 
contribute to the presence of non-voiding contractions either directly (e.g., by increasing 
spontaneous firing) or indirectly by facilitating functional changes in detrusor smooth 
muscle myocytes (Brading et al., 1997; Comiter et al., 2010).  Comiter et al., (2010) 
demonstrate that sacral nerve stimulation decreases the number of non-voiding 
contractions observed in a model of bladder outlet obstruction without affecting detrusor 
contractility.  Interestingly, sacral nerve stimulation also attenuates structural changes 
such as hypertrophy and fibrosis observed in the bladder following outlet obstruction 
(Comiter et al., 2010).  Therefore, the genesis of non-voiding contractions may reflect a 
combination of neuronal and muscular changes that could reciprocally influence each 
other to produce phenotypic changes observed in bladder pathology.  Other explanations 
include changes in the sensory machinery of the urothelium that may alter the bladder’s 
response to distension, possibly via communication to the bladder afferents, interstitial 
cells or detrusor smooth muscle located deep to the urothelium (Herrera et al., 2003). 
II. Micturition in Injury or Disease 
 
Bladder function elies entirely on central nervous system (CNS) control and, 
thereofore, is vulnerable to injury or disease.  When orchestration of the circuitry fails, 
the effects can range from total incontinence to complete retention of urine, but it almost 
always results in a decreased quality of life.  Symptoms depend on the location of lesion 
or nature of synaptic rearrangement.  Brain lesions usually lead to a hyperreflexic bladder 
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due to its strong inhibitory influence on micturition behavior.  Changes in the spinal cord 
grey or white matter can have different effects such as bladder hypo- or hyperreflexia and 
bladder associated pain. 
A. Spinal Cord Injury  
 
Spinal cord injury presents a multitude of challenges, and loss of continence can 
be one of the toughest emotional hurdles with which to cope.  Spinal cord injury triggers 
an immediate and acute shock response of the nervous system followed by a period of 
reorganization and partial recovery (Yoshimura, 1999).  For injuries at or above the 
lumbosacral spinal cord, the bladder becomes completely flaccid and areflexic causing 
total retention; however, after a recovery period, synaptic changes in the peripheral 
innervation of the LUT allow the detrusor to regain slowly its contractile properties (de 
Groat et al., 1982; Yoshimura, 1999).  Despite a partial recovery of the micturition reflex, 
synaptic rearrangements and loss of precise coupling between somatic relaxation of the 
external urethral sphincter muscle with parasympathetic contraction of the detrusor 
smooth muscle causes detrusor-sphincter dyssynergia; in other words, as detrusor 
contraction attempts to expel the bladder in full, the urinary sphincter rhythmically 
tightens, thus retaining residual urine within the bladder (Yoshimura, 1999; Fowler et al., 
2008).  Incomplete or failed emptying necessitates repeated catheterizations that 
increases risk for urinary tract infections.  This situation is particularly dangerous because 
urinary tract infections can trigger the potentially fatal, autonomic dysreflexia syndrome 
in spinal cord patients (Kingsley, 1996). 
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B.  Multiple Sclerosis 
 
Multiple sclerosis (MS), a demyelinating disease of the central nervous system, 
also may interrupt normal micturition pathways.  Depending on the site of lesion, urinary 
symptoms exhibited by many MS patients include detrusor hyperreflexia, hyporeflexia 
and/or detrusor-sphincter-dyssynergia (Haensch and Jörg, 2006).  Functionally, these 
symptoms relate to sensations of urgency, the need for frequent elimination and/or 
incomplete bladder emptying. Lesions to the cortex most likely lead to a hyperreflexic 
bladder due to its main inhibitory influence over the micturition reflex.  Lesions in the 
pons or suprasacral spinal cord can lead to detrusor hyporeflexia or detrusor-sphincter-
dyssynergia because they disrupt the pathways responsible for precise coordination of all 
divisions of the nervous system during the switch from the storage phase to the emptying 
phase (Betts et al., 1993; Araki et al., 2003; Haensch and Jörg, 2006).   
C.  Parkinson’s Disease 
 
Parkinson’s disease (PD), a progressive degenerative disorder of the CNS, also 
affects autonomic functions including micturition.  PD results from a loss of 
dopaminergic neurons in the substantia nigra.  Normally, these dopaminergic neurons 
facilitate an overall inhibitory effect on micturition.  With a disrupted dopaminergic 
circuitry, the PMC fails to receive adequate inhibition resulting in a hyperreflexic bladder 
(Kitta et al., 2008).  In addition, evidence suggests that under normal circumstances, the 
D1 dopaminergic pathway may send collateral inhibitory GABAergic collaterals to the 
PMC thus further increasing its role in the storage phase of micturition (Kitta et al., 
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2008).  Not surprisingly, 45-93% of PD patients suffer from overactive bladders (Kitta et 
al., 2008). 
  D. Interstitial Cystitis/ Painful Bladder Syndrome (IC/BPS) 
 
While much is unknown about the micturition defects observed in MS and PD 
patients, still other disease mechanisms remain even more elusive.  Interstitial Cystitis/ 
Bladder Pain Syndrome (IC/BPS) is a chronic bladder syndrome with presenting 
symptoms of urgency, frequency, nocturia, suprapubic and pelvic pain.  IC/BPS patients 
have a lower threshold for sensing bladder volume and often feel pain at normal bladder 
volumes which leads to decreased bladder capacities (FitzGerald et al., 2005; Nazif et al., 
2007).  Additionally, pain localization extends beyond the region of the bladder.   In 
patients with IC/BPS, bladder fullness causes discomfort at suprapubic, urethral and 
vulvar sites (Fitzgerald et al., 2005; Warren et al., 2008).  Histopathological findings 
from IC/BPS biopsies reveal edema and vasodilatation in the bladder (Nazif et al., 2007).  
While some theories exist as to the underlying mechanisms of this syndrome, the etiology 
remains largely unclear.  
 Basic research for IC/BPS is crucial because an estimated 1.3-12  million 
Americans are diagnosed with the syndrome (Interstitial Cystitis Association, 2010. 
Home Page. (n.d.) Retrieved from www.ichelp.org; National Kidney and Urologic 
Disease Information Clearinghouse, 2010. Interstitial Cystitis/Painful Bladder Syndrome. 
(n.d.) Retrieved from http://kidney.niddk.nih.gov/kudiseases/pubs/interstitial 
cystitis/index.htm).  Because the symptoms of IC/BPS necessitate frequent trips to the 
bathroom during both the day and nighttime, patients with IC/BPS are often unable to 
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work or may even suffer from depression.  As a result, IC/BPS costs to the government 
include both medical care and loss of productivity which an estimate from 1987 was 
approximately $428 million (Association of Reproductive Health Professionals, 2010. 
Publications and Resources. Screening, Treatment and Management of IC/PBS. May 
2008. Retrieved from www.arhp.org/Publications-and-Resources/Clinical-
Proceedings/Screening-Treatment-and-Management-of-ICPBS/Epidemiology).   
For unknown reasons, women comprise the majority of those diagnosed with 
IC/BPS, accounting for nearly 90%.   However, rates among men are increasing due to 
IC/BPS awareness and the rectifications of incorrect prostatitis diagnoses.  To further 
complicate matters, IC/BPS is probably a multiple disease syndrome as biopsy findings, 
pathologic urinary markers and history of urinary tract infections vary from patient to 
patient (Erikson, 1999).  
 Life stress has been associated with onset and severity of IC/BPS symptoms 
(Rothrock et al., 2001).  Episodes of urgency, pain and nocturia correlate with self 
reported stress and these associations become stronger with increasing severity of 
symptoms (Rothrock et al., 2001).  The lack of understanding of the pathology of IC/BPS 
combined with the heterogeneity of symptoms and patient population present enormous 
challenges when trying to establish effective treatments.  The only FDA-approved 
intravesical treatment for IC/BPS is instillation of dimethyl sulfoxide (DMSO).  DMSO 
moderately reduces IC/BPS symptoms and is thought to act via anti-inflammatory, 
muscle relaxant and/or neuronal desensitization mechanisms (Birder et al., 1997; Wehbe 
et al., 2010).  Other intravesical treatments include instillation of local anesthetics (e.g. 
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lidocaine) or pentosan polysulfate sodium (PPS).  PPS is a polysaccharide that is thought 
to restore the GAG layer and barrier function to the mucosal layer of the bladder.  PPS is 
also the only approved oral medication for the treatment of IC/BPS (Wehbe et al., 2010).   
Other oral remedies include dietary modification, antihistamines, muscle relaxants and 
herbs or other naturally occurring compounds with antioxidizing and anti-inflammatory 
properties such as quercetin, a bioflavinoid found in red wine, green tea, seeds, citrus 
fruits and onions (Whitmore, 2002; Wehbe et al., 2010).  
 Two alternative types of treatment, sacral nerve modulation and myofascial 
trigger point therapy, attempt to reduce heightened tension of the pelvic floor muscles 
that is often present in patients with IC/BPS.  Some researchers argue that pelvic floor 
dysfunction precedes or may cause dysfunctional urinary bladder symptoms.  Sources of 
pelvic floor dysfunction include improper exercise or movement, trauma during sexual 
activity, surgically-induced hypersensitivity or viral infection (Weiss, 2001).  Intense 
sensory afferent firing from somatic sensory nerves innervating the pelvic floor may 
activate convergent bladder afferent neurons in the sacral spinal cord (Weiss, 2001).   In 
fact, a recent controlled, randomized study evaluating the efficacy of myofascial trigger 
point therapy to reduce perceived severity of pain and urinary symptoms demonstrates, 
for the first time in 10 years, statistically significant positive outcomes for the treatment 
of IC/BPS (Payne et al., 2010).  However the lack of positive results from previous 
studies probably reflects the heterogeneity of the IC/BPS population.  Future research 
might reveal that the IC/BPS diagnosis encompasses multiple cohorts of urinary bladder 
dysfunction.  The origin and pathogenesis in each may differ and therefore explain the 
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difficulties in establishing an effective universal treatment for IC/BPS.  Additional 
theories as to the etiology and pathogenesis of IC/ BPS include infection, autoimmune 
disorder, toxic urinary components, deficiency in bladder wall lining and neurogenic 
causes. 
III.  Inflammation and IC/BPS 
 
Despite fundamental differences in the primary cause of IC/BPS symptoms, the 
activation of inflammatory mediators, either as a direct insult or as a secondary result, is a 
common theme in each proposed mechanism. The majority of biopsies from IC/BPS 
patients exhibit infiltration of inflammatory cells or mediators, such as lymphocytes, T 
cells, B cells, mast cells, interleukin-6 and interleukin-2 (Erickson et al., 1997) 
suggesting that inflammatory mediators may contribute to dysfunctional bladder 
symptoms (Batler et al., 2002; Yoshimura et al., 2002; Sant et al., 2007).  Rodent studies 
utilizing chemically-induced cystitis and clinical trials involving patients with IC/BPS 
demonstrate that treatment with an immunoregulator (suplatast tosilate, IPD-1151T)  that 
suppresses cytokine production, immunoglobulin E antibody formation and mast cell 
activation, can increase bladder capacity and reduce pain scores (Ueda et al., 2000; 
Yoshimura et al., 2002). Potential mediators of bladder inflammation are numerous and 
include cytokines, chemokines, neuropeptides, neuroactive compounds and growth 
factors. 
A.  Nerve Growth Factor 
 
Nerve growth factor (NGF), a potent neurotrophin, is also an important mediator 
of somatic and visceral pain and inflammation.  NGF is elevated in the urine and 
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urothelium of patients with IC/BPS and therefore research has focused on the 
contributions of NGF/ receptor signaling to symptoms associated with IC/BPS such as 
bladder hyperreflexia and referred somatic pain (Okragly et al., 1999; Lowe et al., 2007).  
Chemically-induced bladder inflammation in rodent models has demonstrated changes of 
NGF and its associate receptors, TrkA, TrkB and p75NTR in the urinary bladder, bladder 
primary afferents and major pelvic ganglia (Vizzard, 2000; Qiao and Vizzard, 2002; 
Murray et al., 2004; Klinger et al., 2008).  Addition and subtraction experiments have 
demonstrated functional roles for NGF in micturition reflex pathways.  For example, 
direct application of NGF to the detrusor smooth muscle, lumen of the bladder, 
lumbosacral intrathecal space or adenovirus-induced NGF expression in the detrusor 
smooth muscle causes sensitization of bladder afferents and bladder hyperreflexia as 
evidenced by decreased bladder capacity and intercontraction intervals (Dmitrieva et al., 
1997; Chuang et al., 2001; Lamb et al., 2004; Yoshimura et al., 2006; Zvara and Vizzard, 
2007).  Chronic application of NGF to the detrusor smooth muscle induces expressional 
increases and spatial alterations of both Fos protein, a marker of cellular activation, and 
calcitonin gene-related peptide (CGRP), a protein known to be involved in noxious 
sensation in the lumbosacral spinal cord (Zvara and Vizzard, 2007).  Conversely, agents 
that decrease NGF levels can attenuate its hyperreflexic effects (Dmitrieva et al. 1997; 
Hu et al., 2005).  Most interestingly, transgenic mice overexpressing NGF under the 
urothelium-specific uroplakin II promoter exhibit symptoms similar to those observed in 
IC/BPS: hyperinnervation of unmyelinated and myelinated sensory fibers as well as 
sympathetic nerves in the suburothelial plexus, increased urinary bladder reflex activity 
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and referred somatic hypersensitivity in the pelvic region (Schnegelsberg et al., 2010).  
These data strongly implicate a role for NGF signaling in bladder sensory/physiology 
dysfunction. 
B.  In vivo Models of Urinary Bladder Inflammation 
 
The etiology of IC/BPS remains elusive; therefore, development of a model to 
study the underlying mechanisms produces challenges.  Various models attempt to mimic 
the histopathological and functional changes affecting the urinary bladder observed in 
IC/BPS, but no one model encompasses all aspects of the syndrome; therefore, no single 
model is accepted universally as the standard to study IC/BPS.  
B.1 Intravesical infusion of noxious chemicals 
Some models of bladder inflammation involve intravesical infusion of noxious 
chemicals, such as acetone (Kato et al., 1990), acetic acid (Birder and de Groat, 1992; Yu 
and de Groat, 1998; Chuang et al., 2004), hydrochloric acid (Rivas et al., 1997; Wang et 
al., 2000; Cayan et al., 2003; Kirimoto et al., 2007), mustard oil and turpentine 
(McMahon and Abel, 1987) via transurethral catheterization.  While the goal of such 
models is to induce inflammation, catheterization can induce tissue irritation and 
inflammation in rodents because of anatomical relationaships and the small size of the 
urethra.  Additionally, transurethral catheterization of chemical irritants increases the risk 
of introducing bacteria to the LUT, thus potentially causing urinary tract infection.  Both 
potential side effects could confound results illustrating bladder hyperreflexia or 
increased suprapubic and pelvic pain.  The toxic nature of the chemicals may cause tissue 
necrosis, a characteristic not found in biopsies of IC/BPS bladders (Kato et al., 1990).  
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Nevertheless, these agents induce histopathological and functional changes that appear 
similar to those observed in human IC/BPS (Rivas et al., 1997; Kirimoto et al., 2007).  
For example, hydrochloric acid causes edema in the lamina propria, infiltration of 
inflammatory cells as well as increased voiding frequency (Rivas et al., 1997; Kirimoto et 
al., 2007).  Turpentine and mustard oil stimulate leukocyte infiltration and bladder 
hyperreflexia (McMahon and Abel, 1987).  Although studies utilizing intravesical 
instillation of noxious chemicals have advanced knowledge in the IC/BPS field, short 
lasting effects of the method render translation of results for the human syndrome 
difficult.  In humans, the syndrome is characterized by chronic, long lasting alterations in 
bladder activity and the tissues of the LUT; however, intravesical treatment with 
chemicals such as mustard oil and turpentine have induced bladder hyperreflexia that 
lasts only a relatively short 6 and 24 hours, respectively (McMahon and Abel, 1987). 
B.2 Urothelial Damage: Protamine Sulfate 
An interesting technique using protamine sulfate (PS) attempts to mimic 
urothelial barrier dysfunction observed in the bladders of IC/BPS patients.  PS increases 
urothelial permeability allowing urinary components to diffuse into the bladder tissue 
(Tzan et al., 1993).  Solutes such as potassium ions may depolarize bladder sensory 
neurons thus potentiating bladder overactivity.  Chuang et al. (2003) showed that 
following intravesical infusion of PS, infusion of physiological saline solution into the 
bladder induces overactivity.  While this technique offers insight into to the role of the 
urothelium, it lacks any inflammatory component.  Since most IC/BPS bladder biopsies 
reveal some degree of inflammation (Rivas et al., 1997; Kirimoto et al., 2007), a model 
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that incorporates an inflammatory element is essential.  Stein and colleagues (1996) 
followed PS treatment with endotoxin lipopolysaccharide (LPS) intravesical instillation.  
LPS is a well known model to stimulate visceral-specific inflammation (Stein et al., 
1996).  PS-LPS consecutive instillation caused urothelial breakdown and neutrophil and 
macrophage infiltration similar to histologic finding in patients with IC/BPS (Erickson et 
al., 1997).  Although no functional studies were performed, this model may be a more 
accurate simulation of IC/BPS because it incorporates urothelial breakdown with an 
inflammatory component.  Although models utilizing PS offer some insight to 
mechanisms underlying of IC/BPS, these models constrain hypotheses to focus on a 
dysfunctional urothelium as the cause of IC/BPS.  While urothelial dysfunction is thought 
to contribute to symptoms of IC/BPS, other factors such as altered bladder sensory 
circuitry may also contribute to signs and symptoms of IC/BPS.  Not only do PS models 
fail to incorporate other well-studied aspects of bladder dysfunction, but they also 
lack the ability to study the initiating factors of urothelial breakdown in IC/BPS bladders. 
B.3 Naturally occurring Feline Interstitial Cystitis (FIC) 
FIC is a naturally occurring model of IC/BPS.  Using all inclusion and exclusion 
criteria applicable to humans, cats with FIC meet the National Institute of Health criteria 
for IC (Westropp and Buffington, 2002).  Cats with FIC exhibit similar symptoms of 
urgency and frequency in the absence of bacterial infection (Lavelle et al., 2000).  
Histopathological changes in the bladders of cats with FIC are similar to those in humans 
with IC/BPS as they exhibit urothelial lesions and nonspecific inflammation (Levelle et 
al., 2000).  Additionally, as in humans, onset of the syndrome is spontaneous, may occur 
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at any age, and symptoms may enter a pattern of relapse and remission partially 
influenced by environmental stress (Westropp and Buffington, 2002).  Despite many 
similarities between human IC/BPS and FIC, gender ratios of those afflicted in the two 
populations differ immensely.  In the feline population, FIC occurs equally amongst 
males and females; however, in the human population, females account for 90% of 
IC/BPS cases.  This disparity, along with other limitations associated with the model, 
deter many from using the FIC model to study IC/BPS.  Because FIC is not definitively 
genetic and occurs spontaneously at any age, acquisition of sufficient numbers of animals 
to perform scientific investigations presents enormous challenges.  Purchasing and 
animal care costs of FIC cats are much higher in comparison to rodents (Westropp and 
Buffington, 2002).  Finally, because any cat with FIC in a study already has the 
syndrome, studies are limited to investigating the maintenance of the syndrome and 
cannot easily address the mechanisms underlying the initiation of the syndrome. 
B.4 Cyclophosphamide Treatment 
An alternative to direct instillation of noxious substances into the bladder to 
induce inflammation is intraperitoneal injection of cyclophosphamide (CYP).  CYP is an 
antineoplastic agent with harsh side effects including hemorrhagic cystitis (Cox, 1979; 
Maggie et al., 1992).  CYP is metabolized in the liver by P450 enzymes into mustard 
alkylating agents (Batsita et al., 2006).  A urinary metabolite, acrolein, accumulates in the 
bladder and exerts a toxic effect by direct contact with the mucosal surface of the bladder.  
Acrolein induces histological and functional changes in the bladder similar to those seen 
in patients with IC/BPS.  Histologic features include edema, vascular permeability, and 
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hemorrhage (Boucher at al., 2000; Bautista et al., 2006).  Functionally, acrolein causes 
decreased bladder capacity, increased void frequency and somatic hypersensitivity 
(Guerios et al., 2006; Klinger et al., 2008; Studeny et al., 2008).  Additionally, Eichel et 
al. (2001) showed that CYP increases urothelial permeability that lasted for 2 weeks after 
treatment.  Because IC/BPS is a chronic and not an acute syndrome, such long term side 
effects resulting from CYP treatment correlate well with IC/BPS symptoms lending to its 
ability to model inflammation associated with IC/BPS.   
The hyperreflexia and somatic sensitivity resulting from acrolein treatment are 
thought to be mediated, at least in part, by activation of capsaicin- sensitive c-fiber 
afferents (Maggie et al., 1992; Ahluwalia et al., 1994).  This activation of c-fibers is 
similar to the “awakening of c-fibers” that mediates a variety of bladder dysfunction 
symptoms as described earlier.  The effects of acrolein are mediated through transient 
receptor potential (TRP) channels, TRPA1 and/or TRPV1 (Dinis et al., 2004; Bautista et 
al., 2006; Wang et al., 2008).  TRPA1 is activated by isothiocyanate or thiosulfinate 
compounds, the pungent components of mustard oil and garlic. TRPV1 is activated by 
heat and capsaicin, the pungent component of chili peppers.   In vitro, acrolein 
application elicits depolarizing currents in TRPA1 positive neurons, but not TRPV1 
positive neurons (Bautista et al., 2006).  However, CYP-treated TRPV-1 knockout mice 
fail to develop hindpaw mechanical hypersensitivity that wild type counterparts exhibit 
(Wang et al., 2008).  Additionally, an endogenous TRPV1 agonist, anandamide, increases 
in urinary bladder with CYP-induced cystitis and direct application to the serosal surface 
causes increased bladder reflex activity (Dinis et al., 2004).  Activation of primary 
29 
 
sensory neurons can lead to central or peripheral release of neuropeptides, vasodilation 
and other neurogenic inflammatory effects, which in turn contribute to somatic 
hypersensitivity and bladder hyperreflexia (Maggie et al., 1992; Ahluwalia et al., 1994; 
Gepetti et al., 2008).  In fact, bladder biopsies from patients with IC/BPS demonstrate 
elevated neuronal TRPV1 levels and that TRPV1 density correlates with pain scores 
(Mukerji et al., 2006). 
Although the CYP model of bladder inflammation is well characterized and 
commonly used in current literature, it does not completely model symptoms of IC/BPS.  
The gross inflammation produced by CYP is more extreme than oberserved in the 
majority of bladders from IC/BPS patients.  Additionally, the model does not enable 
researchers to address the underlying causes of urinary bladder inflammation.  However, 
the model does allow scientists to identify chemical mediators of inflammation in the 
urinary bladder and to examine how these changes may affect bladder function.  
Additionally, the relative ease of the model makes it an attractive alternative in the 
laboratory.  For example, CYP can be injected intraperitoneally and does not require the 
use of transurethral catheters and even with a non-localized injection site, visceral 
inflammation is limited to the bladder, while other viscera are spared (Boucher at al., 
2000).  Therefore, induction of bladder inflammation using CYP is relatively simple, 














Frequency Yes Yes Yes Yes Yes 
Referred Pain ? Yes ? Yes Yes 
↑  Urothelial  
    Permeability 
Yes Yes Yes Yes ? 
↑  NGF ? Yes ? Yes Yes 
↑  Inflammatory 
    mediators 
Yes Yes ? Yes ? 
↑  suburothelial  
    nerve plexus 
    fibers 
? ? ? No Yes 
Table 1: Models of Urinary Bladder Inflammation as they relate to symptoms of   
               IC/BPS 
C.  Inflammation and Plasticity within the LUT and Innervation    
 
Plasticity within micturition reflex pathways leading to bladder hyperreflexia and 
associated pain includes changes in neurochemical, electrophysiological and 
organizational properties of primary bladder afferents and central connections.  
Numerous studies have demonstrated the ability of inflammation to induce such changes 
in visceral afferent pathways, including CYP-induced changes in bladder reflex circuitry 
(Figure 3). 
Changes in the neurochemical properties of micturition reflex pathways may 
contribute to abnormal bladder function and associated pain.  CYP-induced bladder 
inflammation produces plasticity in hormonal, peptidergic, neurotrophic and purinergic 
chemical profiles in sensory and autonomic motor innervation of the urinary bladder. 
Corticotropin releasing hormone (CRH) is a hormone and neurotransmitter involved in 
stress responses.  CRH is present in the urinary bladder, SPN, and the suburothelial nerve 
plexus, and expression increases in these locations with CYP-induced cystitis (LaBerge et 
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al., 2006).  CRH receptor -2 is also present in the suburothelial nerve plexus and 
urothelium of rat urinary bladders, and this expression increases following CYP-induced 
cystitis.  These findings are interesting considering evidence for a link between stress and 
symptom onset and severity in IC/BPS patients (Rothrock et al., 2001).  Developmental 
studies have demonstrated that changes in CRH expression may underlie the emergence 
of mature voiding reflexes (LaBerge et al., 2006; LaBerge et al., 2008).  Functionally, 
exogenous application or genetic over expression of the CRH protein produces bladder 
hyperreflexia (Klausner et al., 2005; Million et al., 2007), and CRH antagonists can 
attenuate this effect (Klausner et al., 2005).  Therefore CRH expression may mediate 
functional plasticity in micturition reflex circuitry under developmental and pathological 
conditions. 
Expression of several neuropeptides changes in micturition reflex pathways with 
bladder inflammation.  Following CYP-induced cystitis, bladder associated DRG and 
spinal cord cells with basal expression demonstrate increased amounts of neuropeptides 
such as CGRP, SP, pituitary adenylate cyclase-activating polypeptide (PACAP) and 
galanin in (Vizzard, 2000; Vizzard, 2001; Zvarova and Vizzard, 2006).  Additionally, 
bladder associated DRG and spinal cord segments display a higher percentage of 
neuropeptide expressing cells after CYP-induced bladder inflammation (Vizzard, 2000; 
Vizzard, 2001).   In the spinal cord, neuropeptide expression increases in the superficial 
DH (lamina I and II), LCP, DCM, SPN and IML (Vizzard, 2000; Vizzard, 2001; Zvarova 










Figure 3.  Physiologic events leading to symptoms of IC/BPS.  Changes in 
neurotrophin or cytokine/ chemokine signaling can initiate a cascade of events leading to 








Neurotrophic changes following CYP-induced bladder inflammation also occurs.  
Neurotrophins (e.g. NGF, brain-derived neurotrophic factor (BDNF)) and trophic 
receptors TrkA, TrkB and p75NTR are present throughout micturition reflex pathways 
including the MPG, suburothelial nerve plexus and bladder associated DRG and spinal 
cord segments in control animals. Expression of neurotrophins and associated receptors 
increases following CYP-induced cystitis (Qiao and Vizzard, 2002; Murray et al., 2004; 
Klinger and Vizzard, 2008).   
Functional purinergic receptor expression increases in bladder sensory afferents 
with bladder inflammation (Dang et al., 2008).  Dissociated neurons from rats with CYP-
induced cystitis demonstrate increased P2X receptor expression.  Additionally, more 
fibers respond to purinergic agonists in comparison to neurons from animals without 
bladder inflammation (Dang et al., 2008).  Alterations of purinergic signaling, together 
with other neurochemical changes, may contribute to the sensitization of bladder reflex 
pathways potentially provoking bladder hyperreflexia and pain. 
Bladder inflammation also alters the electrical properties of bladder afferent 
neurons.  After CYP-treatment, bladder afferent fibers exhibit a lower threshold for 
action potential generation and increased firing in response to isotonic distention 
(Yoshimura and de Groat, 1999; Dang et al., 2008; Yu and de Groat, 2008).  CYP 
treatment increases receptive field size and causes a significant hypertrophy of afferent 
cell bodies in L6-S1 DRG (rat) (Dang et al., 2008).  These data clearly demonstrate the 
ability of inflammation to change electrophysiological properties of neurons in the 
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sensory limb of micturition circuitry.  Electrophysiological plasticity could translate to 
dysfunctional bladder symptoms such as hyperreflexia. 
Organizational changes in micturition reflex pathways induced by CYP occur at 
the level of the urinary bladder and its central connections.  CYP treatment increases 
CGRP- positive sensory afferent fibers in the bladder urothelium and detrusor smooth 
muscle and parasympathetic innervation in the urothelium (Dickson et al., 2006).  Studies 
also demonstrate inflammatory-induced central changes such as an increase in post 
synaptic connections (Vizzard and Boyle, 1999; Vizzard, 2000).  Growth- associated 
protein-43 (GAP-43) is a calmodulin-binding protein associated with synapse formation.  
CYP-induced cystitis increases GAP-43 expression in central micturition processing 
areas such as the DCM, DH, LCP, SPN and IML of the spinal cord (Vizzard and Boyle, 
1999). Additionally, the protein gene product of the immediate early gene c-fos (Fos), 
that marks postsynaptic activation of spinal cord neurons receiving afferent information 
from the lower urinary tract, increases in number and spatial location in appropriate 
bladder spinal cord segments.  These alterations mimic noxious irritation in non-inflamed 
bladders suggesting that inflammatory mediated central changes in Fos expression may 
be involved in pain mechanisms (Vizzard, 2000).  Together these data implicate that 
inflammatory-induced synaptic plasticity of micturition reflex pathways (e.g. 
neurochemical, electrophysiological, organizational) may contribute to functional 





IV. The Urothelium as a Sensory Organ 
 
Recently, the functional contribution of the urothelium has advanced beyond the 
view of a passive barrier and is now suggested to have “neuron-like properties such as 
plasticity, sensory transduction and signaling capabilities, especially in the context of 
bladder inflammation (Birder et al., 2001; Birder et al., 2005).  Urothelial cells express 
numerous receptors similar to those found in DRG such as purinergic, norepinephrine, 
acetylcholine, neuropeptide- and protease-activated receptors, acid sensing ion channels, 
neurotrophin receptors and transient receptor potential (TRP) channels (Birder, 2006; 
Apodaca et al., 2007; Birder & de Groat 2007).  Functional receptor expression enables 
the urothelium to respond to diverse stimuli including stretch/ distention of the urinary 
bladder, soluble factors, neuroactive compounds and changes in pH (Birder, 2006; 
Apodaca et al., 2007).  In addition to receptive sensory capabilities, the urothelium also 
releases a variety of signaling molecules (Birder, 2006; Apodaca et al., 2007).  The 
anatomical proximity of underlying structures including bladder afferent neurons in the 
suburothelial plexus, interstitial cells in the suburothelial lamina propria and detrusor 
smooth muscle suggests the possibility of reciprocal connection with the urothelium 
(Figure 4).  In support of this hypothesis, studies have demonstrated that urothelial-
derived chemical mediators can influence the activity of underlying bladder afferent 
neurons and detrusor smooth muscle (Birder et al., 1998; Templeman et al., 2002; Birder 






Figure 4.  Schematic diagram illustrating the relationship of urothelial-derived 
factors and potential sites of receptor activation.  Functional receptor expression and 
secretion capabilities enable the urothelium to respond to mechanical and chemical 
stimuli and to communicate with other tissues in the bladder.  Substances released by the 
urothelium may activate receptors on urothelial cells, suburothelial plexus nerve fibers or 









For example, chemical or mechanical stimulation of the bladder facilitates the release of 
NO from urothelial cells which can then alter the activity of bladder afferent neurons 
(Birder et al., 1998; Andersson et al., 2008; Smith et al., 2008).  Additional studies 
demonstrate that urothelial secreted factors modulate the spontaneous activity of detrusor 
smooth muscle (Templeman et al., 2002; Ikeda et al., 2007).  These data suggest that the 
urothelium is a functional component of bladder sensory/ physiology.      
Changes in chemical/receptor expression or secretion within the urothelium may 
mediate functional symptoms of various types of bladder dysfunction.  For example, 
urine from IC/BPS patients contains elevated levels of ATP (Sun et al., 2001).  ATP 
signals via ligand-gated ion purinergic receptors, specifically the P2X family.  Urothelial 
cells and many sensory neurons terminating in the suburothelial plexus densely express a 
member of the P2X family, P2X3 (Sun et al., 2001).  In response to stretch, urothelial 
cells release ATP that can then bind P2X3 receptors in bladder sensory neurons (Sun et 
al., 2001; Sun and Chai, 2004 and 2006).  Bladders from IC/BPS patients show enhanced 
ATP release from urothelial cells in response to stretch (Sun et al., 2001), and increased 
expression of P2X3 receptors in urothelial cells possibly enhancing purinergic signaling 
(Sun and Chai, 2004 and 2006).  Additionally, P2X3 agonists decrease the threshold for 
activation in bladder nociceptive neurons (Rong et al., 2002).   Increased ATP release 
from urothelial cells combined with increased density of P2X3 receptors may alter the 
bladder’s response to distension effectively enhancing the afferent limb of the micturition 
reflex and leading to dysfunctional bladder symptoms such as hyperreflexia and 
associated pain.  
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The urothelium can be damaged by injury or inflammation (Birder and de Groat, 
2007).  When the urothelial barrier becomes compromised, proliferation and 
differentiation mechanisms attempt to restore the barrier integrity.  Proliferation is 
thought to be responsible, at least in part, for the elevated levels of NGF in the bladder 
urothelium and urine from IC/BPS patients.  As previously described, urinary bladder 
expression of NGF and associated receptors, TrkA, TrkB and p75NTR is modulated with 
CYP-induced bladder inflammation (Vizzard, 2000; Murray et al., 2004; Klinger and 
Vizzard, 2008).  Of substantial importance, transgenic mice over-expressing NGF 
achieved through the use of a urothelium-specific uroplakin II promoter exhibit 
phenotypic changes in the LUT similar to those shown in various forms of bladder 
dysfunction including IC/BPS and overactive bladder syndrome (Schnegelsberg et al., 
2010).  These changes include hyperinnervation of the suburothelial plexus, decreased 
bladder capacity and referred somatic sensitivity in the pelvic region.  These studies 
demonstrate that urothelial-derived chemical mediators can contribute to functional 
changes in the urinary bladder and its innervation leading to hyperreflexia and associated 
pain.  Additional studies demonstrate CYP-induced changes in urothelial expression and 
function of other neurochemicals such as neuropeptides (e.g., PACAP) and associated 
receptors (Girard et al., 2008), chemokines (Yuridullah et al., 2006; Vera et al., 2008) and 
signaling molecules (Corrow and Vizzard, 2007; Chung et al., 2010).  Together, these 
data suggest that molecular changes within the organ itself (i.e. non-neuronal) can 
contribute to sensory and functional abnormalities including those extending beyond the 
scope of the bladder such as referred somatic pain to the body wall.  This dissertation will 
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focus on inflammatory-induced molecular plasticity in the urinary bladder and how these 
changes mediate symptoms of bladder dysfunction. 
V. The Role Chemokines in IC/BPS 
 
Using the CYP-induced bladder inflammation model, we aim to characterize 
further the role of immune mediators in the development and/or maintenance of neuronal 
sensitization and chronic pain states associated with IC/BPS.  Mechanical nerve injury, 
inflammatory insult and infection are all events that conjure immune activation.  
Chemical (e.g. cytokines, chemokines) and cellular (e.g. mast cells, leukocytes) 
mediators of the immune response are implicated in the initiation and maintenance of 
chronic pain states (White et al., 2007; Jung et al., 2008). The immune response consists 
of two stages: the innate response and the acquired response.  Innate immunity initiates 
the body’s immediate and general reaction to pathogen infiltration which includes, but is 
not limited to, the activation of phagocytic cells such as macrophages and neutrophils.  
Adaptive immunity on the other hand, because it relies on immunological memory of 
previous exposures to similar pathogens, responds much more slowly, is highly specific 
and offers future protection against similar pathogen infiltration.  Evidence suggests that 
mediators of the innate immune response play a role in the development of abnormal pain 
states (White et al., 2007; Jung et al., 2008).  Receptors expressed by immune cells 
recognize conserved molecular patterns of infectious agents (e.g., bacteria, viruses) or 
cellular debris (e.g., as generated during processes such as wallerian degeneration) and 
respond by increasing cytokine synthesis and secretion (White et al., 2007).  Cytokines 
spark a cascade of immunological events that involves production of more inflammatory 
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mediators in other cell types and extravasation of leukocytes to the site of injury/ 
inflammation. The immune response acts to heal the injured/ inflamed area and also to 
sensitize nociceptive neurons, thus increasing the pain response in order to prevent 
further insult (White et al., 2007).  While initial immune activation and sensitization of 
sensory neurons is protective, prolonged immune activity and sensory sensitization 
occurring after tissue healing are associated with chronic pain syndromes and are 
suggested to underlie mechanisms of neuropathic pain.  Neuropathic pain persists in the 
absence of physiologic neuronal stimuli and often manifests in the form of hyperalgesia 
or allodynia.   Chronic neuropathies are common in patients who suffer from diseases or 
injury such as human immunodeficiency virus (HIV) (Oh et al., 2001), MS (Haensch and 
Jörg, 2006), SCI (Yoshimura, 1999) and IC/BPS (Erikson, 1999).  Unfortunately, pain 
management becomes problematic because neuropathic pain is often resistant to non-
steroidal anti-inflammatory drugs (NSAIDs) and opioid treatment (e.g. morphine). 
 A. Overview of Chemokines  
 
Potential chemical mediators responsible for nociceptive sensitization include 
chemokines, otherwise known as chemotactic cytokines.  Chemokines are a large family 
of structurally and functionally related proteins that are important mediators of immune 
responses, inflammatory processes and nociception.  In the immune response, 
chemokines facilitate tissue recovery by causing the extravasation of leukocytes from 
blood plasma to the site of injury.  Chemokine receptors present on leukocytes sense 
increasing chemotactic concentration gradients and facilitate cellular motility towards 
them (Rutkowski and DeLeo, 2002). 
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Approximately 100 amino acids in length, chemokines are small, secreted 
proteins that comprise 4 subfamilies: CC, CXC, CX3C and C (for review see White, 
2005).  Each subfamily is named for the first cysteine residue motif from its amino 
terminus.  Families of chemokines exert their actions by binding to related G-coupled 
protein receptors (GPCRs).  Within each subfamily, receptor and ligand pairing is not 
mutually exclusive; in multiple ligands can bind the same receptor and visa versa (for 
review see White, 2005).   The complexity of chemokine receptor binding presents 
challenges when elucidating the functional role of chemokine signaling.  Despite 
difficulties, unveiling the role of chemokines and their receptors in both physiological 
and pathological states could provide insights to possible therapeutic interventions in a 
variety of chronic pain conditions including IC/BPS.   
B. Chemokines and Altered Sensory Processing 
 
Inflammatory mediators such as proinflammatory cytokines (e.g., tumor necrosis (TNF)-
α, interleukin (IL)-6, IL-1β), COX-2, NGF, protons, prostaglandins and bradykinin have 
been implicated in the direct sensitization of nociceptive afferents (Cheng and Ji, 2008).  
Traditionally, chemokines were not thought to assert direct effects on primary sensory 
neurons.  Rather, chemokine/ receptor interaction on the plasma membrane of leukocytes 
was thought to stimulate leukocyte-release of nociceptive mediators via GCPR signaling 
mechanisms (White et al., 2007).  However, electrophysiological, expressional and 
functional pain studies have demonstrated the possibility of direct chemokine-mediated 
neuronal hypersensitivity and pain (Figure 5).  For example, in vitro, exogenous 
chemokine application can physiologically alter sensory neurons by changing membrane 
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potentials (Sun et al., 2006), decreasing thresholds for action potential generation (Sun et 
al., 2006), increasing excitability and evoking discharges (White et al., 2005; Sun et al., 
2006).  Various chemokines including CXCL12 can modulate calcium ion currents in 
cultured DRG cells, potentially facilitating hyperexcitability (Oh et al., 2001; Oh et al., 
2002; Bhangoo et al., 2007a and b).  In a neuronal injury model, chronic compression of 
the DRG elicits a depolarizing response to chemokines that was not detected in control 
(non-compressed) DRG (White et al., 2005).  These data suggest that direct chemokine 
action may contribute to altered neuronal function associated with neuropathies. 
Under basal conditions, with the exception of CXCL12 (White et al., 2007), 
neuronal chemokine expression is sparse; however, following nerve injury or 
inflammation, expression of chemokines and associated receptors increases significantly 
in macrophages and infiltrating T-cells, but more importantly in sensory neurons and glia 
(Rutkowski and DeLeo, 2002; Tanaka et al., 2004; Verge et al., 2004; White et al., 2005; 
Bhangoo et al., 2007a, b and 2009, Jung et al., 2008).  Additionally, increased neuronal 
activity, as would occur during injury/ inflammation, has been shown to induce 
chemokine transcription (Jung and Miller, 2008).  Chemokine expression in, and 
subsequent secretion from the various cell types would enable chemokines, by diffusion, 
to interact with functional chemokine receptors on DRG neurons thus facilitating 









Figure 5.  Indirect vs. direct neuronal modulation by chemokine signaling.  After the 
initiation of extravasation, chemokines were thought to influence neuronal functioning 
indirectly by facilitating the release of other excitatory chemicals from leukocytes via 
GCPR downstream signaling pathways (left panel).  However more recent evidence 
suggests that neurons released from leukocytes, glial cells, neurons or epithelial cells can 




In conjunction with expressional increases during pathological conditions, studies 
illustrate a strong relationship between chemokines and pain.  Oh and colleagues (2001) 
published an early example of nociceptive chemokine function when they showed that 
intraplantar administration of various chemokines such as CXCL12, CCL5 and CCL22 
induce mechanical hypersensitivity lasting for at least 3 hours.   Since then numerous 
studies have reported that either exogenous peripheral (e.g. intradermal) or central (e.g. 
intrathecal) chemokine application induces mechanical hypersensitivity and/ or  thermal 
hyperalgesia (Milligan et al, 2004; Tanaka et al., 2004; Qin et al., 2005; Zhang et al., 
2005; Dansereau et al., 2008, Bogan et al., 2009).  Intrathecal administration of CCL2 
can produce mechanical hypersensitivity within 30 minutes and hyperalgesic effects can 
be detected up to 4 days after administration (Dansereau et al., 2008).   In contrast, 
CCL2-induced thermal hypersensitivity resolves 24 hours after administration 
(Dansereau et al., 2008).    Interestingly, transgenic mice lacking the CCR2 receptor 
(principle receptor for CCL2) are resistant to the development of mechanical 
hypersensitivity following mechanical nerve injury; however, following Complete 
Freund’s Adjuvant (CFA)-induced neural inflammation, these mice display only a small, 
insignificant decrease in mechanical sensitivity compared to control animals and show no 
changes in thermal nociception (Abbadie et al., 2003).  These data suggest specificity for 
chemokine function with respect to type of injury and pain modality. 
Studies utilizing antagonists against chemokine signaling provide evidence for a 
therapeutic role with respect to neuropathic pain.  In two different models of HIV-1 
associated neuropathy, Bhangoo et al., (2007b and 2009) demonstrate that anti-retroviral 
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drug- or viral coat protein, gp120-, induced mechanical hypersensitivity is attenuated by 
acute, systemic treatment with CCR2 or CXCR4 antagonists (Bhangoo et al., 2007b).  
Other pain eliciting models such as focal demyelination, CFA- induced inflammation and 
partial sciatic nerve ligation have demonstrated the therapeutic effects of chemokine 
receptor antagonists (Milligan et al., 2004; Bhangoo et al., 2007a; Manjavachi et al., 
2009). 
One potential mechanism underlying chemokine nociceptive properties is 
sensitization of the TRPV1 receptor.  In vitro, pre treatment of DRG neurons with 
chemokines enhances the response to capsaicin or anandamide (Jung et al., 2008; Zhang 
et al., 2005).  Possible signaling mechanisms involved in chemokine-induced TRPV1 
sensitization include PLC and PKC mediated signaling pathways (Zhang et al., 2005; 
Jung et al., 2008).  
 Various chemokines and receptors colocalize with neuronal TRPV1 as well as 
neuropeptides known be released in a TRPV1-dependent manner (Oh et al., 2001; Zhang 
et al., 2005;  Dansereau et al., 2008; Jung et al., 2008).  Notably, Jung et al. (2008) 
showed large dense-core vesicles containing both CCL2 and CGRP.  Dansereau et al., 
(2008) demonstrate calcium-evoked release of CCL2 following incubation of DRG 
neurons with potassium or capsaicin.  Functioning as a neurotransmitter-like molecule, 
vesicular chemokine release could assert pro-inflammatory and neuronal 
hyperexcitability effects in neighboring DRG cells or spinal cord dorsal horn neurons and 
glia (discussed later).  Chemokines released from central primary afferent terminals could 
exert either direct activation of SDH neurons via functional chemokine receptor 
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expression or indirect sensitization via activation of microglia and astrocytes that 
subsequently release nociceptive mediators.  
Heightened DRG neuronal activity may produce neurologic pain by increasing 
central input to the spinal cord.  Repetitive firing of the DRG neuron could increase 
nociceptive neurotransmitter (e.g. substance P and CGRP) release into the dorsal horn of 
the spinal cord, therefore increasing activity of spinal neurons that mediate both local 
reflexes and ascend to higher brain centers.  In vitro, chemokine application can evoke 
release of both SP and CGRP from neurons (Oh et al., 2001; Qin et al., 2005).  Such 
events could potentially lead to a phenomenon known as “central sensitization” where 
intensely heightened peripheral input decreases thresholds necessary to elicit action 
potentials in DH neurons thus facilitating increased pain signal transduction to the brain 
(Oh et al., 2001; White et al., 2007).  Increased primary afferent signaling may also 
induce organizational and neurochemical changes in central synapses underlying central 
sensitization and chronic pain syndromes. 
B. Chemokines, Glial Activation and Pain  
 
 Altered sensory functioning is not limited to peripheral sensory neurons, but may 
also affect higher order neurons in the spinal cord and/or brainstem and brain (White et 
al., 2007).  The central nervous system, once thought of as an immunologic devoid 
network, is now considered to play major role in inflammatory pain (Rutkowski and 
DeLeo, 2002).  Activated astrocytes and microglia have the capability to respond to 
noxious stimuli by releasing inflammatory mediators such as cytokines and chemokines 
that can then diffuse to other cells including neurons and thus accentuate neuronal 
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activity (Rutkowski and DeLeo, 2002; Watkins and Maier, 2003; Tsuda et al., 2005; 
Milligan et al., 2008; Gao and Ji, 2010; Figure 6). 
Astrocytes serve a regulatory role under physiologic conditions.  Their 
juxtaposition to neuronal somas, dendrites and pre- and post- synaptic terminals enables 
them to monitor and modulate extracellular ion and neurotransmitter concentrations, 
availability of chemical precursors and pH (Watkins and Maier, 2003).  Microglia are 
normally quiescent and express relatively few cell surface receptors until they become 
activated by invading pathogens or noxious stimuli (Watkins and Maier, 2003). The term 
activation represents a multitude of orchestrated expressional and functional changes that 
occur within a cell enabling it to engage in activities not previously possible (Watkins 
and Maier, 2003).   Upon activation astrocytes and microglia undergo morphologic and 
functional changes enabling them to initiate pro-inflammatory cytokine production, 
signaling cascades and secretion of cytokines and neurochemicals (Watkins and Maier, 
2003; Tsuda et al., 2005; Milligan et al., 2008; Gao and Ji; 2010; Figure 6).  Activated 
astrocytes exhibit hypertrophy and an increase in the amount of intermediate filaments, 
specifically glial fibrillary acidic protein (GFAP), a marker of activated astrocytes 
(Garrison et a., 1991).  Functionally, astrocytes increase cytokine production (Watkins 
and Maier, 2003).  Microglia demonstrate retracted processes, hypertrophy and 
proliferation in response to activation.  Microglia become phagocytic, migrate to areas of 
infection/ damage and upregulate cytokines and numerous cell surface receptors 
including chemokine, cytokine and purinergic (Watkins and Maier, 2003; Lindia et al., 
2005).   
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A variety of functional receptors are present on astrocytes including NMDA and 
non NMDA ionotropic receptors, metabotropic glutamate receptors and purinergic and 
SP receptors (Milligan et al., 2008).  Functional receptor expression enables astrocytes 
and microglia to respond to proinflammatory cytokines (i.e., TNF-α, IL-1β, IL-6), SP, 
excitatory amino acids (EAAs; e.g., glutamate) and ATP (Figure 6).  In response, glial 
cells release the same cytokines (Milligan et al., 2008) in addition to chemokines, 
(Rostene et al., 2007) neurotransmitters, nitric oxide (Burgher et al., 1997) and 
prostaglandins (Halassa et al., 2007; Pocock and Kettenment 2007; Figure 6).  
Neurochemicals released by glial cells can diffuse away to directly excite sensory 
neurons and can lead to increased SP and EAA release from primary afferent neurons 
either centrally or peripherally (Malcangio et al., 1996; Aimar et al., 1998; Southall et al., 
1998; Inoue et al., 1999; Guo and Schluesener, 2007).  Alternatively, glial-derived 
neurochemicals can indirectly excite neurons by inducing transcription of pro-nociceptive 
mediators such as COX-2 (increases production of prostaglandins) in neurons or other 
glial cells resulting in further enhancement of the inflammatory response and pain signal 







Figure 6.  Schematic diagram illustrating the relationship of activated glial cells and 
inflammatory signaling molecules.  Mediators causing glial activation include viruses 
and bacteria or substances released by primary afferent or spinal tract neurons.  NO, nitric 
oxide; DH, dorsal horn; PGs, prostaglandins; EAAs, excitatory amino acids; SP, 







 Garrison and colleagues (1991) were the first to correlate glial activation and 
nociception.  They showed that increased glial activation coincides with hyperalgesia 
following peripheral nerve injury.  Since then numerous studies have demonstrated that 
neuropathic pain resulting from inflammation or injury to peripheral tissues can be 
blocked with pharmacological agents that disrupt glial viability (Meller et al., 1994; 
Watkins et al., 1997; Milligan et al., 2000; Raghavendra et al., 2003; Watkins and Maier, 
2003).  
Chemokines have been investigated for their potential role in glial activation 
because they are putative signaling molecules of the immune system and contribute to 
pain process, therefore their presence in astrocytes or microglia should not be surprising.  
Indeed chemokines and receptors are detected in dorsal horn neurons and activated 
astrocytes and microglia in numerous models of neuropathic pain including peripheral or 
central nerve damage or tissue inflammation (Harrison et al., 1998; Bajetto et al., 1999; 
Mennicken et al., 1999; Bajetto et al., 2002; Cartier et al., 2005; Mines et al., 2007; Gao 
and Ji, 2010). Blockade of chemokine signaling reduces hyper-nociceptive pain behaviors 
after injury/inflammation (Milligan et al., 2004; Bhangoo et al., 2007; Manjavachi et al., 
2009).  
Chemokines may act as relay messengers, communicating back and forth between 
glial cells and neurons inducing pro-inflammatory effects such as neuronal 
hyperexcitability and neuronal and/ or glial release of neurochemicals.  Chemokine 
expression in glial cells is thought to be driven by pro-inflammatory cytokines, TNF-α, 
IL-1 and IL-6 (Milligan et al., 2004; Milligan et al., 2008; Gao et al., 2009).  Exposure of 
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astrocytes to TNF-α, a pro-inflammatory cytokine, induces a substantial (>100-fold) 
increase in CCL2 expression and secretion (Gao et al., 2009; Gao and Ji, 2010).  
Considering that CCR2 receptors are constitutively expressed on dorsal horn neurons and 
the juxtaposition of astrocytes to neurons, glial-released CCL2 could, by simple 
diffusion, bind to receptors on dorsal horn neurons (Gosselin et al., 2005; Gao et al., 
2009).  Chemokine signaling on sensory neurons may induce electrophysiological (Gao 
et al., 2009), transcriptional (Ye, 2001) neurochemical (Gao et al., 2009) and 
organizational changes that underlie chronic pain phenotypes. 
Communication between glial cells and neurons is suggested to be reciprocal 
(Milligan et al., 2008; Gao and Ji, 2010).  As such, neuronally-derived chemokines can 
signal to glial cells in the opposite direction (Milligan et al., 2008; Gao and Ji, 2010).  
CX3CL1 (a.k.a. fractalkine) is a striking example of this phenomenon.  In the CNS, 
fractalkine is expressed on the cell surface of neurons only; the fractalkine receptor 
however, is expressed only on microglial cells in the CNS (Harrison et al., 1998; Watkins 
and Maier, 2003; Verge et al., 2004; Lindia et al., 2005; Milligan et al., 2008).  
Fractalkine exists in both membrane-bound and soluble forms.  Under physiologic 
conditions, fractalkine most often binds its cognate receptor CX3CR1 in the membrane-
bound form.  However, increased neuronal firing increases fractalkine shedding via 
matrix metalloproteinase mechanisms and the soluble form of fractalkine can diffuse 
away and bind receptors on microglial cells (Chapman et al., 2000; Watkins and Maier, 
2003; Milligan et al., 2008).  Fractalkine signaling has been associated with inflammatory 
neuropathological diseases such as MS (Krumbholz et al., 2006) and amyotrophic lateral 
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sclerosis (ALS) (Milligan et al., 2008).  Chemokine signaling between bladder sensory 
afferents and glial cells could modulate symptoms of IC/BPS especially considering that 
peripheral injury or inflammation (e.g., bladder) can induce central glial activation.  
D. Chemokines and Visceral Inflammation  
 
Both rodent and clinical studies assessing patients with various pelvic 
inflammatory/ pain syndromes indicate a role for chemokines in the initiation or 
maintenance of visceral inflammation.  For example, in a model of chemically-induced 
colitis, blockade of CXCR2 signaling reduces neutrophil influx, myeloperoxidase (MPO) 
activity, iNOS and COX-2 expression and infiltration of cytokines and chemokines 
(Bento et al., 2008).  CXCR4 peripheral T-cell expression is increased in patients with 
ulcerative colitis and expression levels correlate with disease activity (Mikami et al., 
2008).  Additionally, chemically-induced colitis in mice leads to an increase of CXCR4-
positive leukocytes and CXCL12 expression in colonic tissue (Mikami et al., 2008).  
Administration of a CXCR4 antagonist reduces these inflammatory effects (Mikami et 
al., 2008).  Elevated chemokine levels have been detected in the seminal plasma of 
patients with chronic prostatitis or chronic pelvic pain syndrome (Penna et al., 2007).  
Similarly, patients with IC/BPS exhibit elevated chemokine expression in bladder 
lymphocytes and mice treated with CYP display similar expressional patterns (Sakthivel 
et al., 2008).  Blockade of CXCL10 signaling reduces severity of CYP-induced bladder 
inflammation by reducing hyperplasia, pithelial erosions and infiltration of T cells, mast 
cells and killer T cells in the bladder urothelium of rats (Sakthivel et al., 2008). 
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Urothelial chemokine signaling may contribute to inflammatory related bladder 
hyperreflexia.  Agace et al., (1993) demonstrate an early example of urothelial-derived 
chemokine expression; following exposure to Escherichia coli, urothelial cells produce 
copious amounts of CXCL8.  Similarly, urothelial expression of chemokines such as 
CX3CL1 and CXCL12 and associated receptors, CX3CR1 and CXCR4 respectively, 
increases in the urothelium after CYP-induced cystitis in rodents (Yuridullah et al., 2006; 
Vera et al., 2008).  Considering the extensive data implicating a sensory and signaling 
role for the urothelium, it is possible that urothelial-derived chemokines contribute to 
symptoms of bladder dysfunction. 
E. Chemokines and Opioid Desensitization 
 
Chronic neuropathic pain management associated with IC/BPS, SCI or HIV-
associated neuropathy is problematic because of its tendency to develop tolerance to 
opioid drugs (e.g. morphine).  Opioid receptors (subtypes µ, δ and κ) are GCPRs that are 
present on the plasma membrane in sensory neurons (Zhang et al., 2004).  Opioid 
signaling initiates a variety of downstream signaling events via G-protein signaling 
mechanisms including activation of inward rectifying potassium channels and inhibition 
of calcium channels (Zhang and Oppenheim, 2005).  These effects block neuronal 
membrane depolarization, action potential generation, neurotransmitter release and 
therefore pain signals fail to propagate and analgesia is observed (Zhang and Oppenheim, 
2005).   A phenomenon termed “heterologous desensitization” describes the ability of 
one type of receptor to inhibit the actions of a different receptor, usually via inhibition of 
G-protein activity (Zhang and Oppenheim, 2005), and may explain the tolerance to 
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opioid substances that occurs in the presence of neuropathic pain.  Chemokine receptors 
are also coupled to G-proteins and expressed on the cell surface of neurons.  In vitro, 
chemokine application prior to an µ-opioid agonist, DAMGO, induces µ-opioid receptor 
internalization as evidenced by a reduction in the amount of cell surface expression 
(Zhang et al., 2004).  In vivo, DAMGO asserts analgesic effects in the cold water tail-
flick test by increasing the time until a rat removes its tail from the cold water stimulus 
(Szabo et al., 2002).  Application of a variety of chemokines into the PAG prior to 
DAMGO treatment reverses the DAMGO-induced tail-flick latency (Szabo et al., 2002).  
Chemokine signaling may contribute to neuropathic pain not only by sensitizing afferent 
neurons but also activating glia or desensitizing the body’s anti-pain mechanisms. 
 
VI. Involvement of PI-3K/ AKT Signaling in Inflammatory Pain 
A.  PI-3K/AKT Signaling Overview 
 
Phosphoinositide 3-kinase (PI-3K) signaling via AKT is a common cellular 
signaling pathway that exerts numerous functions and is present in a variety of cell types 
(for review see Scheid and Woodgett, 2001).  PI-3K functionally activates AKT by 
indirect phosphorylation (Burgering and Coffer, 1995).  Extracellular stimuli activate cell 
surface receptors that are coupled to intracellular signaling pathways such as PI3-K.  
Activated PI3-K then phosphorylates membrane inositol phospholipids to generate 
PI(3,4)P2 and PI(3,4,5)P3.  PI(3,4)P2 and PI(3,4,5)P3 act as landing sites for both AKT 
and phosphoinositol-dependent kinase (PDK1).  Both AKT and PDK1 have pleckstrin 
homology (PH) domains that target them to PI(3,4)P2 and PI(3,4,5)P3 in the plasma 
membrane.  After binding the membrane inositol phospholipids, AKT and PDK1 undergo 
55 
 
conformational changes, which then, due to close proximity, allow PDK1 to 
phosphorylate (activate) AKT at both serine (473) and threonine (308) sites.  Finally, 
AKT dissociates from the plasma membrane into the cytosol where it will play a role(s) 
in other signaling cascades (Scheid and Woodgett, 2001). 
B. PI-3K/AKT Signaling in Altered Sensory Processing 
 
Although AKT is best known for its role in cell survival via anti-apoptotic effects, 
recent studies have demonstrated novel roles for AKT signaling in altered sensory/pain 
processing.  For example, basal phosphorylated (p) AKT expression is present in rodent 
lumbosacral DRG (Sun et al., 2007; Shi et al., 2009) and superficial laminae of the spinal 
cord (Sun et al., 2006; Guedes et al., 2008) and significantly increases following 
peripheral nerve/ tissue injury or inflammation (Sun et al., 2006; Sun et al., 2007; Xu et 
al., 2007; Guedes et al., 2008, Pezet et al., 2008; Shi et al., 2009).  Additionally, 
colocalization of pAKT with markers of unmyelinated pain transducing c-fibers such as 
isolectin- IB4, TrkA, CGRP and TRPV1 (Zhuang et al., 2004; Sun et al., 2007; Xu et al., 
2007; Shi et al., 2009) has been demonstrated.  Specific inhibitors of AKT signaling can 
attenuate mechanical hyperalgesia resulting from peripheral nerve injury or inflammation 
(Sun et al., 2006; Sun et al., 2007; Xu et al., 2007) suggesting a nociceptive role for AKT 
signaling.  Both prophylactic treatment (i.e. administered prior to peripheral nerve injury/ 
inflammation) and therapeutic treatment (administered after peripheral nerve injury/ 
inflammation and the development of hyperalgesia) with inhibitors of AKT 
phosphorylation reduce peripheral injury-/ inflammation- induced pain.  Therefore AKT 
56 
 
is thought to play a role in both the initiation and maintenance of peripheral hyperalgesia 
(Sun et al., 2006; Xu et al., 2007).   
In addition to the mediation of somatic pain processes, AKT signaling may also 
mediate visceral inflammation.  After chemically-induced colitis in rodents, basal pAKT 
expression in the superficial dorsal horn increases significantly (Qiao and Grider, 2009).  
Furthermore, urothelial pAKT expression has been detected in mice, thus raising the 
possibility of pAKT participation in urothelial-mediated effects on bladder sensory 
physiology (Tamarkin et al., 2006).  As a result, PI-3K/AKT signaling may be a target for 
therapeutic intervention in various peripheral injury/ inflammatory conditions, including 
IC/BPS.  
Potential upstream effectors of AKT activation include NGF and other growth 
factors such as platelet derived growth factor, epidermal growth factor and insulin-like 
growth factor, interleukins, cytokines and reactive oxygen species (Datta et al., 1999).  
For the purpose of this dissertation, only NGF and chemokine regulated AKT 
phosphorylation will be discussed because of their relevance to bladder dysfunction.   
NGF interactions with the high affinity receptor, TrkA, are known to activate PI3-
K/ AKT pathways (Datta et al., 1999).  Elevated NGF levels are detected in the 
urothelium and urine from patients with IC/BPS (Lowe et al., 1997; Okragly et al., 1999).  
Numerous rodent studies demonstrate the functional capacity of elevated NGF signaling 
in the bladder because they demonstrate that exogenously- or endogenously- induced 
elevated NGF results in sensitization of bladder afferents and bladder hyperreflexia 
(Dmitrieva et al., 1997; Chuang et al., 2001; Lamb et al., 2004; Yoshimura et al., 2006; 
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Zvara and Vizzard, 2007; Schnegelsberg et al., 2010).  CYP-induced bladder 
inflammation modulates the expression of NGF and TrkA in the urinary bladder 
(Vizzard, 2000; Murray et al., 2004), bladder primary afferents (Qiao and Vizzard, 2002) 
and major pelvic ganglia (Murray et al., 2004); therefore, activation of TrkA may 
contribute to phosphorylated AKT expression in the urinary bladder or micturition reflex 
pathways during bladder inflammation.  Other NGF/TrkA downstream effectors 
including extracellular signal-regulated kinase (ERK)1/2 (Corrow and Vizzard, 2007; 
Chung et al., 2010) and c-Jun N-terminal kinase (JNK) (Chung et al., 2010) increase in 
the urinary bladder in an NGF-dependent manner following CYP-induced cystitis (Chung 
et al., 2010).  Corrow and Vizzard (2007) demonstrated that inhibition of ERK 
phosphorylation significantly reduces CYP-induced bladder hyperreflexia in rats, 
therefore, NGF-mediated signaling may potentiate phenotypic symptoms associated with 
bladder dysfunction.  
C. Chemokine Influence on PI-3K/AKT Signaling  
 
Inflammation induced PI-3K signaling may be a direct effect of inflammatory 
mediators themselves.  For example, chemokines regulate AKT phosphorylation in 
normal processes such as brain development (Bajetto et al., 2001) and lymphopoiesis 
(Tilton et al., 1997 and 2000), as well as in disease states such as HIV (Poggi et al., 
2004), diabetes (Liu et al., 2008), breast cancer (Fernandis et al., 2004), and brain 
tumoriogenesis (Bajetto et al., 2001).  In particular, CXCL12 promotes AKT 
phosphorylation in a variety of cell types including lymphocytes (Tilton et al., 2000), 
astrocytes (Bajetto et al., 2001), hepatocytes (Liu et al., 2008) and breast, endometrial 
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and prostate cancer cell lines (Fernandis et al., 2004; Wang et al., 2005; Zhao et al., 
2006).  Therefore it is possible that chemokines can influence PI-3K/AKT signaling in 
bladder cells.  Noxious stimulation of the bladder either by mechanical stretch or 
infection induces PI-3K/AKT signaling in smooth muscle cells (Adam et al., 2003; 
Stover and Nagatomi, 2007) or the urothelium (Tamarkin et al., 2006), but the role of 
chemokine regulation is not known. 
As described earlier, various chemokines, including CXCL12, can modulate 
calcium ion currents and increase excitability in a number of cells including primary 
DRG neurons (Oh et al., 2001; Oh et al., 2002; Nelson and Gruol, 2004; White, 2005; 
Bhangoo et al., 2007).   Additionally, the PI-3K/AKT signaling pathway can be activated 
via neuronal activity or calcium ion influx in a variety of cell types such as bladder 
smooth muscle cells (Stover and Nagatomi, 2007), striatal neurons (Perkinton et al., 
2002), sympathetic neurons  (Vaillant et al., 1999) and DRG neurons (Pezet et al., 2005).  
Chemokine induced neuronal hyperexcitability could potentially lead to activation of the 
PI3-K/ AKT signaling pathway.  Considering that chemokines, chemokine receptors and 
AKT have been detected in sensory afferents, an inflammatory-induced activation of 
AKT seems plausible (Oh et al., 2001; Tanaka et al., 2004; Verge et al., 2004; Pezet et 
al., 2005; Zhang et al., 2005). 
D. AKT and TRPV1 Sensitization 
 
One mechanism phosphorylated AKT may contribute to nociceptive processes is 
via sensitization of the TRPV1 receptor.  Either neurotrophin- or chemokine- induced 
activation of AKT could lead to TRPV1 upregulation or sensitization.  For example, PI3-
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K activation has been implicated in NGF-induced TRPV1 expression and trafficking to 
the plasma membrane (Chuang et al., 2001; Bron et al., 2003; Zhang et al., 2005; Stein et 
al., 2006).  AKT is not the sole downstream target of PI3-K activation therefore its role in 
NGF- mediated TRPV1 trafficking or expression, while plausible, is not definitive.  
Similarly, studies demonstrate that direct NGF-induced TRPV1 sensitization (i.e. 
increased intracellular cation flux) can be mediated by each of the major NGF/ TrkA 
downstream signaling pathways, PI3-K, MAPK and PLC; however, there is no consensus 
on the contribution of each pathway alone, or in combination, on NGF-evoked TRPV1 
sensitization. 
E.  AKT and Central Sensitization 
 
Central sensitization involves a number of changes within with spinal cord 
circuitry, resulting from high frequency input from peripheral primary neurons that 
renders central nociceptive neurons hyperexcitable (Man et al., 2003; Pezet et al., 2008).  
The molecular changes underlying central sensitization are similar to those observed in 
other forms of synaptic plasticity such as long term potentiation (LTP) in the 
hippocampus, the major mechanism thought to underlie learning and memory.  
Similarities include increased intracellular calcium flux through N-methyl-D-aspartic 
acid (NMDA) receptors (NMDARs) that leads to functional changes of post-synaptic α-
amino-3-hyroxyl-5-methyl-4-isoxazole-propionate (AMPA) receptors (AMPARs) (Bliss 
and Collingridge, 1993; Zhuo and Hawkins, 1995; Malenka and Nicoll, 1999; Soderling 
and Derkach, 2000; Ji et al., 2003; Man et al., 2003; Pezet et al., 2008).   Furthermore, 
PI3-K signaling has been implicated in the development of neuronal properties associated 
60 
 
with LTP.  For example, PI3-K signaling is necessary for high frequency stimulus (HFS)-
induced LTP in the hippocampus and amygdala (Lin et al., 2001; Sanna et al., 2002; 
Opazo et al., 2003; Karpova et al., 2006).  Inhibitors of PI3-K block NMDAR 
downstream signaling effects such as activation of MAPK signaling pathways (Pezet et 
al., 2008) and GluR1 AMPAR subunit trafficking to the plasma membrane (Man et al., 
2003; Pezet et al., 2008).  Increased activation of AKT occurs concomitantly with PI3-K- 
dependent LTP and therefore may contribute to the development or maintenance of LTP 
(Lin et al., 2001; Sanna et al., 2002; Karpova et al., 2006).  For example, blockade of 
AKT phosphorylation reduces the number of postsynaptic excitatory potentials (EPSPs) 
after HFS-induced LTP (Karpova et al., 2006).  Due to similarities between underlying 
mechanisms of LTP in the brain and central sensitization in the spinal cord, AKT may 
contribute to plasticity within DH synapses leading to central sensitization and ultimately 
to heightened pain signal transduction. 
VII. Summary 
 
Cellular sources of chemokines and phosphorylated AKT include urothelial 
(Tamarkin et al., 2006; Yuridullah et al., 2006), inflammatory (Mikami et al., 2008; 
Sakthivel et al., 2008), glial (Lindia et al., 2005) and neuronal cells (Verge et al., 2004; 
Zhuang et al., 2004).  After injury or inflammation, expressional increases or secretion 
from any of these cell types may lead to neuronal hypersensitivity facilitating pain signal 
transduction (Oh et al., 2001; Karpova et al., 2006). Neuronal sensitization may result 
from direct enhancement of cation channel activity (e.g. TRPV1) (Zhu and Oxford, 2007) 
or indirectly via transcriptional mechanisms (Watkins and Maier, 2003; Bento et al., 
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2008). Increased peripheral sensory activity enhances central and peripheral SP and 
CGRP release which will ignite further inflammatory cascades in glial cells (centrally) or 
leukocytes (peripherally) (Oh et al., 2001; Qin et al., 2005).  Such signaling mechanisms 
would lead to a cyclic inflammatory/ neural sensitization response with no clear “stop” 
signal.  These inflammatory-induced changes may contribute to chronic hyperreflexic 
bladder and pain symptoms associated with bladder inflammatory conditions such as 
IC/BPS.   
VIII. Project Aims and Hypotheses 
 
The purpose of this dissertation study was to evaluate the expression of chemical 
mediators and associated signaling pathways in urinary bladder inflammation and how 
these mediators relate to micturition function/ dysfunction.  The overall hypothesis for 
this proposal is that changes at the level of the urinary bladder can result in altered 
bladder sensory physiology that results in a hyperactive bladder state.  Specifically, we 
examined the expression of the chemokine/receptor pair, CXCL12/CXCR4, in the urinary 
bladder both in the presence and absence of CYP-induced inflammation.  We also 
evaluated the contribution of CXCL12/CXCR4 signaling to functional micturition in 
control rats and those treated with CYP.  The activation (phosphorylation) of a ubiquitous 
signaling molecule, AKT was also examined in control and inflamed rat urinary bladders 
and its functional contribution to micturition was evaluated in control and CYP-treated 
rats.   
Clinical studies including patients with various pelvic inflammatory/ pain 
syndromes and rodent models of visceral inflammation correlate elevated chemokine/ 
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receptor expression with inflammation.  Chemokine expressional changes have already 
been demonstrated in the urinary bladder with CYP-induced cystitis (Yuridullah et al., 
2006; Sakthivel et al., 2008; Vera et al., 2008).  Additionally, elevated chemokines levels 
have been detected in the seminal plasma and peripheral immune cells of patients with 
pelvic inflammatory/ pain syndromes such as ulcerative colitis, chronic prostatitis, 
chronic pelvic pain syndrome and IC/BPS (Penna et al., 2007; Mikami et al., 2008; 
Sakthivel et al., 2008).  Blockade of the chemokine CXCL10 reduces symptoms of CYP-
induced bladder inflammation such as hyperplasia and infiltration of immune cells 
(Sakthivel et al., 2008).  Despite the numerous reports correlating chemokine expression 
with visceral inflammation, few studies have examined functional roles for chemokine 
signaling in urinary bladder function.  We hypothesized that expression of 
CXCL12/CXCR4 would increase with CYP-induced bladder inflammation and blockade 
of CXCR4 receptor signaling with AMD3100, a specific CXCR4 antagonist, would 
reduce CYP-induced bladder hyperreflexia.  These hypotheses encompass aims 1 and 2 
and are described in chapter 2. 
AKT is a putative mediator of cellular survival, however recent studies implicate 
the signaling molecule in visceral inflammation, pain processes (Sun et al., 2006; Sun et 
al., 2007; Xu et al., 2007; Shi et al., 2009) and plasticity associated with long term effects 
(i.e. LTP, central sensitization).  Phosphorylation of AKT increases in the spinal cord DH 
after chemically-induced colitis and increases in the urinary bladder with CYP-induced 
bladder inflammation (Chung et al., 2010).  The functional contribution of pAKT to 
micturition had not been evaluated previously.  Therefore, aim 3 of this dissertation 
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examined activation of AKT in the urinary bladder with CYP-induced cystitis of varying 
duration; in addition, aim 3 addresses the functional contribution of pAKT to both 
inflamed and no inflamed micturition via the use of inhibitors of AKT phosphorylation, 
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Chapter 2:  Expression and Function of CXCL12/CXCR4 in Rat 
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Chemokines, otherwise known as chemotactic cytokines, are pro-inflammatory mediators 
of the immune response and have been implicated in altered sensory processing, 
hyperalgesia and central sensitization following tissue injury or inflammation.  To 
address the role of CXCL12/CXCR4 signaling in normal micturition and inflammation-
induced bladder hyperreflexia, bladder inflammation in adult female Wistar rats (175-
250g) was induced by injecting CYP intraperitoneally at acute (150 mg/kg; 4 hr), 
intermediate (150 mg/kg; 48 hr) and chronic (75 mg/kg; every third day for 10 days) time 
points. CXCL12, and its receptor, CXCR4, were examined in the whole urinary bladder 
of control and CYP-treated rats using enzyme-linked immunosorbent assays (ELISAs), 
quantitative PCR (qRT-PCR) and immunostaining techniques.  ELISAs, qRT-PCR and 
immunostaining experiments revealed a significant (p ≤ 0.01) increase in CXCL12 and 
CXCR4 expression in the whole urinary bladder, and particularly in the urothelium, with 
CYP treatment.  The functional role of CXCL12/CXCR4 signaling in micturition was 
evaluated using conscious cystometry with continuous instillation of saline and CXCR4 
receptor antagonist (AMD3100; 5 µM) administration in control and CYP (48 hr)-treated 
rats.  Receptor blockade of CXCR4 using AMD3100 increased bladder capacity in 
control (no CYP) rats and reduced CYP-induced bladder hyperexcitability as 
demonstrated by significant (p ≤  0.01) increase s in intercontraction interval, bladder 
capacity and void volume.  These results suggest a role for CXCL12/CXCR4 signaling in 






Chemokines, chemotactic cytokines, are a large family of structurally and 
functionally related agents that are well known mediators of immune responses and 
inflammatory processes (53, 57).  More recently however, studies suggest roles for 
chemokine signaling in sensory and nociceptive processes.  Under physiologic 
conditions, with the exception of CXCL12 (73), neuronal chemokine expression is 
sparse; however, following nerve injury or inflammation, expression of chemokines and 
associated receptors increases significantly in sensory neurons, glia, macrophages, 
infiltrating T-cells, spinal cord and dorsal root ganglia (6, 7, 41, 53, 65, 67, 74).  
Additionally, elevated neuronal chemokine expression or exogenous application 
correlates with the maintenance of persistent pain while blockade of chemokine signaling 
attenuates pain behavior (6, 46, 49). 
Interstitial cystitis/ painful bladder syndrome (IC/ PBS) is a chronic bladder 
syndrome with symptoms of urgency, frequency, nocturia, suprapubic and pelvic pain 
(51).  IC/PBS patients have a lower threshold for sensing bladder volume and often 
experience pain at normal bladder pressures which suggests altered sensory processing 
within the urinary tract and/or its innervation (20, 47).  Although some theories exist as to 
the underlying mechanisms of this syndrome, the etiology remains largely unclear (18, 
30, 32, 50, 51, 55).  However, the majority of bladder biopsies from IC/PBS patients 
reveal some degree of inflammatory infiltration (56) suggesting that inflammatory 
mediators, including chemokines may contribute to inflammatory-induced changes 
including urinary bladder and sensory dysfunction.   
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Potential roles chemokine/receptor signaling in the urinary bladder are emerging. 
Previous studies have shown that the expression of chemokines and/or receptors is 
increased following cyclophosphamide (CYP) – induced bladder inflammation (54, 66, 
78).   Recent studies demonstrated increased serum expression of chemokines in IC/PBS 
patients (54).  Furthermore, in chemically-induced colitis CXCL12 is increased in the 
colon, and its main receptor, CXCR4, is increased in peripheral T-cells and leukocytes 
(45).  More recently, CXCR7 has been demonstrated as a second receptor binding to 
CXCL12 (79, 81).  Blockade of CXCR4 reduces colonic inflammation (45) and 
attenuates somatic sensitivity (7).  CYP causes bladder hyperreflexia and induces 
neurochemical (68, 69, 71, 83), organizational (69, 72) and electrophysiological (31, 77) 
changes within the bladder and bladder afferent neurons.  Potential mediators of urinary 
bladder inflammation are numerous:  cytokines (19, 40, 43), chemokines (54, 66, 78), 
neuropeptides (12, 68), neuroactive compounds (11) and growth factors (70, 76, 82).  
 The present study addresses CXCL12/CXCR4 expression and regulation in 
urinary bladder and micturition reflexes using a CYP-induced model of bladder 
inflammation.  We determined 1) expression and regulation of CXCL12 and its receptor 
CXCR4 in the urinary bladder using immunohistochemistry, quantitative PCR (qRT-
PCR) and enzyme-linked immunosorbent assays (ELISA) with CYP-induced bladder 
inflammation of varying duration and 2) the effects of CXCR4 blockade with AMD3100, 
a compound known to specifically block CXCR4 (26, 44), on micturition reflexes using 
conscious cystometry with continuous intravesical instillation of saline in both CYP-
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treated and control (non-inflamed) female rats.  Parts of these studies have been 
published in abstract form (3). 
Materials and Methods 
 
Animals  
Adult female Wistar rats (150-250g), purchased from Charles River Canada (St. 
Constant, PQ, Canada), were housed two per cage and maintained in standard laboratory 
conditions with free access to food and water.  The University of Vermont Institutional 
Animal Care and Use Committee approved all animal use procedures (protocol 08-085). 
Animal experimentation was carried out in accordance with the National Institutes of 
Health Guide for the Care and Use of Laboratory Animals. 
  Induction of CYP-induced cystitis  
Rats were anesthetized with isoflurane (2%) and received intraperitoneal (i.p.) 
injection(s) of CYP (Sigma Aldrich, St. Louis, MO) to produce urinary bladder 
inflammation.  To induce chronic bladder inflammation, CYP was injected (75 mg/kg; 
i.p.) every third day for 10 days with euthanasia occurring on the tenth day (16, 37, 38).  
To induce acute bladder inflammation, CYP was injected (150 mg/kg; i.p.) with 
euthanasia occurring 4 or 48 hours after injection (16, 37, 38).  Control rats received no 
treatment.  For conscious cystometry studies, rats received CYP as described with 
bladder function testing occurring 48 hours after injection. 
 
Preparation of tissue samples for enzyme-linked immunosorbent assays (ELISAs)   
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Rats from all experimental groups (control, 4 hr, 48 hr and chronic; n = 4) were 
euthanized with isoflurane (4%), a thoracotomy performed and the urinary bladder was 
harvested.  Individual bladders were immediately weighed and solubilized in tissue 
protein extraction reagent (1 g tissue/ 20 ml; Pierce Biotechnology, Woburn, MA) and 
treated with Complete protease inhibitor cocktail tablets (Roche Indianapolis, IN) (14, 
78).  Tissue was homogenized using a Polytron homogenizer and centrifuged (10,000 
rpm for 10 min).  The resulting supernatant was used for CXCL12 protein quantification.  
Total protein was determined using the Coomassie Plus Protein Assay Reagent Kit 
(Pierce).  CXCL12 was quantified using standard 96-well ELISA plates (R&D Systems, 
Minneapolis, MN) according to the manufacturer’s recommendations. 
ELISAs for CXCL12 in urinary bladder 
Microtiter plates (R&D Systems) were coated with anti-CXCL12 antibody.  Sample and 
standard solutions were run in duplicate.  Horseradish peroxidase-streptavidin conjugate 
was used to detect the antibody complex.  Tetramethylbenzidine was the substrate, and 
the enzyme activity was measured by the change in optical density.  The standards 
generated produced a linear curve.  The absorbance values of standards and samples were 
corrected by the subtraction of the background value (absorbance due to nonspecific 
binding).  Samples were not diluted and no samples fell below the detection limits of the 
assays.  
Immunohistochemical localization of CXCL12 and CXCR4 in the urothelium 
The bladders were rapidly dissected, placed in 4% paraformaldehyde followed by 
overnight incubation in 30% sucrose in 0.1M phosphate buffered-saline (PBS) for 
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cryoprotection.  Tissue was frozen in optimal cutting temperature (O.C.T.) compound, 
sectioned (20 µm) on a freezing cryostat and mounted directly onto gelled (0.5%) 
microscope slides (14, 16).  Sections were incubated overnight at room temperature in 
rabbit anti-CXCL12 (1:500; Santa Cruz Biotechnology, Santa Cruz, CA) or rabbit anti-
CXCR4 (1:2000; Sigma Aldrich, St. Louis, MO).  Antibodies were diluted in 1% goat 
serum and 0.1 M phosphate buffer.  After overnight incubation, sections were washed (3 
x 10 min) with 0.1 M PBS (pH 7.4).  Sections were then incubated with Cy3-conjugated, 
species-specific secondary antibodies for 2 hours at room temperature followed by 
washes (3 x 10 min) with PBS and coverslipping with Citifluor (Citifluor Ltd., London).  
Control tissue sections were incubated with 1% goat serum and 0.1 M phosphate buffer 
alone (no primary antibody), followed by normal washing and incubation with secondary 
antibodies in order to evaluate background staining levels.  In the absence of primary 
antibody, no positive immunostaining was observed.  
Visualization and semi-quantitative analysis of CXCL12 and CXCR4 in urothelium 
CXCL12- and CXCR4-IR staining in bladder sections was visualized and images were 
captured using an Olympus fluorescence photomicroscope.  The filter was set with an 
excitation range of 560-569 nm and emission range of 610-655 nm for visualization of 
Cy3.  Images were captured, acquired in tiff format and imported into Meta Morph image 
analysis software (version 4.5r4; University Imaging, Downingtown, PA) (14, 16).  The 
free hand drawing tool was used to select the urothelium and the urothelium was 
measured in total pixels area (14, 16).  A threshold encompassing an intensity range of 
100-250 grayscale values was applied to the region of interest in the least brightly stained 
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condition first.  The threshold was adjusted for each experimental series using 
concomitantly processed negative controls as a guide for setting background 
fluorescence.  The same threshold was subsequently used for all images.  
Immunoreactivity was considered to be positive only when the staining for the marker of 
interest (CXCL12 or CXCR4) exceeded the established threshold.  Percent marker 
expression above threshold in the total area selected was calculated. 
Assessment of immunohistochemical staining in urinary bladder regions 
Immunohistochemistry and subsequent evaluation of CXCL12- and CXCR4-IR in 
bladder sections or whole mount preparations were performed on control and 
experimental tissues simultaneously to reduce the incidence of staining variation that can 
occur between tissues processed on different days.  Staining in experimental tissue was 
compared with that in experiment-matched negative controls.  Urinary bladder sections or 
whole mounts exhibiting immunoreactivity that was greater than background level in 
experiment-matched negative controls were considered positively stained.  Control 
sections incubated in the absence of primary or secondary antibody were also processed 
and evaluated for specificity or background staining levels.  In the absence of primary 
antibody, no positive immunostaining was observed.  Preabsorption of CXCL12 or 
CXCR4 antisera with appropriate immunogen (CXCL12: 1µg/ ml; CXCR4: 1-3 µg/ ml) 
reduced staining to background levels. 
 During pilot studies, additional antibodies for both CXCL12 (1:100; R&D 
Systems, Minneapolis, MN) and CXCR4 (1:1000; MBL, Woburn, MA) were evaluated 
to determine if staining was comparable in urinary bladder with CYP-induced cystitis.   
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The pattern of staining observed for both CXCL12 and both CXCR4 antibodies in 
urinary bladder after CYP treatment was consistent. 
Immunohistochemical localization of CXCL12 and CXCR4 in suburothelial nerve plexus 
in urinary bladder whole mounts 
The urinary bladder was dissected rapidly and placed into oxygenated (95% O2 and 5% 
CO2) physiologic saline solution (119.0 mmol NaCl, 4.7 mmol KCl, 24.0 mmol NaHCO3, 
1.2 mmol KH2PO4, 1.2 mmol MgSO4*7H2O, 11.0 mmol Glucose) (14, 37, 78).  Starting 
at the urethra, a midline incision was made through the bladder and it was pinned flat 
onto a Sylgard-coated dish, maximally stretched, and then fixed in 2% paraformaldehyde 
+ 0.2% picric acid for 1.5 hours.  After fixation, the urothelium was separated from the 
detrusor layer using fine-tip forceps, iris scissors and a dissecting microscope as 
previously described (14, 37, 78).  Notches were made in the region of the bladder neck 
in order to track orientation and assess regional immunoreactivity of the bladder.  
Urothelium and bladder musculature were processed for CXCL12- and CXCR4-IR as 
described previously.  In some whole mounts processed for CXCL12- and CXCR4-IR, 
nerve fibers in the suburothelial nerve plexus were also stained with the pan-neuronal 
marker protein gene product (PGP9.5, 1: 3000; AbD Serotec, Raleigh, NC) and stained 
with Cy2-conjugated species-specific secondary antibodies.    
 




Whole mount tissue from control and experimental groups were examined with a 
multiband filter set for simultaneous visualization of the Cy3 and Cy2 fluorophores.  Cy2 
was viewed using a filter with an excitation range of 447-501 nm and an emission range 
from 510-540 nm.  Double-labeling in whole mount preparations of urothelium and 
detrusor was assessed by confocal laser scanning microscopy (Bio-Rad Laboratories, CA 
and Zeiss LSM 510 Meta, Carl Zeiss, Inc., NY; 38).  For each z-axis interval (1-2 µm), 
tissue sections were scanned twice using argon lasers with specific excitation 
wavelengths and sequential images were captured for computer-generated overlay and 
analysis. 
 
CXCL12 and CXCR4 transcript expression in urinary bladder using Real-Time 
Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR) 
Bladders were harvested and the urothelium was separated from the detrusor as described 
above.  Total RNA was extracted using the STAT-60 total RNA/mRNA isolation reagent 
(Tel-Test‘B’, Friendswood, TX, USA) as previously described (22, 38). One to 2 mg of 
RNA per sample was used to synthesize complementary DNA using SuperScript II 
reverse transcriptase and random hexamer primers with the SuperScript II 
Preamplification System (Invitrogen, Carlsbad, CA, USA) in a 20 µl final reaction 
volume.  Amplification of cDNA was performed using oligonucleotide primers specific 
for CXCL12, CXCR4, CXCR7, L32 and 18S. Oligonucleotide primer sequences were as 
follows: TGCATCAGTGACGGTAAGCCA (upper, CXCL12 130U21), 
ATCCACTTTAATTTCGGGTCAA (lower, CXCL12 296L22), 
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TCCTGCCCACCATCTATTTTATC (upper, CXCR4 185U23), 
ATGATATGCACAGCCTTACAT (lower, CXCR4 390L21), 
ACGTGCAAGATCACACACCTCAT (upper, rCXCR7 346U23) and 
GATCTTCCGGCTGCTGTGTTTCT (lower, rCXCR7 737L23).  
The quantitative PCR standards for all transcripts were prepared with the 
amplified CXCL12, CXCR4, CXCR7, L32 and 18S cDNA products ligated directly into 
pCR2.1 TOPO vector using the TOPO TA cloning kit (Invitrogen). The nucleotide 
sequences of the inserts were verified by automated fluorescent dideoxy dye terminator 
sequencing (Vermont Cancer Center DNA Analysis Facility). To estimate the relative 
expression of the receptor transcripts, 10-fold serial dilutions of stock plasmids were 
prepared as quantitative standards. The range of standard concentrations was determined 
empirically. 
Real-time quantitative PCR was performed using SYBR Green I detection (22, 
38).  Complementary DNA templates, diluted 10-fold to minimize the inhibitory effects 
of the reverse transcription reaction components, were assayed using HotStart-IT SYBR 
Green qPCR Master Mix (USB Corporation, Cleveland, Ohio) containing 5 mM MgCl2, 
0.4 mM dATP, dGTP, dCTP and dTTP, HotStart-IT Taq DNA polymerase and 300 nM 
of each primer in a final 25-ml reaction volume. The real-time quantitative PCR was 
performed on an Applied Biosystems 7500 Fast real-time PCR system (Applied 
Biosystems, Foster City, CA, USA) (22, 38) using the following standard conditions: (i) 
94 ˚C for 2 min; (ii) amplification over 40 cycles at 94 ˚C for 15 s and 58 to 60 ˚C 
depending on primer set for 30 s. 
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The amplified product from these amplification parameters was subjected to 
SYBR Green I melting analysis by ramping the temperature of the reaction samples from 
60 °C to 95 °C. A single DNA melting profile was observed under these dissociation 
assay conditions demonstrating amplification of a single unique product free of primer 
dimers or other anomalous products.   
For data analyses, a standard curve was constructed by amplification of serially 
diluted plasmids containing the target sequence. Data were analyzed at the termination of 
each assay using the Sequence Detection Software version 1.3.1 (Applied Biosystems, 
Norwalk, CT).  In standard assays, default baseline settings were selected. The increase 
in SYBR Green I fluorescence intensity (∆Rn) was plotted as a function of cycle number 
and the threshold cycle was determined by the software as the amplification cycle at 
which the ∆Rn first intersects the established baseline. All data are expressed as the 
relative quantity of the gene of interest normalized to the relative quantity of 
housekeeping gene.  Control samples were set equal to 100%. 
Intravesical Catheter Implant 
A lower midline abdominal incision was performed under general anesthesia with 2-3% 
isoflurane using aseptic techniques (13, 29, 39).  The end of polyethylene tubing (PE-50, 
Clay Adams, Parsippany, NJ) was flared with heat and inserted into the dome of bladder 
and secured in place with a 6-0 nylon purse-string suture (13, 29, 39).  The distal end of 
the tubing was sealed and tunneled subcutaneously to the back of the neck where it was 
externalized, out of the animal’s reach (13, 29, 39).  Rats received buprenorphine (0.05 
mg/kg, s.c.) starting at the time of surgery and then every 8-12 hours postoperatively for a 
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total of 4 doses. Animals were maintained for 72 hours after surgery before conscious 
cystometry was initiated to ensure complete recovery.  
Conscious cystometry with continuous intravesical infusion of saline and CXCR4 
blockade 
The effects of CXCR4 blockade on bladder function in control (no inflammation) and 
CYP-treated rats (48 hours) were evaluated by pharmacological receptor blockade with 
infusion of AMD3100 (5 µM; Sigma Aldrich, St. Louis, MO), known to specifically 
block CXCR4 (26, 44) using conscious cystometry and continuous infusion of 
intravesical saline.  During cystometry, unrestrained and conscious rats were placed in a 
recording cage over a scale and pan in order to collect and measure voided urine.  To 
elicit repetitive bladder contractions, room temperature saline was infused at a constant 
rate (10 ml/hr). At least six reproducible micturition cycles were recorded after an initial 
stabilization period (25 - 30 minutes).  Intravesical pressure changes were recorded using 
a Small Animal Cystometry System (Med Associates, Inc., St. Albans, VT) (13, 38).  
Baseline resting pressure, pressure threshold for voiding, maximal voiding pressure and 
intercontraction interval were measured prior to AMD3100 instillation.  Non-voiding 
bladder contractions (NVCs), defined as rhythmic intravesical pressure increases 7 cm 
H20 above baseline without the release of fluid from the urethra, were also determined 
per voiding cycle. Bladder capacity was measured as the amount of saline infused into 
the bladder at the time when micturition commenced (10, 27).   
 To evaluate the effects of CXCR4 blockade on bladder function, immediately 
following the baseline recordings, rats were anesthetized (1-2% isoflurane) and 
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AMD3100 (5 µM), known to specifically block CXCR4 (25, 41), was intravesically 
infused for 30 minutes.  The concentration selected for evaluation was based upon 
published studies (35).  Prior to intravesical drug infusion, the bladder was manually 
emptied via the Credé maneuver.  Bladders were then infused with approximately 1 ml 
(less than bladder capacity to not elicit a bladder contraction and expulsion of instillate) 
of AMD3100 (5 µM) according to prior published studies (13, 39).  Rats remained 
anesthetized (1-2% isoflurane) to subdue the micturition reflex and prevent expulsion of 
the CXCR4 receptor antagonist from the bladder.  Immediately following drug treatment, 
bladder function testing was repeated.  To avoid potential variation resulting from 
circadian rhythms, experiments were conducted at similar times of the day (17).  At the 
conclusion of the study, rats were euthanized as described above.   To determine if the 
experimental design of the studies (i.e., baseline bladder function recordings, anesthesia 
and intravesical drug instillation, additional bladder function recordings) could affect 
cystometric recordings, additional rats (control, no inflammation and 48 hour CYP-
treated) underwent baseline recordings, anesthesia and intravesical saline instillation and 
additional cystometric analyses.  These studies with identical experimental design and 
intravesical saline instillation revealed no changes in cystometric parameters analyzed 
(data not shown). 
Exclusion Criteria 
Rats were removed from the study when adverse events occurred that included: 20% 
reduction in body weight post surgery, a significant postoperative event, lethargy, pain, or 
distress not relieved by our IACUC-approved regimen of postoperative analgesics or 
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hematuria in control rodents (13, 39). In the present study, no rats were excluded from the 
study or from analysis due to any of these exclusion criteria. In addition, behavioral 
movements such as grooming, standing, walking, and defecation rendered bladder 
pressure recordings during these events unusable.  
 
Materials 
 AMD3100 was purchased from Sigma Aldrich (St. Louis, MO), prepared as 
concentrated stock solutions, aliquoted and stored at -20 oC until usage.  Aliquots were 
diluted with saline to achieve final concentration. 
Figure Preparation  
Digital images were obtained using a charge-coupled device camera (MagnaFire SP, 
Optronics; Optical Analysis) and LG-3 frame grabber attached to an Olympus microscope 
(Optical Analysis, Nashua, NH). Exposure times were held constant when acquiring 
images from control and experimental animals processed and analyzed on the same day. 
Images were imported into Adobe Photoshop 8.0 (Adobe Systems, San Jose, CA) where 
groups of images were assembled and labeled.  
Statistical Analyses  
All values represent mean ± SEM. Data were compared with analysis of variance 
(ANOVA) or repeated measures ANOVA, where appropriate.   When F ratios exceeded 
the critical value (P  0.05), the Newman-Keul’s or Dunnett’s post hoc tests were used to 




CXCL12 Protein Expression in the Rat Urinary Bladder with CYP-Induced Cystitis 
CXCL12 protein expression in the whole urinary bladder increased significantly 
(p ≤ 0.01) after 48 hr (1.8-fold) and chronic CYP treatment (1.9-fold; Fig. 1) as 
determined with ELISAs.  CXCL12 bladder expression with 48 hr CYP treatment did not 
differ from chronic CYP treatment.  No change in CXCL12 urinary bladder expression 
was observed with 4 hr CYP treatment.   
 
CXCL12, CXCR4 and CXCR7 mRNA Expression in the Urinary Bladder of Rats with and 
without CYP-Induced Cystitis 
 Quantitative PCR demonstrated a significant (p ≤ 0.01) increase in CXCL12 
mRNA in both the urothelium and detrusor with 48 hr and chronic CYP treatment but not 
4 hr CYP treatment (Fig. 2A, B).  CXCR4 mRNA was increased significantly (p ≤ 0.05) 
with 48 hr CYP treatment in both the urothelium and detrusor (Fig. 2C, D).  No change in 
CXCR4 mRNA expression was observed at 4 hr or chronic CYP-treatment time points 
(Fig. 2C, D).  CXCR7 increased significantly (p ≤ 0.05) after chronic CYP -treatment in 
both the urothelium and the detrusor (Fig. 3A, B).  No change in CXCR7 mRNA 
expression was observed at the 4 hr or 48 hr CYP-treatment time points (Fig. 3A, B). 
 
CXCL12 and CXCR4 Immunoreactivity (IR) in Urinary Bladder with CYP-induced 
Cystitis 
Urinary bladder sections  Basal CXCL12-IR expression was present in the urothelium in 
all urothelial layers (basal, intermediate and apical), lamina propria and more diffusely in 
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the detrusor in control (no inflammation) urinary bladder (Fig. 4A, C).  When examining 
CXCL12-IR following CYP treatment, we focused on the 48 hr time point because it is 
the earliest CYP treatment where we observed an increase in CXCL12 mRNA and 
protein expression in the whole urinary bladder.  Additionally, neither CXCL12 mRNA 
nor the protein expression levels differed from the chronic CYP treatment time point.  
Following 48 hr CYP-treatment, CXCL12-IR expression was robust in the urothelium 
and lamina propria (Fig. 4B, D).  We focused our analyses of CXCL12 expression in the 
urothelium because expression was most dramatically upregulated in the urothelium with 
CYP-treatment.  Urothelial CXCL12-IR was significantly (p ≤ 0.01) increased (2.4 -fold) 
with 48 hour CYP-treatment (Fig. 5A).   In control (no inflammation) bladders, CXCR4-
IR expression was virtually absent in the lamina propria and detrusor, but basal urothelial 
CXCR4-IR expression was present (Fig. 4E, G). Following 48 hr CYP treatment, 
urothelial CXCR4-IR increased significantly (p ≤ 0.01; 3.5 -fold; Fig. 4F, H; Fig 5B). 
 
Bladder whole mounts  CXCL12- or CXCR4-IR in the suburothelial nerve plexus was 
not observed in control or CYP-treated whole mount bladder preparations.  Multiple 
attempts (n =  6-10) with different species-specific secondary antibodies to visualize 
CXCL12- or CXCR4-IR in the suburothelial plexus were not successful (data not 
shown).  Further, despite PGP immunostaining of the suburothelial nerve plexus, 
colocalization with either CXCL12- or CXCR4-IR was not observed with confocal or 
indirect immunofluorescence techniques (data not shown).  In contrast, whole mount 
preparations exhibited urothelial, lamina propria and detrusor smooth muscle staining for 
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CXCL12 or CXCR4 consistent with staining observed in cryostat bladder sections (data 
not shown).  
 
CXCR4 Blockade with Intravesical Infusion of AMD3100 using Conscious Cystometry in 
Rats with and without CYP-induced cystitis  
Control (no inflammation).  Conscious cystometry was performed in control rats prior to 
drug treatment to establish baseline voiding frequency, bladder capacity and void volume 
(Figs. 6A and 7).  Following intravesical infusion of AMD3100 (5 µM), a CXCR4 
receptor antagonist, the same rats exhibited decreased voiding frequency coupled with an 
increase (1.3-fold) in both bladder capacity, as measured as the amount of saline infused 
into the bladder at the time when micturition commenced (p ≤ 0.01; Figs. 6B and 7), and 
duration of intercontraction interval (ICI; p ≤ 0.01; Figs. 6B and 7), and an increase (1.3-
fold) in void volume (p ≤ 0.05; Figs. 6B and 7).  There were no changes in threshold, 
filling or peak micturition pressures following AMD3100 treatment in control rats (Table 
1). 
CYP treatment.  As previously demonstrated (13, 28, 29, 39), CYP treatment (48 hr) 
increased void frequency and decreased bladder capacity, ICI and void volume (Figs. 8A 
and 9).  Additionally, CYP treatment increased (p ≤ 0.01) filling, threshold and 
micturition pressures (Table 1).  Following intravesical infusion of AMD3100 (5 µM), 
the same rats exhibited decreased voiding frequency and significantly (p ≤ 0.001) 
increased bladder capacity (1.9-fold), as measured as the amount of saline infused into 
the bladder at the time when micturition commenced, ICI (1.9-fold) and increased void 
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volume (2.2-fold; Figs. 8 and 9).  There were no changes in threshold, filling or peak 
micturition pressures following AMD3100 treatment in CYP treated (48 hr) rats (Table 
1). 
Non-voiding contractions (NVCs; increases in baseline pressure with an 
amplitude ≥ 7cm H2O without the expulsion of urine) occurred very infrequently in the 
evaluated rats with CYP treatment before or after intravesical infusion of AMD3100. 






 These studies demonstrate several novel findings with respect to 
chemokine/receptor regulation and function in micturition reflexes under normal or 
inflamed bladder conditions in female rats.  We have previously shown CYP-induced 
changes in urinary bladder expression of the chemokine/ receptor pair: 
CX3CL1/CX3CR1 (78).  In the present studies we demonstrate that a second chemokine 
receptor pair, CXCL12/CXCR4: (1) has low basal expression in the urinary bladder; (2) 
increases in the urinary bladder following CYP-treatment of varying duration; (3) 
exhibits strong expression in the urothelium following CYP-induced cystitis; and (4) 
plays a role in bladder function in both normal (no CYP) and CYP-treated rats.  CXCR4 
blockade at the level of the urinary bladder increased bladder capacity and void volume 
in normal and, to a greater extent, in CYP-treated rats.  To the best of our knowledge, 
these studies are the first to demonstrate roles for chemokine/receptor signaling in 
bladder function.  Therefore, chemokines may represent a novel class of potential 
molecular targets for pharmaceutical intervention with respect to bladder inflammation. 
Interstitial cystitis (IC)/ painful bladder syndrome (PBS) is a chronic bladder 
syndrome with symptoms of urgency, frequency, nocturia and suprapubic and pelvic pain 
(51).  Although the etiology and pathogenesis of IC are unknown, numerous theories 
including infection, autoimmune disorder, toxic urinary components, deficiency in 
bladder wall lining and neurogenic causes have been proposed (18, 30, 32, 50, 51, 55).  
We have hypothesized that pain associated with IC/ PBS involves alteration of visceral 
sensation/ bladder sensory physiology.  Altered visceral sensations from the bladder (i.e. 
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pain at low or moderate bladder filling) that accompany IC/ PBS may be mediated by 
many factors including changes in the properties of peripheral bladder afferent pathways 
such that bladder afferent neurons respond in an exaggerated manner to normally 
innocuous stimuli (allodynia).  These changes may be mediated, in part, by inflammatory 
changes in the urinary bladder. Potential mediators of urinary bladder inflammation are 
numerous:  cytokines (19, 40, 43), neuropeptides (12, 68), neuroactive compounds (11), 
growth factors (70, 76, 82) and chemokines (54, 66, 78).  Increased serum levels of 
chemokines (e.g., CXCL9-CXCL11) in IC/PBS patients have been demonstrated (54).  
Using the CYP-induced bladder inflammation model (16, 37), we aimed to 
characterize further the role of immune mediators, specifically chemokines, in the 
development and/or maintenance of altered bladder sensory physiology associated with 
urinary bladder inflammation.  Chemokines are mediators of the innate immune response 
and assert protective effects by attracting leukocytes to sites of injury and by initiating 
extravasation and developing guiding chemotactic gradients (53, 57).  Recently, 
mediators of the immune response, including chemokines, have received considerable 
attention for their potential role in heightened sensory processing and pain (53, 73).  For 
example, exogenous administration of chemokines induces thermal hyperalgesia and 
mechanical allodynia (46, 49, 65).  Additionally, in a model of neuropathic pain, 
hyperalgesia occurs concomitantly with increased chemokine signaling, through CXCR4 
specifically (6).  In contrast, antagonists to chemokine receptors can reduce nociceptive 
behavior (6, 46) and certain chemokine knockout mice fail to develop somatic sensitivity 
(1).  Recently, Foster et al. (21) showed that hindpaw mechanical hypersensitivity 
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induced by unilateral injections of acidic saline into the pelvic floor muscles of rats can 
be ameliorated by administration of AMD3100.  CYP-induced bladder inflammation in 
mice and rats is associated with increased, referred somatic sensitivity (13, 24, 59).  
Effects of CXCR4 receptor blockade on CYP-induced referred somatic sensitivity were 
not evaluated in this study due to experimental procedures including a laparotomy.  
Studies to assess the contribution of CXCR4 to CYP-induced referred somatic sensitivity 
would however be of interest in the future. Thus, chemokine signaling may contribute to 
altered somatic sensation but roles in bladder sensory physiology have not yet been 
considered. 
 Previous studies demonstrated increased bladder chemokine expression following 
CYP treatment (66, 78).  Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) 
expression were increased in the urothelium with CYP-induced cystitis (48 hour and 
chronic).  Similar to the present studies with CXCL12/CXCR4, fractalkine and 
fractalkine receptor were upregulated in the urothelium with little effect being observed 
in the detrusor smooth muscle (78).  Further, neither CX3CL1/CX3CR1 nor 
CXCL12/CXCR4 was expressed in the suburothelial nerve plexus (78).  Previous studies 
by Vera et al. (66) demonstrated increased CXCR4 expression and altered distribution in 
the urothelium of male, Sprague-Dawley rats treated chronically with CYP.  However, no 
increased expression of CXCL12 was noted in the bladder with CYP treatment (66).  
Further, basal expression of CXCR4 in urothelium of control (no CYP) was greater (66) 
than that observed in the present study.  Differences in CXCR4 and CXCL12 bladder 
expression between the study by Vera et al. (66) and the current study may be due to 
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gender and strain differences in the rats studied and/or CYP dosing differences.  Gender 
differences may be very likely given observations that estrogen regulates 
chemokine/receptor expression (58). The present studies extend previous studies (54, 66, 
78) by demonstrating regulation as well as function of CXCL12/CXCR4 signaling in the 
urinary bladder with urinary bladder inflammation induced by CYP treatment.  Increases 
in CXCL12 and its cognate receptor CXCR4 were observed in the urinary bladder 
following CYP treatment using multiple techniques including qRT-PCR, ELISAs and 
immunostaining.   
 Blockade of CXCR4 with a CXCR4 receptor antagonist, AMD3100, reduced 
CYP-induced bladder hyperreflexia as evidenced by increased bladder capacity and 
decreased voiding frequency.  In these studies, AMD3100 is most likely acting at the 
level of the urothelium for several reasons: (1) both mRNA and histologic analyses 
showed that the greatest expressional increase for both CXCL12 and CXCR4 following 
CYP treatment was in the urothelium; (2) histologically, CXCR4 had a restricted 
presentation being expressed only in the urothelium in both control and CYP treated 
bladders; (3) repeated attempts did not demonstrate CXCL12- or CXCR4-IR in the 
suburothelial nerve plexus.  Furthermore, CXCR4 receptor blockade with AMD3100 also 
significantly increased bladder capacity in control animals (no inflammation) that, 
without CYP treatment, should have an intact urothelium.  The urothelium creates an 
impermeable barrier and has the highest junction potential of any cell type (75).  Thus, 
drug penetration through the urothelium to underlying structures (e.g. suburothelial 
plexus or detrusor smooth muscle) without use of a disrupting agent (e.g. protamine 
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sulfate) is unlikely (15, 39).  Changes in bladder function following AMD3100 treatment 
in control animals should not be surprising as bladders from these animals exhibit basal 
urothelial CXCL12 and CXCR4 expression.  The magnitude of the increase in bladder 
capacity observed in control animals following AMD3100 infusion was less than that 
observed in CYP treated rats following AMD3100 infusion.  The increased magnitude of 
the change elicited with CXCR4 receptor blockade in CYP-treated rats may be due to: (1) 
increased CXCL12 and CXCR4 expression in the urinary bladder following CYP 
treatment and (2) a more prominent role for CXCL12/CXCR4 signaling in bladder 
function during inflammation. 
AMD3100 is a selective CXCR4 antagonist (26, 44) however, potential actions of 
CXCL12 through a second receptor, CXCR7, must also be considered (23).  Balabanian 
et al., (5) showed that CXCL12 also binds CXCR7 in T lymphocytes and that this 
interaction partially mediates chemotaxis.  In this study, we demonstrate using qRT-PCR 
studies that CXCR4 as well as CXCR7 mRNA expression is regulated in the urinary 
bladder following CYP-induced cystitis.  However, the regulation of CXCR7 mRNA 
expression in urinary bladder with CYP treatment differs from that observed for CXCR4.  
CXCR4 mRNA expression is significantly increased in urinary bladder with 48 hr CYP-
treatment.  In contrast, CXCR7 transcripts significantly increase in urinary bladder with 
chronic CYP-treatment but not with 4 hr or 48 hr CYP-treatment.  Effects of AMD3100 
were observed when evaluated in 48 hr CYP treated rats consistent with blockade of 
CXCR4.  Although CXCR7 mRNA expression did not increase with 48 hr CYP 
treatment, basal urinary bladder expression of CXCR7 could be sufficient to contribute to 
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the observed changes in bladder function.  Although AMD3100 is a selective CXCR4 
antagonist (26, 44), AMD3100 can act as a substantially weaker CXCR7 antagonist (42, 
79).  In cultured cell lines, AMD3100 did not significantly affect CXCL12/CXCR7 
interactions at high concentrations although AMD3100 did selectively block binding of 
CXCL12/CXCR4 (42).  Further, a recent study also suggests that AMD3100 is a CXCR7 
ligand with agonist properties when used at high concentrations (100-1000 µM) (36).  
Thus, AMD3100 may have opposite effects on the two receptors, CXCR4 and CXCR7, 
depending on concentrations and context being evaluated (36, 79).  In the current study, 
AMD3100 was used below the concentration ranges documented to result in agonist 
effects mediated through the CXCR7 receptor and it is clear that AMD3100 is more 
effective at blocking binding of CXCL12/CXCR4 (42).  However, studies of the roles of 
CXCL12/CXCR4 and/or CXCL12/CXCR7 in the urinary bladder of control rats and 
those with urinary bladder inflammation are novel, not previously evaluated.  Thus, 
potential effects of CXCR7 receptor blockade cannot be ruled out and it is a possibility 
that the overall changes in bladder function observed with AMD3100 intravesical 
administration represent effects, perhaps opposite (36) or those involving cross-talk (25) 
between CXCR4 and CXCR7.  Future studies using high-affinity and selective CXCR7 
ligands such as CCX771 (79) should be considered when defining the role of CXCR7 in 
bladder function. 
To our knowledge, this is the first time the CXCR4 receptor antagonist, 
AMD3100, has been intravesically infused, thus we needed to determine working 
dilutions empirically. Based on stromal cell adherence experiments, a concentration of 50 
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µM was attempted first in pilot studies (4).  Whereas this concentration (50 µM) of 
AMD3100 induced a similar increase in bladder capacity, an undesirable decrease in 
peak micturition pressure was also observed.  Based on a concentration used in cultured 
epithelial cells (35) we then used 5 µM AMD3100 and observed an increase in bladder 
capacity without changes in pressure; therefore, 5 µM AMD3100 was used throughout 
the experiments in this study.  This dose may not be optimal as there is no literature 
precedent for intravesical instillation of AMD3100.  The effects on bladder function were 
observed in control and CYP-treated rats treated with this AMD3100 dose; the effects 
were only observed on intercontraction interval and bladder capacity - not on bladder 
pressures.  The absence of broad effects on all cystometric parameters suggests 
specificity in AMD3100 action at the dose used in this study.  Lack of effects on 
micturition pressures (i.e., baseline and peak micturition) in control and CYP-treated rats 
also suggests little or no effects on urethral outlet resistance. 
Recently, the functional contribution of the urothelial lining of the urinary bladder 
has advanced beyond the view of the urothelium as a passive barrier to that of an active 
sensor with a potential signaling (i.e. sensory) role especially in the context of urinary 
bladder inflammation (8).  Urothelial cells share a number of similarities with sensory 
neurons and the urothelium has been suggested (2, 8, 9, 61, 62, 63, 64) to have ‘neuronal-
like’ properties.  Urothelial cells express numerous receptors similar to those found in 
dorsal root ganglia (DRG) neurons such as purinergic, norepinephrine, acetylcholine, 
neuropeptide and protease-activated receptors, acid sensing ion channels, neurotrophin 
receptors, and transient receptor potential channels (2, 8, 9, 61, 62, 63, 64).  Therefore it 
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was not surprising to observe CXCL12/CXCR4 expression in the urothelium in control or 
CYP-treated rats given distribution of chemokines and associated receptors in DRG (6, 7, 
33, 34, 49, 52, 60, 65, 67, 74, 80).  The present study adds to the growing list of 
similarities between urothelial cells and sensory neurons.   
In the present studies, we did not observe CXCL12 or CXCR4 immunostaining in 
the suburothelial plexus and this was surprising especially for CXCR4 given the 
numerous reports of CXCR4 expression in DRG cells (6, 7, 48, 49).  Although we did not 
observe CXCL12/CXCR4 immunostaining in the suburothelial nerve plexus in whole 
mounts, urothelial cells (CXCL12 and CXCR4) and detrusor smooth muscle (CXCL12; 
data not shown) did exhibit immunostaining, so technical limitations such as antibody 
penetration do not seem plausible.  Given the expression of CXCL12/CXCR4 in 
urothelial cells and detrusor smooth muscle but not in the suburothelial plexus, the 
mechanism(s) of action of CXCL12 likely excludes direct effects on the suburothelial 
nerve plexus.  Urothelial cells secrete many signaling molecules in response to distention 
and exhibit altered secretion with bladder inflammation (2, 8, 9).  Such signaling 
molecules include: neurotrophins, neuropeptides, adenosine triphosphate (ATP), 
acetylcholine, prostanoids, nitric oxide (NO) and cytokines (2, 8, 9).  Functional receptor 
expression coupled with chemical secretion capabilities enables the urothelium to 
respond to stimuli and reciprocally communicate with detrusor smooth muscle cells, 
suburothelial nerve plexus and/ or interstitial cells (2, 8, 9).  Therefore, it is possible that 
CXCL12 signaling via CXCR4 expression in urothelial cells may activate downstream 
targets that consequently facilitate the release of other mediators.  Urothelial derived 
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mediators such as ATP or NO may then influence the suburothelial nerve plexus to affect 
micturition reflex function (2, 8, 9).  Future studies assessing CXCL12-induced secretion 
of ATP and/or NO in urothelial cells and CXCL12-mediated effects on detrusor 
contractility in the presence and absence of urothelium are logical future directions to 




 These studies demonstrate a functional role for CXCL12/CXCR4 signaling in 
bladder function in normal rats and those with urinary bladder inflammation induced by 
CYP. Chemokines and associated receptors signaling may serve as potential targets for 
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Figure 1:  Time dependent changes in CXCL12 protein expression in whole urinary 
bladder following CYP treatment as determined with ELISAs.  CXCL12 expression 
increased significantly (*, p ≤ 0.01) at 48 hour (hr) and chronic time points compared to 







Figure 2:  Time dependent and regional changes in CXCL12 and CXCR4 mRNA 
expression in urinary bladder as detected by qRT-PCR.  Following 48 hr and chronic 
CYP treatment, CXCL12 mRNA expression was significantly increased in both the 
urothelium (A; **, p ≤ 0.01) and the detrusor (B; **, p ≤ 0.01).  CXCR4 mRNA 
expression was significantly increased after 48 hr CYP treatment in both the urothelium 





         
Figure 3:  Time dependent and regional changes in CXCR7 mRNA expression in urinary 
bladder as detected by qRT-PCR.  CXCR7 mRNA expression increased significantly in 
both the urothelium (A; *, p ≤ 0.05) and the detrusor (B; *, p ≤ 0.05) following chronic 
CYP-treatment but not 4 hr or 48 hr CYP-treatment (n = 5-7 for each group). 
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Figure 4:  Regulation of CXCL12 (A-D) and CXCR4 (E-H) expression in cryostat 
sections of urinary bladder after CYP treatment.  The urothelium was outlined in red and 
images were thresholded (A, B, E and F).  All pixels above threshold are depicted in 
yellow.  Corresponding fluorescence images of CXCL12 expression in control or after 48 
hour (hr) CYP treatment are shown in C and D, respectively.  Fluorescence images of 
CXCR4 expression in urinary bladder of control or after 48 hr CYP treatment are shown 
in G and H, respectively.  (L: lumen; U: urothelium; Sub U; suburothelium).  Calibration 
bar represents 50 µm. 
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Figure 5:  Summary histogram of CXCL12- (A) and CXCR4-IR (B) expression in the 
urothelium of the urinary bladder of control rats and those treated with CYP (48 hr).  






Figure 6:  Representative cystometrogram recordings of effects of CXCR4 receptor 
blockade in control (no inflammation) rats using continuous intravesical infusion of 
saline.  Pre AMD3100 (A) and Post AMD3100 (B) drug treatments in control rats (no 
CYP treatment) with continuous intravesical instillation of saline.  CXCR4 receptor 
blockade with intravesical infusion of AMD3100 (5 µM) increased both bladder capacity 
(as measured as the amount of saline infused into the bladder at the time when 
micturition commenced) and void volume in comparison to pre-treatment conditions (A).  




                     
Figure 7:  Summary histograms of the effects of CXCR4 receptor blockade with 
AMD3100 intravesical infusion in control rats (no CYP treatment).  A: Infusion of 
AMD3100 (5 µM) significantly (**, p ≤ 0.01) increased intercontraction interval.  B: 
Bladder capacity was also significantly (**, p ≤ 0.01) increased along with a significantly 






Figure 8:  Representative cystometrogram recordings of effects of CXCR4 receptor 
blockade in CYP treated (48 hr) rats using continuous intravesical infusion of saline.  Pre 
AMD3100 (A) and Post AMD3100 (B) drug treatments in 48 hr CYP treated rats with 
continuous intravesical instillation of saline.  CXCR4 receptor blockade with intravesical 
infusion of AMD3100 (5 µM) increased both bladder capacity (as measured as the 
amount of saline infused into the bladder at the time when micturition commenced) and 
void volume in comparison to pre-treatment conditions (A). Bladder function recordings 




                  
 
Figure 9:  Summary histograms of effects of CXCR4 receptor blockade with AMD3100 
intravesical infusion in 48 hr CYP treated rats.  A: Infusion of AMD3100 (5 µM) 
significantly (**, p ≤ 0.01) increased intercontraction interval.  B: Bladder capacity was 
also significantly (**, p ≤ 0.01) increased alo ng with a significantly (**, p ≤ 0.01) 




Table 1: Threshold, peak micturition and filling pressures during conscious 




Table 1:   Values presented are mean ± SEM; n = 4-6 in each group. 
No pressure changes were observed within experimental groups (i.e. control pre-AMD 
vs. post-AMD or CYP pre-AMD vs. post-AMD) following AMD3100 (5 µM) 
instillation; however, CYP treatment (48 hr) significantly (*, p ≤ 0.05) increased 
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AKT phosphorylation following peripheral nerve injury or inflammation may 
play a role in somatic pain processes and visceral inflammation.  To examine such a role 
in bladder inflammation and function we induced bladder inflammation in adult female 
Wistar rats (200-300g) by injecting CYP intraperitoneally at acute (150 mg/kg; 4hr), 
intermediate (150 mg/kg; 48 hr) and chronic (75 mg/kg; every third day for 10 days) time 
points.  Western blot analyses of whole urinary bladders showed significant increases (P 
≤ 0.01) of pAKT at all time points; however, the magnitude of pAKT expression varied 
with duration of CYP-treatment.   Immunohistochemical analyses of pAKT-
immunoreactivity (IR) cryostat bladder sections demonstrated duration-dependent, 
significant (p ≤ 0.01) increases in pAKT - IR in both the urothelium and detrusor smooth 
muscle of CYP-inflamed bladders.  Additionally, a suburothelial population of pAKT-IR 
positive macrophages (CD68-positive) was present in chronic CYP-treated bladders.   
The functional role of pAKT in micturition was evaluated using open, conscious 
cystometry with continuous instillation of saline in conjunction with administration two 
different inhibitors of AKT phosphorylation (AKT inhibitor IV, 0.6 µg/10µl and 
Deguelin, 1.0 µg/ 10 µl) or vehicle (1% DMSO in saline) in control (no inflammation) 
and CYP (48 hr)-treated rats.  Bladder capacity, void volume and intercontraction void 
interval increased significantly (P ≤ 0.05) following intravesical instillation of AKT 
Inhibitor IV or Deguelin in CYP (48 h)- treated rats or following instillation of AKT 
Inhibitor IV in control rats. These results suggest pAKT expression in the urinary bladder 
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AKT is a putative cellular survival signal (14).  Recent studies have demonstrated 
novel roles for activated (phosphorylated; p) AKT in the initiation and maintenance of 
neuropathic pain and visceral inflammation (36, 42, 43, 52).  Immunohistochemical 
techniques show AKT activation in pain transducing c-fiber primary afferents and dorsal 
horn neurons following peripheral neuronal injury or tissue inflammation (19, 41, 42, 43, 
52).  In visceral inflammation, pAKT levels increase in the spinal cord dorsal horn 
following TNBS-induced colitis (36).  Chung et al. (12) previously detected increases of 
pAKT levels with cyclophosphamide (CYP)-induced bladder inflammation and 
determined that inflammation-induced elevation of pAKT levels was dependent on the 
presence of NGF, as was increased levels of pERK1/2 and pJNK. 
Expressional and functional studies demonstrate the physiologic roles of NGF and 
associated receptors (TrkA, TrkB and p75NTR) in micturition reflex pathways with and 
without inflammation (11, 15, 29, 32, 37, 40, 51, 53, 56).  For example, direct application 
of NGF to the detrusor smooth muscle, lumen of the bladder, lumbosacral intrathecal 
space or adenovirus-induced NGF expression in the detrusor smooth muscle causes 
bladder hyperreflexia, sensitization of bladder afferents and increases FOS and calcitonin 
gene-related peptide (CGRP) expression in the lumbosacral spinal cord in response to 
bladder distension (11, 15, 29, 53, 56).  Transgenic mice overexpressing NGF under the 
urothelium-specific uroplakin II promoter exhibit hyperinnervation of unmyelinated and 
myelinated sensory nerves and sympathetic nerves in the suburothelial plexus, as well as 
increased urinary bladder reflex activity and referred somatic hypersensitivity in the 
131 
 
pelvic region (40).  Conversely, agents that decrease NGF in the urinary bladder can 
reduce or attenuate chemically-induced bladder hyperreflexia (15, 23).  
AKT, ERK1/2 and JNK are all potential signaling pathways downstream of NGF/ 
receptor signaling in the inflamed urinary bladder with inflammation (12). Corrow and 
Vizzard (13) demonstrated a functional role for pERK in micturition reflexes as treatment 
with an upstream inhibitor of ERK phosphorylation significantly decreased CYP-induced 
bladder hyperreflexia in rats.  This study addresses the contribution of AKT signaling in 
bladder function. 
 Interstitial cystitis (IC)/bladder pain syndrome (BPS) is a chronic urinary bladder 
syndrome of unknown etiology with symptoms of urgency, frequency, nocturia, 
suprapubic and pelvic pain (35).  Bladder biopsies and urine from IC/BPS patients 
express elevated levels of NGF suggesting that neurotrophin-induced changes within the 
bladder and/ or micturition reflex pathways may contribute to IC/BPS symptoms (30, 33).  
These factors combined with the numerous reports implicating AKT signaling in sensory 
pain processes or visceral inflammation (36, 42, 43, 52), especially in the presence of 
NGF (12), suggest that AKT signaling may contribute to bladder dysfunction subsequent 
to NGF receptor activation.  To begin addressing the role of AKT signaling in urinary 
bladder inflammation, we used a CYP-induced model of bladder inflammation and 
determined: 1) pAKT protein expression and regulation in the urinary bladder following 
CYP treatment of varying duration using western blot analyses, immunohistochemistry 
and semiquantitative image analyses and 2) the functional effects of the upstream 
inhibitors of AKT phosphorylation (AKT Inhibitor IV and Deguelin) on bladder function 
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in control (non-inflamed) and CYP-treated female rats using open-void continuous 




Materials and Methods 
 
Animals  
Adult female Wistar rats (200-300 g), purchased from Charles River Canada (St. 
Constant, PQ, Canada), were housed two per cage and maintained in standard laboratory 
conditions with free access to food and water.  The University of Vermont Institutional 
Animal Care and Use Committee approved all animal use procedures (protocol 08-085). 
Animal experimentation was carried out in accordance with the National Institutes of 
Health Guide for the Care and Use of Laboratory Animals. 
Induction of CYP-induced cystitis  
Rats were anesthetized with isoflurane (2%) and received intraperitoneal (i.p.) 
injection(s) of CYP (Sigma Aldrich, St. Louis, MO) to produce urinary bladder 
inflammation.  To induce chronic bladder inflammation, CYP was injected (75 mg/kg; 
i.p.) every third day for 10 days with euthanasia occurring on the tenth day (2, 13, 27).  
To induce acute bladder inflammation, CYP was injected (150 mg/kg; i.p.) with 
euthanasia occurring 4 or 48 h after injection (2, 13, 27).  Control rats received no 
treatment.  For conscious cystometry studies, rats received CYP as described with 
bladder function testing occurring 48 h after injection. 
Western Blotting for pAKT Expression in Whole Urinary Bladder 
 Whole urinary bladders were homogenized separately in tissue protein extraction 
agent (T-PER; Roche, Indianapolis, IN), a mild zwitterionic dialyzable detergent in 25 
mM bicine, 150 mM sodium chloride (pH 7.6) containing a protease inhibitor mix 
(Sigma-Aldrich, St. Louis, MO; 16 µg/ml benzamidine, 2 µg/ml leupeptin, 50 µg/ml lima 
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bean trypsin inhibitor and 2 µg/ml pepstatin A) and aliquots were removed for protein 
assay.  Samples (25 µg) were suspended in sample buffer for fractionation on gels and 
subjected to SDS-PAGE.  Proteins were transferred to nitrocellulose membranes, and 
efficiency of transfer was evaluated.  Membranes were blocked for 1 h in a solution of 
5% milk in Tris-buffered saline with 0.1% Tween for 4 h at room temperature.  
Membranes were incubated in anti-pAKT (1:1,000; 736Ell, Cell Signaling Technology, 
Danvers, MA) in 5% bovine serum albumin in Tris-buffered saline with 0.1% Tween.  
Washed membranes were incubated in a species-specific secondary antibody (1:2,000; 
goat anti-rabbit horseradish peroxidase) in 5% milk in Tris-buffered saline with 0.1% 
Tween for 2 h at room temperature for enhanced chemiluminescence detection (Pierce, 
Rockford, IL).  Blots were exposed to Biomax film (Kodak, Rochester, NY) and 
developed.  The intensity of each band was analyzed, and background intensities were 
subtracted using Un-Scan It software (Silk Scientific, Orem, UT). Western blot analysis 
of AKT (1:1,000; Cell Signaling Technology) in samples was used as a loading control.  
Immunohistochemical localization of pAKT in cryostat bladder sections 
The bladders were rapidly dissected, placed in 4% paraformaldehyde followed by 
overnight incubation in 30% sucrose in 0.1M phosphate buffered-saline (PBS) for 
cryoprotection.  Tissue was frozen in optimal cutting temperature (O.C.T.) compound, 
sectioned (20 µm) on a freezing cryostat and mounted directly onto gelled (0.5%) 
microscope slides (2, 10, 13).  Sections were incubated overnight at room temperature in 
rabbit anti-pAKT (1:500; D9, Cell Signaling Technology) diluted in 1% goat serum and 
0.1 M phosphate buffer.  After overnight incubation, sections were washed (3 x 10 min) 
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with 0.1 M PBS (pH 7.4).  Sections were then incubated with goat anti- rabbit Cy3-
conjugated secondary antibody (1:500; Jackson ImmunoResearch Laboratories, West 
Grove, PA) for 2 h at room temperature followed by washes (3 x 10 min) with PBS and 
coverslipping with antifade medium (Citifluor, Fisher Scientific, Pittsburgh, PA).  
Control tissue sections were incubated with 1% goat serum and 0.1 M phosphate buffer 
alone (no primary antibody), followed by normal washing and incubation with secondary 
antibodies in order to evaluate background staining levels.  In the absence of primary 
antibody, no positive immunostaining was observed.   
 To determine the cellular identity of pAKT-immunoreactive inflammatory cell 
infiltrates, some bladder sections were also immunostained with CD68 (ED1 rat 
homologue; 1:750 AbD Serotec, Raleigh, NC), a marker of macrophages.  Urinary 
bladder sections were incubated in a cocktail of primary antibodies against pAKT and 
CD68 followed by incubation in species-specific secondary antibodies (Cy2 for CD68; 
1:200; Jackson ImmunoResearch Laboratories) and processed as described above.  
Visualization and semi-quantitative analysis of pAKT in urothelium and detrusor smooth 
muscle 
pAKT-immunoreactivity (IR) in bladder sections was visualized and images were 
captured using an Olympus fluorescence photomicroscope (Optical Analysis 
Corporation, Nashua, NH).  The filter was set to an excitation range of 560-569 nm and 
an emission range of 610-655 nm for visualization of Cy3.  Images were captured, 
acquired in tagged image file format (TIFF) and imported into image analysis software 
(Meta Morph, version 4.5r4; University Imaging, Downingtown, PA) (2, 10, 13).  The 
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free hand drawing tool was used to select the urothelium and the urothelium was 
measured in total pixels area (2, 10, 13).  To evaluate staining in the detrusor smooth 
muscle, being careful to avoid non-detrusor structures (e.g., blood vessels, inflammatory 
cells), a rectangle of fixed dimension (125 x 125 pixels) was placed on the section 
according to random x and y coordinates.  This process was repeated 5 times for each 
image without overlap (10, 26).  A threshold encompassing an intensity range of 100-250 
grayscale values was applied to the region of interest in the least brightly stained 
condition first.  The threshold was adjusted for each experimental series using 
concomitantly processed negative controls as a guide for setting background 
fluorescence.  The same threshold was subsequently used for all images.  
Immunoreactivity was considered to be positive only when the staining for pAKT 
exceeded the established threshold.  Percent pAKT-IR above threshold in the total area 
selected was calculated.  For the detrusor smooth muscle, the percent pAKT-IR above 
threshold was calculated by averaging the data collected from all rectangles placed on the 
image (10, 26). 
Assessment of immunohistochemical staining in urinary bladder regions 
Immunohistochemistry and subsequent evaluation of pAKT-IR in bladder 
sections or whole mount preparations were performed on control and experimental 
tissues simultaneously to reduce the incidence of staining variation that can occur 
between tissues processed on different days.  Staining in experimental tissue was 
compared with that in experiment-matched negative controls.  Urinary bladder sections or 
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whole mounts exhibiting immunoreactivity that was greater than background level in 
experiment-matched negative controls were considered positively stained.   
Immunohistochemical localization of pAKT in suburothelial nerve plexus in urinary 
bladder whole mounts 
The urinary bladder was dissected rapidly and placed into oxygenated (95% O2 
and 5% CO2) physiologic saline solution (119.0 mmol NaCl, 4.7 mmol KCl, 24.0 mmol 
NaHCO3, 1.2 mmol KH2PO4, 1.2 mmol MgSO4*7H2O, 11.0 mmol Glucose) (10, 27, 54).  
Starting at the urethra, a midline incision was made through the bladder.  It was then 
pinned flat onto a silicon-coated plate (Sylgard, Dow Corning Corporation, Midland, 
MI), maximally stretched, and then fixed in 2% paraformaldehyde + 0.2% picric acid for 
1.5 h.  After fixation, the urothelium was separated from the detrusor layer using fine-tip 
forceps, iris scissors and a dissecting microscope as previously described (10, 27, 54).  
Notches were made in the region of the bladder neck in order to track orientation and 
assess regional immunoreactivity of the bladder.  Urothelium and bladder musculature 
were processed for pAKT-IR as described previously.  In some whole mounts processed 
for pAKT-IR, nerve fibers in the suburothelial nerve plexus were also stained with the 
pan-neuronal marker protein gene product (PGP9.5, 1: 3000; AbD Serotec, Raleigh, NC) 
to determine potential expression of pAKT in suburothelial nerve fibers and visualized 
with Cy2-conjugated species-specific secondary antibodies (1:200; Jackson 
ImmunoResearch Laboratories).    
Visualization of pAKT-IR in suburothelial plexus in bladder whole mounts  
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Whole mount tissues from control and experimental groups were examined using 
an Olympus fluorescence photomicroscope (Optical Analysis Corporation) with a 
multiband filter set for simultaneous visualization of the Cy3 and Cy2 fluorophores.  Cy2 
was viewed using a filter with an excitation range of 447-501 nm and an emission range 
from 510-540 nm.   
Intravesical Catheter Implant 
A lower midline abdominal incision was performed under general anesthesia with 
2-3% isoflurane using aseptic techniques (2, 9, 23, 26).  The end of polyethylene tubing 
(PE-50, Clay Adams, Parsippany, NJ) was flared with heat, inserted into the dome of the 
bladder and secured in place with a 6-0 nylon purse-string suture (2, 9, 23, 26).  The 
distal end of the tubing was sealed and tunneled subcutaneously to the back of the neck 
where it was externalized, out of the animal’s reach (2, 9, 23, 26).  Rats received 
buprenorphine (0.05 mg/kg, s.c.) starting at the time of surgery and then every 8-12 h 
postoperatively for a total of 4 doses. Animals were maintained for 96 h after surgery 
before conscious cystometry was initiated to ensure complete recovery and absence of 
post-operative analgesics.  
Conscious cystometry with continuous intravesical infusion of saline and inhibition of 
AKT phosphorylation 
The effects of pAKT on bladder function in control (no inflammation) and CYP-
treated rats (48 h) were evaluated with upstream inhibitors of AKT phosphorylation, 
AKT Inhibitor IV (0.6 µg/ 10 µl; EMD4Biosciences, EMD Chemicals, Gibbstown, NJ) 
and Deguelin (1.0 µg/ 10 µl; EMD4Biosciences, EMD Chemicals) using conscious 
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cystometry and continuous infusion of intravesical saline.   During cystometry, 
unrestrained and conscious rats were placed in a recording cage over a scale and pan in 
order to collect and measure voided urine.  To elicit repetitive bladder contractions, room 
temperature saline was infused at a constant rate (10 ml/h). At least six reproducible 
micturition cycles were recorded after an initial stabilization period (15 - 30 min).  
Intravesical pressure changes were recorded using a Small Animal Cystometry System 
(Med Associates, Inc., St. Albans, VT) (2, 9, 13, 26).  Filling pressure, pressure threshold 
for voiding, maximal voiding pressure and intercontraction interval were evaluated.  
Non-voiding bladder contractions (NVCs), defined as rhythmic intravesical pressure 
increases 7 cm H20 above baseline without the release of fluid from the urethra, were also 
determined per voiding cycle.  Bladder capacity was measured as the amount of saline 
infused into the bladder at the time when micturition commenced (7, 22).   
 To evaluate the effects of pAKT on bladder function, rats were anesthetized (1-
2% isoflurane) and vehicle (1% dimethylsulfoxide (DMSO; Sigma-Aldrich, St. Louis, 
MO) in saline) or specific upstream inhibitors of AKT phosphorylation, AKT Inhibitor 
IV (EMD4Biosciences, EMD Chemicals;  0.6 µg/ 10 µl) or Deguelin (EMD4Biosciences, 
EMD Chemicals; 1.0 µg/ 10 µl), was intravesically infused for 30 min.  The 
concentrations of inhibitors selected for evaluation were based upon previous studies (42, 
43, 52).  Prior to intravesical drug infusion, the bladder was manually emptied using the 
Credé maneuver.  Bladders were then infused with approximately 1 ml (less than bladder 
capacity to not elicit a bladder contraction and expulsion of instillate) of vehicle (1% 
dimethylsulfoxide (DMSO; Sigma-Aldrich) in saline), AKT Inhibitor IV 
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(EMD4Biosciences, EMD Chemicals; 0.6 µg/ 10 µl) or Deguelin (EMD4Biosciences, 
EMD Chemicals; 1.0 µg/ 10 µl) according to prior published studies (2, 9, 26).  Rats 
remained anesthetized (1-2% isoflurane) to subdue the micturition reflex and prevent 
expulsion of drug from the bladder.  To avoid potential variation resulting from circadian 
rhythms, experiments were conducted at similar times of the day (16).  At the conclusion 
of the study, rats were euthanized as described above.  Baseline recordings and effects of 
AKT inhibitor IV and Deguelin were evaluated in the same rats. 
Exclusion Criteria 
Rats were removed from the study when adverse events occurred that included: 
20% reduction in body weight post surgery, a significant postoperative event, lethargy, 
pain, or distress not relieved by our IACUC-approved regimen of postoperative 
analgesics or hematuria in control rodents (2, 15, 26). In the present study, no rats were 
excluded from the study or from analysis due to any of these exclusion criteria.  In 
addition, behavioral movements such as grooming, standing, walking, and defecation 
rendered bladder pressure recordings during these events unusable.  
 Materials 
 AKT Inhibitor IV and Deguelin were prepared as concentrated stock solutions in 
DMSO, aliquoted and stored at -20o C until usage.  Aliquots were diluted with saline to 
achieve final concentration. 
Figure Preparation  
Digital images were obtained using a charge-coupled device camera (MagnaFire 
SP, Optronics; Optical Analysis Corporation) and LG-3 frame grabber attached to an 
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Olympus fluorescence photomicroscope (Optical Analysis Corporation).  Exposure times 
were held constant when acquiring images from control and experimental animals 
processed and analyzed on the same day.  Images were imported into a graphics editing 
program (Adobe Photoshop, version 8.0, Adobe Systems, San Jose, CA) where groups of 
images were assembled and labeled.  
Statistical Analyses  
All values represent mean ± S.E.M. Data were compared with analysis of 
variance (ANOVA) or repeated measures ANOVA, where appropriate.   When F ratios 
exceeded the critical value (P  0.05), the Newman-Keul’s or Dunnett’s post hoc tests 





pAKT protein expression and effects of cyclophosphamide (CYP)-induced cystitis in the 
whole rat urinary bladder  
pAKT protein expression increases significantly (P ≤ 0.01) following 4 h (5.7 -
fold), 48 h (3.4-fold) and chronic (2.9-fold) CYP-treatment as determined with western 
blot analyses (Fig. 1). 4 h CYP-treatment induced the greatest upregulation of pAKT 
expression which was significantly (P ≤ 0.01) greater than expression after 48 h (1.7 -
fold) and chronic (2.0-fold) CYP-treatment (Fig. 1). 
pAKT-immunoreactivity (IR) in the urothelium and detrusor after CYP-induced cystitis 
Urothelium.  Patchy, low intensity basal pAKT-IR was present in the urothelium of 
control rat bladders (Fig. 2, A and B).  CYP-treatment increased urothelial pAKT-IR 
significantly (P ≤ 0.01) a t the 48 h (2.3-fold) time point, but not 4 h or chronic time 
points examined (Figs. 2 and 4A).  pAKT-IR at the 48 h time point was also significantly 
(P ≤ 0.01) greater than 4 h (1.5-fold) and chronic (3.6-fold) CYP-treatment (Figs. 2, C-H 
and 4A).  Although 4 h CYP-treatment did not significantly increase pAKT-IR versus 
control, pAKT expression did increase significantly (P ≤ 0.01) in comparison to chronic 
(2.3-fold) CYP-treatment (Figs. 2, C,D,G,H and 4A).  Double-labeling experiments 
demonstrated that the pAKT-immunoreactive suburothelial inflammatory cells present in 
chronic CYP-treated bladders (Fig. 2H) also stained positively for CD68 (ED1 rat 
homologue), a marker of macrophages (data not shown). 
Detrusor.  The expression of pAKT-IR was very low to absent in the detrusor smooth 
muscle of control rat bladders (Fig. 3A).  Forty-eight (48) h CYP-treatment significantly 
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(P ≤ 0.05; 2.5-fold) increased detrusor pAKT-IR (Figs. 3C and 4B).  There was no 
difference between control, 4 h or chronic pAKT-IR expression in the detrusor (Figs. 3 
A, B, D and 4B).  
Bladder whole mounts.  pAKT-IR was not observed in the suburothelial nerve plexus in 
control or CYP-treated whole mount bladder preparations.  The suburothelial nerve 
plexus did exhibit PGP9.5-IR; however, colocalization with pAKT-IR was not observed 
with indirect immunofluorescence techniques (data not shown).  Whole mount 
preparations exhibited urothelial and detrusor smooth muscle pAKT staining consistent 
with staining observed in cryostat bladder sections described above (data not shown). 
Effect of upstream inhibition of AKT phosphorylation on bladder function in rats with 
and without CYP-induced cystitis 
Conscious, open outlet cystometry with continuous intravesical infusion of saline was 
performed in control and CYP-treated (48 h) rats to establish baseline voiding frequency, 
bladder capacity and void volume.  After baseline bladder function was established, AKT 
Inhibitor IV (0.6 µg/ 10 µl), Deguelin (1.0 µg/ 10 µl) or 1% DMSO in saline (vehicle) 
was intravesically instilled for 30 minutes under  2% isoflurane.  The same rats 
subsequently underwent conscious cystometry for a second time to establish the effects of 
inhibiting AKT phosphorylation using AKT Inhibitor IV or Deguelin or vehicle on 
normal bladder function or CYP-induced bladder hyperreflexia.  The 48 h time point of 
CYP-induced cystitis was evaluated using inhibitors of AKT phosphorylation because 
western blot and immunohistochemical techniques both demonstrated significant 
increases in pAKT expression in the urinary bladder with this duration of CYP treatment.  
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Control (no inflammation).  There was no difference between baseline recordings of 
control rats pre AKT inhibitor IV (no treatment), pre Deguelin (no treatment) or pre 
vehicle treatments; therefore, these three groups were combined into one group referred 
to as the pre treatment group.  Treatment with AKT Inhibitor IV, but not Deguelin, 
significantly (P ≤ 0.0 1) increased intercontraction interval (1.4-fold), bladder capacity 
(1.4-fold) and void volume (1.3-fold) in comparison to baseline recordings (no treatment) 
in the same rats (Fig. 5 A-C).  There were no changes in filling, threshold or peak 
micturition pressures following intravesical instillation of AKT Inhibitor IV, Deguelin or 
vehicle (Table 1).  Residual volume in control rats before or after AKT Inhibitor IV or 
Deguelin treatment was minimal (≤ 10 µl).  
CYP treatment. As previously demonstrated (2, 9, 23, 26), and confirmed here, CYP 
treatment (48 h) increased void frequency and decreased bladder capacity, 
intercontraction interval, and void volume (Figs. 6A and 7A).  Additionally, CYP 
treatment increased filling, threshold, and micturition pressures (Table 1).  There was no 
difference between baseline recordings of CYP-treated rats prior to AKT inhibitor IV, 
Deguelin or vehicle treatments; therefore, these three groups were combined into one 
group referred to as the pre treatment group.  Treatment with AKT Inhibitor IV (Figs. 6 
and 8) or Deguelin (Figs. 7 and 8) significantly (P ≤ 0.05) decreased void frequency as 
measured by increased intercontraction interval (1.9-fold, AKT Inhibitor IV; 2.0-fold, 
Deguelin), increased bladder capacity (1.9-fold, AKT Inhibitor IV; 2.0-fold, Deguelin) 
and increased void volume (2.0-fold, AKT Inhibitor IV; 2.2-fold, Deguelin) in 
comparison to baseline recordings (no treatment) for each treatment.  Effects of AKT 
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Inhibitor IV or Deguelin on bladder function in CYP-treated or normal (see above) rats 
persisted for at least for 2 h and recovery to baseline recordings (no treatment) was not 
observed.  Residual volume in CYP (48 h) - treated rats before or after AKT Inhibitor IV 







These studies demonstrate basal activation (phosphorylation) of AKT in the 
urinary bladder, and inflammation-enhanced phosphorylation of AKT with CYP-induced 
cystitis.  To our knowledge, these studies are the first to demonstrate a functional role for 
AKT signaling in female, rat micturition pathways with normal or inflamed urinary 
bladders.  Studies have previously demonstrated changes of AKT activation levels in 
primary sensory neurons, dorsal horn neurons and urinary bladder (12, 36, 42, 43) 
following tissue inflammation.  The present studies complement previous findings and 
demonstrate a functional significance for AKT signaling in bladder reflex pathways.  
pAKT may be a functional mediator of inflammation-induced bladder dysfunction 
because pAKT: 1) is expressed at low levels in the urothelium of control urinary 
bladders; 2) increases in the urinary bladder after CYP treatment of varying duration; 3) 
increases in the urothelium and detrusor with acute CYP treatment; 4) is present in 
suburothelial inflammatory cells with chronic CYP-treatment and, most interestingly; 5) 
inhibition of AKT phosphorylation with two different inhibitors of AKT phosphorylation, 
AKT Inhibitor IV and Deguelin, increases (2.0-fold) bladder capacity in rats with urinary 
bladder inflammation induced by cyclophosphamide treatment.  Therefore, the AKT 
signaling pathway may represent a novel target for pharmaceutical intervention and 
improving bladder function with respect to bladder inflammation. 
 pAKT is classically known as a putative cellular survival signal (14).  More 
recently, studies have demonstrated novel roles for AKT signaling in altered sensory/ 
pain processing.  For example, basal AKT phosphorylation is present in rodent 
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lumbosacral dorsal root ganglia (DRG) (41, 42) and superficial laminae of the spinal cord 
(19, 43) and significantly increases following peripheral nerve injury or inflammation 
(19, 41, 42, 43, 52).  Additionally, colocalization of pAKT with markers of unmyelinated 
pain transducing c-fibers such as IB4, TrkA, CGRP and transient potential vanilloid-1 
channel (TRPV1) (41, 42, 52, 55) has been demonstrated.  Specific inhibitors of AKT 
signaling including AKT Inhibitor IV,  Deguelin, SH-6 or  NL-71-101 can attenuate 
mechanical hyperalgesia resulting from intradermal hind paw capsaicin injection (42, 43) 
or sciatic nerve ligation (52) suggesting a nociceptive role for AKT signaling in 
peripheral inflammation or injury.  
 In addition to mediation of somatic pain processes, PI3-K/ AKT signaling may 
also mediate visceral inflammation.  For example, basal pAKT expression in the 
superficial dorsal horn of lumbosacral spinal cord increases significantly following 
TNBS-induced colitis (36).  Therefore AKT-mediated inflammation in other pelvic 
viscera such as the bladder seems plausible and pAKT has been localized previously to 
the mouse urothelium (48).   
The present studies demonstrate a functional role for pAKT in bladder 
inflammation because pAKT expression not only increases with CYP- treatment in the 
urinary bladder, but also two different upstream inhibitors of AKT phosphorylation, AKT 
Inhibitor IV and Deguelin, independently decreased voiding frequency, and increased 
bladder capacity and void volume following CYP-induced bladder inflammation.  These 
data suggest that PI3-K/ AKT signaling may mediate or contribute to functional aspects 
of IC/BPS, a chronic bladder syndrome with symptoms of urgency, frequency, nocturia, 
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suprapubic and pelvic pain (35).  Although the etiology and pathogenesis of IC/BPS are 
unknown, numerous theories, including infection, autoimmune disorder, toxic urinary 
components, deficiency in bladder wall lining, and neurogenic causes have been 
proposed (17, 24, 25, 34, 35, 39).  We hypothesized that pain associated with IC/BPS 
involves alteration of visceral sensation/bladder sensory physiology.  Altered visceral 
sensations from the bladder (i.e. pain at low or moderate bladder filling) that accompany 
IC/BPS may be mediated by many factors including changes in the properties of 
peripheral bladder afferent pathways such that bladder afferent neurons respond in an 
exaggerated manner to normally innocuous stimuli (allodynia).  These changes may be 
mediated, in part, by inflammatory changes in the urinary bladder.  Potential mediators of 
bladder inflammation are numerous: cytokines (18, 28, 31), neuropeptides (8, 50), 
neuroactive compounds (6), chemokines (2, 38, 49, 54) and growth factors (51, 53, 56) 
and signaling molecules such as pERK1/2 (13) and pAKT (present study; 12).   
Considering urothelial levels of pAKT in inflamed and non-inflamed bladders, 
AKT signaling may contribute to functional bladder sensory physiology via urothelium- 
mediated mechanisms.  The urothelium, once thought to provide an impermeable barrier 
only, is now suggested to have “neuron-like” properties such as plasticity and sensory, 
transducive and signaling capabilities, especially in the context of bladder inflammation 
(1, 3, 4, 5, 44, 45, 46, 47).  Urothelial cells share a number of similarities with sensory 
neurons, including the expression of receptors such as purinergic, norepinephrine, 
acetylcholine, neuropeptide- and protease-activated receptors, acid sensing ion channels, 
neurotrophin receptors and transient receptor potential (TRP) channels (1, 3, 4, 5, 44, 45, 
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46, 47).  Because of functional receptor expression and secretion capabilities, urothelial-
mediated communication with the detrusor smooth muscle, suburothelial plexus and/ or 
interstitial cells has been suggested (1, 4).  Therefore, inflammatory signaling cascades 
may activate AKT signaling and thus facilitate the release of urothelial derived mediators 
such as ATP, NO or chemokines that may then influence the suburothelial nerve plexus 
to affect micturition function via urothelium-to-neuron- communication (1, 2, 3, 4, 5).  
Alone, or in combination with urothelium-mediated mechanisms, pAKT expression in the 
detrusor smooth muscle may contribute to CYP-induced bladder hyperreflexia.  
Alternative roles for the phosphorylation of AKT in detrusor smooth muscle following 
cystitis may involve NGF-induced increases in type I collagen and resultant bladder 
hypertrophy via activation of AKT (12).  Future studies may address NGF-induced 
release of ATP or NO via AKT signaling using cultured rat urothelial cells and 
pharmacological blockade of AKT phosphorylation.  
Potential upstream activators of AKT phosphorylation during inflammation 
include, but are not limited to, growth factors, cytokines and reactive oxygen species.  
NGF is a bladder inflammatory mediator of particular interest because NGF protein 
levels are increased in the urine and urothelium of patients with IC/BPS (30, 33), and 
NGF is an important mediator of both somatic and visceral inflammation.  NGF 
interactions with the high affinity receptor, TrkA, are known to activate the PI3-K/ AKT 
ERK1/2 and JNK signaling pathways.  Chung et al. (12) demonstrate that AKT and 
ERK1/2 phosphorylation in the urinary bladder with CYP-induced bladder inflammation 
is dependent on the presence of NGF suggesting that NGF constitutes a major upstream 
150 
 
activator of AKT phosphorylation in bladder inflammation. Numerous rodent studies 
demonstrate the physiologic relevance of NGF signaling in the urinary bladder (11, 15, 
23, 29, 40, 53, 56).  Previous (13) and present studies now demonstrate that blockade of 
potential downstream NGF-signaling targets, ERK1/2 or AKT activation, reduces urinary 
bladder hyperreflexia following CYP-induced cystitis.  Whether cross-talk exists between 
these two pathways in the context of urinary bladder inflammation (12) or whether 
further improvement in bladder function can be achieved by blocking both AKT and 
ERK1/2 activation remains to be determined. 
     In the absence of CYP-induced bladder inflammation, intravesical instillation 
of AKT Inhibitor IV significantly increased (1.4-fold) bladder capacity in control rats; 
however, Deguelin treatment was without effect.  AKT signaling may not play a major 
role in non-inflamed bladder function.  However, in this study only a single concentration 
of Deguelin was evaluated so potential effects with higher concentrations are not known. 
The concentrations of AKT phosphorylation inhibitors used in this study were the same 
as those used to reduce pain behavior after peripheral nerve injury or inflammation where 
drugs were administered intrathecally (43, 52) or intradermally (42).  Or perhaps AKT 
Inhibitor IV has greater cell permeability enabling the compound to reach deeper layers 
of the urothelium, detrusor smooth muscle or suburothelial plexus.  Although the exact 
mechanism of drug action is not known, AKT Inhibitor IV is thought to attenuate not 
only future phosphorylation of AKT, but is also thought to disrupt phosphorylated forms 
of AKT activated before and during the time of drug treatment (EMD4Biosciences 
website).  Additionally, Sun et al. (42) and Xu et al. (52) suggest that PI3-K/ AKT 
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signaling does not influence basal thermal or mechanical sensitivity prior to peripheral 
inflammatory or mechanical insult.  This is consistent with the present studies where 
more dramatic effects on bladder function were observed in CYP-treated rats following 
intravesical delivery of inhibitors of AKT phosphorylation. 
In the present studies, inhibitors of AKT phosphorylation when used after 
development of urinary bladder inflammation with CYP-treatment were effective in 
improving urinary bladder function (i.e., reduce bladder hyperreflexia).  Several studies 
have also demonstrated that prophylactic treatment with AKT Inhibitor IV prior to 
peripheral injury or inflammation can reduce the subsequent hyperalgesia suggesting a 
role in the initiation of inflammatory pain (43, 52).  To assess the functional contribution 
of PI3K/ AKT signaling in the initiation of CYP-induced bladder hyperreflexia, in pilot 
studies, we intravesically infused AKT Inhibitor IV before intraperitoneal CYP injection 
and development of urinary bladder inflammation.  The effectiveness of AKT Inhibitor 
IV to reduce CYP-induced bladder hyperreflexia (48 h) was highly variable and did not 
reach statistical significance (data not shown).  Possible explanations for differences in 
the effectiveness of AKT Inhibitor IV to reduce pain behavior or bladder hyperreflexia 
prophylactically may include different administration routes (e.g. intrathecal or 
intraplantar vs. intravesical), somatic vs. visceral systems, injury/ inflammation model 
and/or dosing schedule, or differences between the onset of functional testing after injury 
or inflammation.  Sun et al. (43) and Xu et al. (52) also demonstrate that treatment with 
AKT Inhibitor IV after peripheral nerve injury or inflammation can reduce hyperalgesia.  
Our results are consistent with a role for pAKT with pre-existing urinary bladder 
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inflammation and hyperreflexia further demonstrating the functional relevance of 
blocking AKT activation (i.e., phosphorylation).  It remains to be determined whether 
inhibition of AKT phosphorylation following CYP-induced cystitis can also reduce 
referred somatic (i.e., pelvic) pain, which has also been demonstrated to depend upon 
NGF/Trk interactions (20, 21).  Effects of blocking AKT activation on pelvic sensitivity 
can be evaluated in the future using the NGF-OE mouse model that in addition to 
demonstrating urinary bladder hyperreflexia also exhibits increased pelvic sensitivity 
(40).  
Conclusions 
These studies demonstrate basal expression and increased activation of AKT in 
the urinary bladder after CYP-induced cystitis.  Importantly, a functional role for the 
phosphorylation of AKT in bladder function in normal rats and those with urinary 
bladder inflammation induced by CYP has also been demonstrated.  Blockade of AKT 
activation may be an effective target for a pharmacological intervention aimed at 
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Fig. 1.  A: Representative western blot of phosphorylated (p) AKT expression in whole 
urinary bladders (25 µg) from control rats and those treated with cyclophosphamide 
(CYP) for varying duration.  Total AKT expression was used as a loading control.  B: 
Summary histogram of relative pAKT band density in each group normalized to total 
AKT expression in the same samples.  4 h, 48 h and chronic CYP-treatment significantly 
(P ≤ 0.01) increased pAKT expression in comparison to control urinary bladder.  pAKT 
expression was significantly increased following 4 h CYP treatment in comparison to 48 
h and chronic CYP treatment.  (**P ≤ 0.01. n = 4).  Values are mean ± S.E.M. 
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Fig. 2.  pAKT expression in the urothelium of control rats and those treated with 
cyclophosphamide (CYP).  A,C,E,G:  the urothelium was outlined in green and measured 
in total pixels per area.  To define positive staining, a threshold intensity value was 
determined using the darkest image and the same threshold was subsequently applied to 
all images.  All pixels above threshold are depicted in yellow.  B,D,F,H:  Corresponding 
fluorescence images of pAKT expression in control (B) or after  4 h (D), 48 h (F) and 
chronic (H) CYP-treatment.  U, urothelium; SU, suburothelium; L, lumen.  Calibration 









Fig. 3.  pAKT expression in the detrusor smooth muscle of control (A) rats and following 
4h (B), 48h (C) and chronic (D) treatment.  The top and bottom panels in B demonstrate 
the variability of detrusor smooth muscle staining in 4 h CYP-treated rats.  For all 
images, exposure times were held constant and all tissues were processed simultaneously.  




               
Fig. 4.  Summary histogram of pAKT- immunoreactivity (IR) in the urothelium (A) and 
detrusor (B) of the urinary bladder of control and CYP-treated rats.  Percent pAKT-IR 
above threshold in the urothelium following 48 h CYP treatment was significantly (**P ≤ 
0.01) greater than control, 4 h and chronic CYP-treatment (A).  Four (4) h CYP treatment 
significantly increased percent pAKT-IR in the urothelium compared to chronic CYP-
treatment (A).  B: Percent pAKT-IR above threshold in the detrusor smooth muscle was 
significantly (*P ≤ 0.05) greater following 48 h CYP -treatment.  Values are means ± 
S.E.M. (n = 4 in each group).  
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Fig. 5.  Summary histograms of the effects of vehicle, AKT Inhibitor IV and Deguelin 
treatments on intercontraction interval, infused volume and void volume in control (no 
inflammation) rats.  There was no difference between baseline recordings of control rats 
prior to vehicle, AKT Inhibitor IV or Deguelin treatments; therefore, these three groups 
were combined into one group: pre treatment.  Statistical analyses however, were 
performed between pre (no treatment) and post treatments within a drug treatment group.  
Treatment with AKT Inhibitor IV only, significantly (**P ≤ 0.01) increased 
intercontraction interval (A), infused volume (B) and void volume (C) in control (no 
inflammation) rats in comparison to baseline recording prior to AKT Inhibitor IV 




Fig. 6.  Representative cystometrogram recordings of effects of blocking upstream AKT 
phosphorylation with AKT Inhibitor IV in CYP-treated (48 h) rats using continuous 
intravesical infusion of saline in conscious rats with an open outlet.  A, B: Pre AKT 
Inhibitor IV (no treatment) (A) and post AKT Inhibitor IV treatment (B) in 48h CYP-
treated rats with continuous intravesical infusion of saline in conscious rats.  Bladder 
function recordings in A and B are from the same rat.  Arrows (A, bladder pressure 




Fig. 7.  Representative cystometrogram recordings of effects of blocking upstream AKT 
phosphorylation with Deguelin in CYP-treated (48 h) rats using continuous intravesical 
infusion of saline in conscious rats with an open outlet.  A, B:  Pre Deguelin (no 
treatment) (A) and post Deguelin treatment (B) in 48h CYP-treated rats with continuous 
intravesical infusion of saline.  Bladder function recordings in A and B are from the same 
rat.  Arrows (A, bladder pressure trace) indicate non-voiding contractions as defined in 




                        
 
 
Fig. 8.  Summary histograms of the effects of vehicle, AKT Inhibitor IV and Deguelin 
treatments on intercontraction interval, infused volume and void volume in CYP-treated 
(48 h) rats.  There was no difference between baseline recordings of 48 h CYP-treated 
rats prior to vehicle, AKT Inhibitor IV or Deguelin treatments; therefore, these three 
groups were combined into one group: pre treatment. Statistical comparisons however, 
were performed between pre and post treatments within a drug treatment group (e.g.. pre 
vehicle was compared to post vehicle treatment only).  Treatment with AKT Inhibitor IV 
or Deguelin significantly (*P ≤ 0.05) increased intercontraction interval (A) , infused 
volume (B) and void volume (C) in CYP-treated (48 h) rats in comparison to pre AKT 











Table 1.  Filling, threshold and peak micturition pressures during conscious cystometry 
for control and 48h CYP-treated rats prior to and after vehicle (1% DMSO in saline), 
AKT Inhibitor IV or Deguelin treatments.  Values are mean ± S.E.M.; n = 4 in each 
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   Chapter 4: Summary and Future Directions 
 
Peripheral inflammation can induce many changes in the bladder and central 
reflex pathways and is thought to underlie symptoms of various dysfunctional bladder 
syndromes (e.g., IC/ BPS).  These changes are neither fully characterized nor understood.  
Systemic treatment with cyclophosphamide, an anti- neoplastic agent, produces overt 
bladder inflammation characterized by infiltration of inflammatory molecules and the 
presence of hemorrhages on the luminal surface.   Functionally, CYP treatment causes 
intense bladder hyperreflexia and referred somatic pain.  Similarities between bladder 
pathologies and symptoms associated with CYP-induced bladder inflammation suggest 
that it is an appropriate model to test hypotheses related to inflammation-induced 
plasticity potentially affecting bladder dysfunction.  Although no consensus has been 
reached regarding the etiology of IC/BPS, examination of the functional roles of 
inflammatory mediators is valuable because 1) mediators of inflammation such as 
leukocytes, mast cells, interleukins and NGF are elevated in the bladders and/or urine of 
patients with IC/BPS (Erickson et al., 1997; Okragly et al., 1999; Lowe et al., 2007), and 
2) suppression of inflammatory activation improves bladder function and pain symptoms 
in rodents with chemically-induced cystitis and, more importantly, in patients with 
IC/BPS (Ueda et al., 2000; Yoshimura et al., 2002). 
Summary and conclusions: Chemokine signaling in the urinary bladder 
 
This dissertation examines the roles of inflammatory mediators belonging to the 
innate immune system and potential downstream signaling pathways.  Specifically, I 
investigated the role of the chemokine/ receptor pair, CXCL12/CXCR4 and the activated 
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form of the intracellular signaling molecule, AKT.  Chemokines are putative mediators of 
immune/ inflammatory responses, and they are now receiving considerable attention for 
potential roles in visceral inflammation and pain modulation.  Bladders from control 
animals (no inflammation) exhibit basal CXCL12 expression in the urothelium, 
suburothelium and detrusor smooth muscle.  The cognate receptor for CXCL12, CXCR4 
protein expression is detected in the urothelium only.  Consistent with previous 
demonstrations of inflammation-induced chemokine expression, urinary bladders from 
CYP-treated animals demonstrate increased CXCL12 and CXCR4 mRNA and protein 
expression after CYP-induced cystitis.  CXCL12 increases throughout the layers of the 
bladder, but most robustly in the urothelium.  Significant CXCL12 increases were 
detected following 48 h and chronic CYP treatment.  CXCR4 mRNA transcript increased 
following 48h treatment only.  Histologically, CXCR4 expression remains limited to the 
urothelium even after CYP treatment.  Neither CXCL12 nor CXCR4 is detected in the 
suburothelial nerve plexus. 
Future Directions: Chemokine signaling in the urinary bladder 
 
We demonstrated the functional role of chemokine signaling in the urinary 
bladder by combining conscious cystometry with continuous intravesical infusion of 
saline with CXCR4 receptor blockade.  Intravesical infusion of AMD3100, a CXCR4 
receptor antagonist, for 30 minutes increases bladder capacity in control rats and reduces 
CYP-induced bladder hyperreflexia.  Considering that CXCR4 expression is limited to 
the urothelium, and neither CXCL12 nor CXCR4 is detected in the suburothelial plexus, 
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CXCL12/CXCR4 signaling may influence bladder function via urothelial- mediated 
mechanisms.   
In order to fully assess the contribution of urothelial chemokine signaling in 
normal or inflamed micturition, additional studies examining chemokine-mediated 
urothelial release of neuroactive compounds should be performed.  Urothelial cells 
express numerous functional receptors on the cell surface thus enabling the urothelium to 
respond to various stimuli such as distention or toxic urinary components (Birder, 2006; 
Apodaca et al., 2007; Birder and de Groat, 2007).  Additionally, urothelial cells can 
release many different signaling molecules such as ATP, NO, neurotrophins, 
neuropeptides, acetylcholine, prostanoids and cytokines in response various external 
stimuli (Birder et al., 1998; Birder et al., 2003; Birder, 2006; Apodaca et al., 2007; Birder 
and de Groat, 2007).  Functional receptor expression in conjunction with secretion 
capabilities allows the urothelium to respond to stimuli and reciprocally communicate 
with detrusor smooth muscle cells, suburothelial nerve plexus/ or interstitial cells.  As 
such, the urothelium is thought to play a role in normal bladder function, but even more 
so in the presence of bladder inflammation.  Importantly, bladder inflammation can alter 
urothelial secretion and potentially facilitate bladder dysfunction (Birder, 2006; Apodaca 
et al., 2007; Birder and de Groat, 2007).  A change in the amount or type of substances 
released by the urothelium may act to sensitize underlying structures (i.e. bladder 
afferents, interstitial cells or the detrusor smooth muscle).  Therefore, it is possible that 
CXCL12 signaling via CXCR4 expression in urothelial cells may consequently activate 
downstream targets that promote either the transcription or the release of other 
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inflammatory mediators or excitatory amino acids.  Urothelial derived mediators such as 
ATP or NO may then influence the suburothelial nerve plexus to affect micturition reflex 
function.  
 To assess chemokine-induced secretion of urothelial mediators, the next group of 
experiments should explore the ability of CXCL12/receptor interactions to induce 
secretion of chemical mediators such as ATP or NO from urothelial cells.  A urothelial 
cell culture model where the cells could be stretched (in order to mimic distention) would 
best address these questions.  Bioflex plates as part of the Flexcell FX-2000 unit (Flexcell 
International Corporation) are best suited for this purpose (Sun et al., 2001).  In the 
presence of exogenously added CXCL12, we would hypothesize that serum collected 
from stretched urothelial cells would contain elevated levels of one or more mediators 
known to influence micturition function.  Techniques to quantify released mediators 
include ELISA, western blot, luciferan-luciferase assays that measure ATP levels based 
on its catalytic effects during the oxidation reaction of luciferan to oxyluciferase plus 
light (Sun et al., 2001; Birder et al., 2002; Sun and Chai, 2006), and porphyrinic micro 
sensors detecting the oxidation of NO to NO+ to measure NO levels (Birder et al., 2001; 
Birder et al., 2002).  The medium collected from the urothelial cells could then be applied 
to cultured afferent neurons in order to evaluate the ability of neurochemicals in the 
serum to modulate neuronal excitability.  We would hypothesize that neuronal 
excitability, as measured by an increase in membrane potential or action potential 
frequency during intracellular current-clamp experiments (Tompkins et al., 2007), would 
dramatically increase after application of serum from CXCL12-treated urothelial cells.  
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The applied CXCL12 would, of course, be removed from the media prior to application 
of neuronal cultures.  Utilizing immunoprecipitation techniques, an anti-CXCL12 
antibody bound to agarose beads would absorb CXCL12 protein, and following 
centrifugation, agarose bound- CXCL12 will separate from the supernatant that can then 
be applied to neuronal cultures.  To confirm that observed electrophysiological changes 
are due to CXCL12 signaling via the CXCR4 receptor, we would next block CXCR4 
with AMD3100 in cultured urothelial cells prior to CXCL12 application.  Theoretically, 
CXCR4 blockade would decrease CXCL12-induced urothelial release of neurochemicals 
and therefore serum applied to neurons from this instance should elicit a lesser response 
from cultured afferent neurons.   
To assess the effect of CXCL12-mediated urothelial release on detrusor smooth 
muscle contractility, similar experiments could be performed ex vivo on bladder smooth 
muscle strips in place of afferent neurons.  Excitability could be evaluated using 
intracellular recordings to measure membrane potential, action potential frequency and 
amplitude of afterhyperpolarization (Heppner et al., 1997).  Additionally, myogenic 
experiments on bladder smooth muscle strips would support urothelial-mediated affects 
on detrusor contractility.  We would first evaluate the contractility of the bladder in the 
presence of CXCL12 but with the urothelium removed.  These experiments should 
demonstrate the ability, if any, of CXCL12 to influence detrusor contractility directly.  
CXCR4-IR was limited to the urothelium and so we would hypothesize that direct 
CXCL12 action on detrusor contractility does not exist or is very limited.   
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A second CXCL12 receptor, CXCR7, may contribute to direct CXCL12 effects 
on detrusor contractility.  We did not evaluate CXCR7 protein expression in the urinary 
bladder, however quantitative PCR experiments demonstrate that detrusor mRNA 
transcript levels do not increase with 48 h CYP treatment in comparison to bladders from 
control rats.  These data may suggest that CXCR7 does not contribute to CYP-induced 
bladder hyperreflexia observed with 48 h CYP treatment, the time point at which all 
cystometry experiments were conducted.  To demonstrate the essential function of the 
urothelium, this experiment would be repeated with detrusor smooth muscle strips in the 
presence of an intact urothelium.  We would predict that CXCL12 application in the 
presence of the urothelium should enhance the contractility of the smooth muscle due to 
chemokine-induced urothelial release of excitatory neurochemicals.   
Summary and conclusions: pAKT signaling in the urinary bladder 
 
We also investigated the contribution of an activated signaling molecule, 
phosphorylated (p) AKT to micturition under control and inflammatory conditions.  In 
the bladder, pAKT has been shown to play a role in the invasiveness of tumor cells (Wu 
et al., 2004), LPS-induced infection (Tamarkin et al., 2006) and tissue remodeling 
following noxious pressure conditions (Stover and Nagatomi, 2007).  Additionally, 
models of colonic inflammation (Qiao and Grider, 2009) and somatic peripheral injury or 
inflammation demonstrate pAKT involvement (Sun et al., 2006; Sun and Chai, 2006; Sun 
et al., 2007).  We detected patchy, low-intensity basal pAKT expression in the urothelium 
of control bladders.  Urothelial expression increases with 48 h CYP treatment, and this 
effect vanishes with chronic CYP-treatment, however, a suburothelial population of 
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pAKT-positive macrophages emerged at this time point.  Staining of the detrusor smooth 
muscle reveals little to no pAKT expression in control bladders, however pAKT 
expression increases significantly with 48 h CYP treatment. 
  Again, conscious cystometry experiments combined with inhibitory 
pharmacological agents demonstrate the functional capacity of pAKT signaling in normal 
and inflamed micturition.  Two different upstream inhibitors of AKT phosphorylation, 
AKT Inhibitor IV and Deguelin, independently increased bladder capacity, void volume 
and intercontraction interval following 48 h CYP-induced bladder inflammation.  AKT 
Inhibitor IV only increased bladder capacity in control rats.  It is possible that the role of 
AKT signaling in bladder function is less significant in non-inflamed micturition and may 
explain why Inhibitor IV, but not deguelin, affected micturition in control animals.  In 
fact, somatic pain studies suggest that AKT signaling does not influence basal thermal or 
mechanical sensitivity prior to peripheral inflammation or injury (Sun et al., 2007; Xu et 
al., 2007).  The present studies are consistent with previous reports where more dramatic 
effects on bladder function were observed in rats with CYP-induced bladder 
inflammation following intravesical delivery of inhibitors to AKT phosphorylation. 
Future Directions: pAKT signaling in the urinary bladder 
 
Future studies should examine potential downstream targets of AKT signaling.  
NGF signaling is known to activate the PI3-K/ AKT signaling pathway.  In the urinary 
bladder CYP-induced activation of AKT is dependent on NGF expression (Chung et al., 
2010).  In addition, neurotrophic signaling molecules (PI3-K, MAPK, PLC) have been 
implicated in sensitization of TRPV1 in DRG neurons by enhancing calcium ion currents 
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(Bonnington and McNaughten, 2003; Galoyan et al., 2003; Zhu and Oxford, 2007).   
These data were collected from afferent neurons, and although we did not detect any 
phosphorylated AKT in the suburothelial plexus nerve fibers, functional TRPV1 
receptors are present in urothelial cells (Birder et al., 2001).  TRPV1 channels are 
responsible for the majority of the inward cation current following stimulation with 
capsaicin (Caterina et al., 2000).  Capsaicin application to cultured urothelial cells yields 
increasing intracellular calcium ion current and release of NO and ATP thus 
demonstrating functional sensory signaling capabilities of the urothelium via TRPV1 
mediated mechanisms.  Because neurotrophic signaling pathways play a role in TRPV1 
sensitization in afferent neurons, activation of these same pathways in urothelial cells 
may produce similar effects. 
 An interesting next step would be, once again, to utilize a urothelial cell culture 
model to help elucidate a potential role for phosphorylated AKT activation in the 
sensitization of TRPV1-positive urothelial cells.  Since capsaicin induces an intracellular 
calcium current in addition to the release of neurochemicals, we hypothesize that 
pretreatment with inhibitors of AKT phosphorylation would attenuate one or both of 
these effects.  Additional studies employing inhibitors of other neurotrophic signaling 
pathways such as MAPK, JNK and PLC alone, or in combination, could help determine 
any cross-talk or synergistic effects of these pathways on TRPV1 sensitization. 
Final conclusions 
 
The data from my dissertation show that expression of the chemokine/ receptor 
pair CXCL12/CXCR4 and activation of the signaling molecule AKT increase in the 
175 
 
urinary bladder with inflammation, but not in suburothelial plexus nerve fibers.  
Pharmacological blockade of CXCL12/CXCR4 signaling or AKT  phosphorylation at the 
level of the urinary bladder rendered changes in micturition reflex function in both non-
inflamed animals and those with CYP-induced bladder inflammation. Therefore plasticity 
that occurs within bladder tissue itself (i.e. non-neuronal) can influence micturition 
function, and therapeutic agents targeted to the bladder can improve inflammation-
induced bladder hyperreflexia (Figure 1).  Perhaps the strongest support for this concept 
is that intravesical blockade of CXCL12 signaling via the CXCR4 receptor antagonist 
AMD3100 in non-inflamed animals increases bladder capacity.  This should not be 
surprising because basal CXCR4 expression is detected in the urothelium from control 
animals; however, the urothelium has the highest junction potential of any cell type 
recorded (Lewis and Diamond, 1976; Lewis, 2000) and therefore drug penetration 
through an intact urothelium (non-inflamed) is not likely.  Therefore the mechanism of 
AMD3100-mediated increases in bladder capacity likely involves urothelial signaling, 
especially considering the localized presentation of the CXCR4 receptor. 
Although we believe that pharmacological blockade at level of the urinary bladder 
is the primary source of improvements observed in these cystometrogram experiments, a 
role for signaling involved at the afferent level should not be entirely ruled out.  
Immunohistochemical techniques are the most common way to determine neuronal 
expression in whole tissue preparations partially due to a lack of alternative 
methodologies, however antibody staining has a multitude of limitations and results 
should be analyzed with caution. We did not perceive any neuronal expression of the 
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proteins examined in these studies, even when using confocal imaging. This was 
surprising considering the numerous reports of chemokine and pAKT expression in 
sensory afferents (Tanaka et al., 2004; Qin et al., 2005; Bhangoo et al., 2007; Sun et al., 
2007; Jung et al., 2008; Shi et al., 2009).  It is possible that protein levels were too low to 
detect or that CXCL12 was secreted too quickly to be visualized with 
immunohistochemical techniques. Additionally, although the antibodies stained the 
urothelium and detrusor well, antibodies do not always stain different types of tissues 
with the same quality.  Alternative primary antibodies were not used in the bladder whole 
mount preparations.  Furthermore, visualization of CXCL12/CXCR4 or pAKT in the cell 
bodies of the primary afferent neurons was not attempted.  Despite not being located in 
the terminals, somal expression could affect neuronal function. 
It remains to be determined if an oral route of pharmacological blockade would be 
at least as beneficial as intravesical instillation when treating urinary bladder 
inflammation symptoms.  This is especially important when considering IC/BPS in 
humans because the need for repeated intravesical instillations in a physician’s office 
would be inconvenient, stressful and possibly painful.  Additionally, evaluating 
micturition parameters with cystometry is somewhat limiting.  During cystometry, the 
bladder is filling much more rapidly with saline than per physiological urine production, 
and the window of evaluation (1-2 h) does not offer insight to potential long-term 
therapeutic effects lasting days or weeks.  Although we did not observe any wash-out 
effects of the drugs, we do not know how long therapeutic effects might last.  Treatments 
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providing only a few hours of relief to patients living with chronic (lasting months to 
years) urgency, frequency and pain would not be sufficient. 
 Despite limitations, the present studies identify potential therapeutic targets that 
can be exploited, or at least tested to improve bladder function in the presence of 
inflammation.  Key symptoms associated with CYP-induced bladder inflammation in rats 
are similar to those exhibited in patients with IC/ BPS such as bladder hyperreflexia and 
referred somatic pain.  The anatomical origin of IC/ BPS symptoms is unknown and hotly 
debated as some argue that the bladder is the primary effector and yet others contest that 
pelvic floor muscles or other pelvic viscera via cross-sensitization contribute to both 
dysfunctional micturition and referred pain symptoms.  The data from this dissertation 
provide further evidence for the efficacy of bladder targeted therapies to reduce 
inflammatory-induced hyperreflexia.  However, the contribution of CXCL12/CXCR4 or 
AKT to CYP-induced referred somatic hypersensitivity was not assessed.  Future studies 
examining the ability of intravesically infused agents to reduce CYP-induced somatic 
hyperalgesia would provide further evidence to the hypothesis that inflammatory-induced 
plasticity in the bladder itself can contribute to functional symptoms both in and beyond 






Fig. 1.  Suggested areas of chemokine or pAKT action relative to IC/BPS symptoms. 
(1) CYP is metabolized to acrolein causing bladder inflammation 
(2) Chemokine or pAKT signaling increases in the urinary bladder. 
(3) Chemokine or pAKT signaling in the bladder indirectly sensitize primary afferent via 
      bladder mediated release of neurochemicals. 
(4) Intense activity of bladder afferent pathways leads to central synaptic changes  
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The urothelium is a highly effective barrier acting as a constant permeability barrier 
protecting the blood from toxic urinary substances.  However, a large and growing body of 
evidence now supports additional roles for the urothelium, including sensory and 
transduction/signaling roles enabling responses to chemical or mechanical stimuli.  Reciprocal 
communication between urothelial cells with closely located bladder nerves and other cell types 
including detrusor smooth muscle and interstitial cells is likely.  Diseases affecting the urinary 
bladder may affect urothelial receptor/channel expression and release of chemical mediators.  
Urothelial neuropeptide/receptor, chemokine/receptor, and neurotrophin/receptor expression, 
signaling/transduction and modulation in animal models of urinary bladder inflammation and 
human studies of bladder dysfunction are presented.  Substrates underlying micturition reflex 
plasticity induced by urinary bladder disease/dysfunction are likely to include bladder primary 







Introduction:  Micturition Overview and Anatomy of Lower Urinary Tract  
Micturition is regulated by neural circuits in the brain and spinal cord that coordinate the 
activity of the smooth and striated muscles of the lower urinary tract (LUT) [1].  These circuits 
act as on-off switches to shift the urinary tract between two modes of operation: storage and 
elimination.  Bladder smooth muscle and the urethral outlet must function reciprocally for 
efficient elimination of urine [1].  The bladder smooth muscle must remain relaxed during 
storage mode to allow for filling, while the urethral outlet is contracted [1].  Elimination mode 
requires contraction of bladder smooth muscle and relaxation of the urethral outlet to allow urine 
flow 1.  Precise coordination of the reciprocal functions of the urinary bladder and urethra and 
complex neural organization are required for normal function [1].  
The LUT, consisting of the urinary bladder, urethra, internal urethral sphincter and 
external urethral sphincter, is composed of both striated and smooth muscle, and therefore under 
both voluntary (somatic) and involuntary (autonomic) influence [1].  The bladder consists of 
three layers: a urothelium on the lumenal surface, a lamina propria just deep to the urothelium 
that contains a suburothelial plexus of nerves and vasculature, and an outer muscle layer, named 
the detrusor, that contains both longitudinal and circular smooth muscle [1].  The urothelium in 
rodents is composed of at least three layers: the basal, intermediate and superficial/umbrella 
layers.  However, in higher mammals including humans, there are additional intermediate layers 
[2].  The umbrella cells are connected by tight junctions and are covered on their apical surface 




Urothelium:  Much more than a passive protective barrier 
 The urothelium is a highly effective barrier acting as a constant permeability barrier 
protecting the blood from toxic urinary substances.  The barrier function of the urothelium is 
dependent upon several features of the umbrella cell layer including formation of tight junction 
complexes and expression of specialized lipid molecules and uroplakins in the apical membrane 
[2].  The apical surface of the urothelium is also covered by a sulfated polysaccharide, 
glycosaminoglycan layer that is thought to act as an anti-adherence factor and defense 
mechanism against infection [3]. However, a large and growing body of evidence now supports 
additional roles for the urothelium, including sensory and transduction/signaling roles [4].  The 
current and emerging evidence suggests that the bladder urothelium not only acts as a functional 
barrier against urine solutes, but also exhibits specialized sensory and transduction/signaling 
properties enabling responses to chemical or mechanical stimuli [4, 5] (Table 1; Figure 1).  
Reciprocal communication between urothelial cells with closely located bladder nerves and other 
cell types including detrusor smooth muscle and interstitial cells is also a possibility based upon 
the anatomical substrates in place [4, 5] (Table 1; Figure 1).  The terminology of an ‘urothelial-
associated sensory web’ has been used to characterize the sensory inputs and sensory outputs of 
the urothelium that result in receptor- and channel-mediated events at the urothelium and 
subsequent release/secretion of chemical mediators [5] (Table 1; Figure 1). 
“Neuron-Like” Properties of the Urothelium  
 
 Urothelial cells share a number of similarities with sensory neurons located in the dorsal 
root ganglia (DRG) resulting in the suggestion by Birder et al. [6-8] that the urothelium exhibits 
‘neuron-like’ properties.  Urothelial cells express a number of receptors and ion channels similar 
to those found in DRG sensory neurons [6, 9] (Table 1).  The urothelial cells function as 
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transducers of some physical and chemical stimuli, secrete a variety of signaling molecules (e.g., 
neurotrophins, neuropeptides, ATP, acetylcholine, prostaglandins, prostacyclin, NO, cytokines) 
[4, 5] and communicate, perhaps reciprocally, with underlying cells including bladder nerves, 
smooth muscle, interstitial cells and inflammatory cells [10, 11] (Figure 1).  It is this 
communication between urothelial cells and bladder nerves and subsequent input to the central 
nervous system in particular that may contribute to the physiology and pathology of bladder 
function and sensation.  
 As recently reviewed [12], there are several factors that are consistent with the suggestion 
that urothelial cells participate in the detection of physical and chemical stimuli.   
Anatomical proximity of nerve fibers to the urothelium  Recent studies have shown that both 
sensory afferent and autonomic efferent nerves are located in a suburothelial plexus in close 
proximity to the urothelium and extending into the urothelium although sensory afferent nerves 
are much more extensive in this plexus [13] (Figure 1).  Studies have also demonstrated 
adrenergic (tyrosine hydroxylase) and cholinergic (choline acetyltransferase, ChAT) nerves in 
close proximity to the urothelium (for review see [12]).  The suburothelial plexus exhibits 
immunoreactivity for neuropeptides (e.g., CGRP, substance P, CRH), purinergic receptors (P2X-
) and transient receptor potential vanilloid receptor 1 (TRPV1) [14, 15].  Intravesical 
administration of the ultrapotent C-fiber neurotoxin, resiniferatoxin, reduced the density of 
TRPV1 and P2X3 immunoreactive suburothelial nerves in humans with neurogenic detrusor 
overactivity, indicating the sensory origin of these nerve fibers [16, 17].  
Urothelial expression of receptors/ion channels  Urothelial cells express numerous receptors/ion 
channels (Table 1) that are linked to mechanoceptive or nociceptive sensations.  Numerous 
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receptors/ion channels [4, 5] have been identified in the urothelium including, purinergic 
receptors (e.g., P2X1-7 and P2Y1,2,4),  norepinephrine (α and β), acetylcholine (muscarinic and 
nicotinic), protease-activated receptors (PARs), acid sensing ion channels (e.g., ASIC2a, ASIC3) 
[Corrow and Vizzard, unpublished], neurotrophin receptors (p75NTR, TrkA, TrkB) [9, 18], 
corticotropin releasing factor receptors (CRHR1 and CRHR2) [15], TRP channels, [4, 5, 19-21], 
neuropeptide receptors (e.g., PAC1, VPAC2) [22, 23], and chemokine receptors (e.g., CXCR4, 
CX3CR1) [24] (Table 1).  With expression of these receptors/ion channels (Table 1), the 
urothelium can respond to diverse inputs from multiple sources. These inputs include increased 
stretch/distention during the bladder filling phase, soluble factors such as nerve growth factor 
(NGF), neuroactive compounds such as pituitary adenylate cyclase activating polypeptide 
(PACAP), vasoactive intestinal polypeptide (VIP), corticotropin releasing factor (CRH), 
acetylcholine, or norepinephrine released from nerves, inflammatory cells [4, 5, 23-25] or 
chemokines released from inflammatory cells and changes in pH resulting from inflammation 
[26-29]. 
Urothelial secretion of transmitters and mediators  The urothelium secretes a variety of 
signaling molecules (e.g., neurotrophins, neuropeptides, ATP, acetylcholine, prostaglandins, 
prostacyclin, NO, cytokines) [4, 5] (Figure 1) and is able to communicate, perhaps reciprocally, 
with underlying cells including bladder nerves, smooth muscle, interstitial cells and 
inflammatory cells [4, 5] (Figure 1).  Urothelial-derived NO released in response to mechanical 
as well as chemical stimulation can either facilitate or inhibit the activity of bladder afferent 
nerves [4].  Additional studies demonstrate that the urothelium can modulate the spontaneous 
activity of the underlying smooth muscle through release of various soluble factors [10, 11]. 
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Modification of the urothelium with injury or inflammation 
 
Although highly effective in maintaining an effective barrier, there are many ways in 
which the integrity of the urothelium can be compromised including mechanical or chemical 
trauma, changes in tissue pH often associated with infection or inflammation, or bacterial 
infection itself [4].  The clinical syndrome of interstitial cystitis (IC)/painful bladder syndrome 
(PBS) is also associated with a compromise in urothelium integrity that can result in water, urea 
and toxic substances passing into underlying neural and smooth muscle tissue layers [30, 31].  A 
compromised urothelial barrier can produce the symptoms of urgency, frequency and pain during 
the filling and elimination phases of the micturition cycle. 
The Clinical Syndrome: Interstitial Cystitis (IC)/Painful Bladder Syndrome (PBS) 
 
 IC/PBS is a chronic inflammatory bladder disease syndrome characterized by urinary 
frequency, urgency, suprapubic and pelvic pain [32, 33].  Numerous theories including infection, 
autoimmune disorder, toxic urinary agents, deficiency in bladder wall lining, neurogenic causes 
and urothelial dysfunction have each been proposed as the underlying cause(s) of IC/PBS.  Pain 
and altered bladder function in IC/PBS may involve a change in visceral sensation/bladder 
sensory physiology.  Altered bladder sensations [32, 33] may be mediated by changes in 
peripheral bladder afferent and central pathways as well as by changes in urothelial signaling to 
bladder nerves in the suburothelial plexus such that bladder afferent neurons respond in an 
exaggerated manner to normally innocuous stimuli (i.e., allodynia) or exhibit heightened 
responses to noxious stimuli (i.e., hyperalgesia).  
 In the following sections, we will discuss some examples of receptors expressed in the 
urothelium (Table 1), responses upon activation and regulation of receptors and signaling 
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properties in animal models of bladder dysfunction and in human studies of bladder dysfunction 
where appropriate.  Although our focus in this chapter is to address some sensory properties (ion 
channels/receptors) and signaling/transduction properties of the urothelium that have not 
received substantial attention previously, we first describe distension-evoked release of ATP [20] 
from the urothelium as a well-characterized and seminal description of the secretory properties 
of the urothelium and subsequent identification of purinergic receptor expression [34] and 
modulation with bladder dysfunction [19, 35].  Many other sensory and transduction properties 
of the urothelium have been recently reviewed [12].   
Role of receptors/ion channels and secretory products in urothelial function 
Urothelium and purinergic receptor/signaling 
 
From the initial report of ATP release from the urothelium upon stretch [20], it was 
apparent that the urothelium could respond to stimuli and secrete a signaling molecule, ATP 
(Figure 1).  ATP signals via ligand-gated ion purinergic receptors, specifically the P2X family.  
Many sensory neurons terminating in the suburothelial plexus of the bladder as well as urothelial 
cells densely express a member of the P2X family, P2X3 [36].  In response to stretch, urothelial 
cells release ATP, which can then act on P2X3 receptors in bladder sensory neurons.  Altered 
ATP purinergic signaling in the bladder may provide a platform for alterations in sensory 
mechanisms associated with IC/PBS.  Interestingly, urine of IC/PBS patients contains elevated 
levels of ATP.  Further, bladders of IC/PBS patients show enhanced ATP release from urothelial 
cells in response to stretch [35], and increased expression of P2X3 receptors in urothelial cells 
[34] possibly enhancing purinergic signaling.  Increased ATP release from urothelial cells 
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combined with increased density of P2X3 receptors may lead to mechanical hypersensitivity and 
pain.    
Urothelium and neurotrophin/receptor signaling 
 
 A variety of local and distant events can damage the urothelium. Injury accelerates and 
induces both proliferation and differentiation to restore the urothelial barrier. The initiation of 
urothelial proliferation is thought to involve upregulation of growth factors such as nerve growth 
factor (NGF).  NGF belongs to the neurotrophin superfamily, which also includes brain-derived 
neurotrophic factor (BDNF), neurotrophin-3 (NT-3), NT-4/5 and NT-6 [37].  All neurotrophins 
bind with low affinity to a membrane spanning receptor molecule, known as the low-affinity 
NGF receptor (p75NTR), a member of the tumor necrosis factor (TNF-α) receptor family [37].  
The trophic effect of all neurotrophins, including NGF, requires binding to recognition molecules 
of the tyrosine kinase (Trk) family of receptors, activated in response to neurotrophin binding, 
although Trk-independent signal transduction through p75NTR can also occur [37].  The 
urothelium expresses p75NTR, TrkA and TrkB and expression is modulated with bladder 
inflammation induced by cyclophosphamide (CYP) [9, 18] (Figure 1).  Intracellular signaling 
cascades activated by Trk receptors include the Ras/ERK pathway, the phosphatidylinositol-3-
kinase (PI3K)/Akt kinase pathway as well as the phospholipase Ccc (PLCcc) cascade.  Recent 
studies have demonstrated the involvement of the ERK1/2, ERK5 and PI3K/Akt kinase 
pathways in CYP-induced cystitis with blockade reducing urinary bladder hyperreflexia [37] 




Although the exact contribution of NGF to bladder function is not clear, NGF seems to 
play a role in bladder hyperreflexia or bladder overactivity.  NGF upregulation occurs at sites of 
tissue injury and inflammation and changes in NGF levels in urine as well as urinary bladder 
have been documented in humans with IC/PBS and rodents with bladder inflammation [37, 38].  
Clinically, elevated levels of neurotrophins have also been detected in the urine of women with 
IC/PBS [39] as well as in the urothelium of individuals with painful bladder conditions [40].  
More recently, it has been demonstrated that urinary NGF levels are increased in patients with 
overactive bladder (OAB) and urinary incontinence and decreased in patients responding to 
botulinum toxin-A treatment [41, 42].  The role(s) of NGF in micturition reflexes and sensation 
have been evaluated using a variety of addition and subtraction techniques (for review see [37]).  
Neurotrophins, through interactions with Trk and/or p75NTR receptors, may contribute to 
neural plasticity of micturition pathways with bladder inflammation and to bladder dysfunction.  
Intravesical instillation of k252a, a pan Trk inhibitor, in CYP-treated rats reduces bladder 
hyperreflexia [37].  In contrast, recent studies demonstrate bladder hyperreflexia or enhanced 
hyperreflexia in control or CYP-treated rats following intravesical blockade of p75NTR [43].  
Thus, one function of p75NTR and NGF- p75NTR interactions in vivo may be to reduce bladder 
activity or to offset bladder hyperreflexia induced by CYP-induced cystitis [43].  Whereas 
p75NTR expression can enhance TrkA-NGF binding in some systems [37], p75NTR may also 
reduce NGF-TrkA signaling by sequestering NGF [43].  Any decrease or perturbation in NGF/ 
p75NTR binding may tip the homeostatic equilibrium, resulting in increased NGF bioavailability 
to enhance NGF/TrkA signaling.  If NGF/TrkA signaling is favored, increased expression or 
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function of ion channels such as the transient receptor potential (TRP) channels (e.g., TRPV1) 
and neuropeptides may contribute to urinary bladder hyperreflexia.  
 
A transgenic mouse model of chronic NGF overexpression (OE) in the bladder  
To further explore the role of NGF in bladder sensory function, a transgenic mouse 
model of chronic NGF OE in the bladder using the urothelial-specific uroplakin II (UPII) 
promoter was generated [38].  The NGF OE mice were generated at Roche Palo Alto by Dr. 
Debra Cockayne in collaboration with Dr. Henry Sun at New York University Medical School.  
NGF was overexpressed at both the mRNA and protein level in the bladders of these transgenics 
compared to WT littermate controls.  Conscious open voiding cystometry studies demonstrated 
that transgenic mice had a reduced bladder capacity and an increase in the number and amplitude 
of non-voiding bladder contractions under baseline conditions.  These changes in bladder 
function were further associated with an increased referred somatic hypersensitivity in the pelvic 
region. NGF OE mice may provide a novel transgenic model for further exploring the role of 
NGF in urinary bladder dysfunction [38]. 
Urothelium and PACAP/VIP and associated receptors signaling 
 
A number of peptides have been established in the LUT and have demonstrated roles in 
regulating the micturition reflex.  PACAP (pituitary adenylate cyclase activating polypeptide) 
and VIP (vasoactive intestinal polypeptide) are members of the glucagon/secretin superfamily of 
hormones [44].  PACAP and VIP share receptor subtypes coupled to different intracellular 
effectors; PACAP peptides exhibit high affinity for the PAC1 receptor, whereas VIP and PACAP 
have similar high affinities for the VPAC1 and VPAC2 receptors [44].  Both PACAP- and VIP-
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immunoreactivity (IR) have been identified in urinary bladder [22, 45].  Widespread PACAP-IR 
exists in nerve fibers in rat LUT with the majority of the PACAP nerve fibers being derived from 
sensory neurons [45].  PACAP receptors have been identified in various tissues of the 
micturition pathway including bladder detrusor smooth muscle and urothelium (Table 1; Figure 
1).   
PACAP/receptors and micturition   
Recent studies support roles for PACAP in micturition and suggest that inflammation-
induced plasticity in PACAP expression in peripheral and central micturition pathways 
contribute to bladder dysfunction with cystitis. We have previously demonstrated facilitatory 
direct effects of PACAP on bladder smooth muscle contractility [22].  PACAP increased bladder 
smooth muscle tone and potentiated electric field stimulation (EFS)-induced contractions [22].  
EFS-induced contractions were superimposed on spontaneous muscle contractions and were 
tetrodotoxin-insensitive suggesting that the responses were direct detrusor smooth muscle effects 
[22].  In a rat CYP-induced cystitis paradigm, intrathecal or intravesical administration of PAC1 
receptor antagonist, PACAP6-38, reduced cystitis-induced bladder hyperreflexia.   
CYP-induced cystitis  With acute CYP-induced cystitis, PAC1 receptor transcript exhibited a 
significant decrease in expression in both urothelium and detrusor; however, a significant 
increase in PAC1 receptor transcript expression in urothelium and detrusor smooth muscle was 
induced by intermediate and chronic CYP-induced cystitis [23].  PACAP transcript expression 
significantly increased in the urothelium with intermediate (48 hr) and chronic (8 days) CYP 
treatment whereas no changes were observed with acute (4 hr) CYP-induced cystitis in either 




VIP/receptors and micturition   
 
VIP exerts species-specific, excitatory or inhibitory actions in neural pathways controlling 
micturition and these functions may be altered with neural injury, disease or inflammation.  A 
number of diverse and conflicting roles for VIP have been demonstrated in the urinary bladder 
from numerous species. These contradictory findings might be attributable to species differences 
[46] and differential VIP receptor distribution.  Surprisingly, VIP had no apparent effects on 
either bladder tone or EFS-stimulated contractions despite VPAC2 receptor transcript expression 
in detrusor [22]. However, as VIP innervation to the urinary bladder is minimal compared to that 
for PACAP [45], these results may be in keeping with suggestions that PACAP and PAC1 
signaling are more prominent regulators of rat bladder physiology [22]. These VIP results are 
consistent with previous studies that demonstrated that VIP application to detrusor smooth 
muscle had no effect on spontaneous or carbachol-induced bladder contractions despite 
facilitation of micturition when VIP was administered intrathecally or intraarterially close to the 
rat bladder [47].  Recent studies [48] using VIP-/- mice reveal that VIP-/- mice exhibit increased 
bladder mass and fewer but larger urine spots on filter paper. VIP-/- mice display increased void 
volumes and shorter intercontraction intervals with continuous intravesical infusion of saline.  
No differences in transepithelial resistance or water permeability were demonstrated between 
VIP-/- and WT mice.  With the induction of bladder inflammation by acute administration of 
CYP, an exaggerated or prolonged bladder hyperreflexia was demonstrated in VIP-/- mice [48].  
The changes in bladder hyperreflexia may reflect increased expression of neurotrophins and/or or 
proinflammatory cytokines in the urinary bladder.   
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CYP-induced cystitis in rat  No regulation of VIP transcript expression was detected at any 
duration of CYP treatment in urothelium or detrusor [23]. CYP-induced changes in VPAC1 and 
VPAC2 expression were similar in both urothelium and detrusor. Acute and intermediate CYP-
induced cystitis increased VPAC1 and VPAC2 receptor transcript expression in both urothelium 
and detrusor. In contrast, chronic CYP induced cystitis decreased VPAC2 receptor transcript 
expression in both urothelium and detrusor [23].  Thus, these cystitis-induced changes may 
further regulate the neural control of micturition. 
PACAP-mediated ATP release from cultured, rat urothelium  
 
 Earlier studies have indicated that the urothelium releases ATP in response to various 
stimuli [49].  In addition, it has been suggested that ATP released from the serosal surface of the 
urothelium during bladder filling stimulates receptors on suburothelial sensory nerve fibers and 
contributes to bladder filling sensation [36] (Figure 1).  PACAP and VIP application evoked 
ATP release from rat urothelial cell cultures; however, ATP release was greatest with PACAP 
treatment and significantly blocked by the PAC1 receptor selective antagonist, M65 [23].  The 
current data further support the suggestion that PACAP and PAC1 signaling are regulators of 
bladder physiology at the level of the urinary bladder and specifically, the urothelium.  
Urothelium and chemokine/receptor systems signaling 
 
Chemokines, chemotactic cytokines, are a large family of structurally and functionally 
related proteins that are important mediators of the immune response, nociception and 
inflammatory processes.  For example, in a model of chemically induced-bladder inflammation, 
CYP treatment increases the urothelial expression of certain chemokines and their receptors such 
as fractalkine (CX3CL1) and its receptor CX3CR1 [24], and CXCL12 and its receptor CXCR4 
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[26] (Table 1; Figure 1).  Receptor blockade of CXCR4 reduces CYP-induced bladder 
hyperexcitability as demonstrated by significant increases in intercontraction interval, bladder 
capacity and void volume [28].   Additionally, blockade of CXCL10 reduces CYP-induced 
symptoms such as urinary bladder leukocyte infiltration, hyperplasia and epithelial erosions [27]. 
The combined CYP-induced expressional disparity and functional changes following 
signaling blockade indicate that chemokine signaling may play a role in altered sensory 
processing of the urinary tract.  Recent studies suggest that chemokines secreted by their host 
cells may signal in a paracrine fashion by binding to their cognate receptors on neighboring 
sensory neurons and thus facilitating hyperexcitability [50] by changing membrane potentials, 
decreasing thresholds for action potential generation, modulating calcium ion currents and 
increasing excitability and evoking discharges [29, 50].  Alternatively, chemokines may signal in 
an autocrine fashion by binding firstly to their cognate receptors on their host cells (e.g. 
urothelial cells) that then communicate to the nervous system secondly.  In either paradigm, the 
proximity of the urothelial cells to the dense layer of sensory nerve terminals in the suburothelial 
plexus beneath provides a potential mechanism for chemokines produced in the bladder to 
induce functional sensory changes.  
Conclusions 
 
IC/PBS is characterized by suprapubic and pelvic pain, urinary frequency and urgency.  
Although the underlying etiology of IC/PBS is not known, several factors, alone or in 
combination, may contribute to the bladder and sensory dysfunction including neurogenic 
inflammation, autoimmune involvement and urothelial dysfunction.  Given the current evidence 
for sensory and transduction/signaling abilities of the urothelium and the ability of the 
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urothelium to influence adjacent tissues including the suburothelial nerve plexus, myofibroblasts 
and detrusor smooth muscle cells, it is likely that changes in the sensory or barrier functions of 
the urothelium contribute to bladder and sensory dysfunction in bladder diseases including 
IC/PBS.  Given the ability of diverse stimuli to influence urothelial release of chemical 
mediators (e.g., neurotrophins, neuropeptides, ATP, acetylcholine, prostaglandins, prostacyclin, 
NO, cytokines) and for receptor/channel expression and release properties to be altered with 
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Table 1: Sensor and receptor properties of urinary bladder urothelial cells 
 
Table 1  Sensor and receptor properties of urinary bladder urothelial cells 
Sensor stimuli     Urothelial Receptor Expression 
Acetylcholine     Nicotinic and muscarinic receptors 
ATP    Purinergic receptors (P2X, P2Y) 
Bradykinin     B1 and B2 bradykinin receptors 
Capsaicin and resiniferatoxin TRPV1    
Chemokines (e.g., CX3CL1, CXCL12) CX3CR1, CXCR4     
Cold    TRPM8, TRPA1   
Corticotropin releasing factor CRHR1, CRHR2     
H+      TRPV1    
H+ ,  cold       ASIC       
Heat    TRPV1, TRPV2, TRPV4  
Moderate heat, osmolarity   TRPV4       
Nerve growth factor  p75NTR , TrkA   
Norepinephrine     α and β adrenergic receptors 
VIP, PACAP   PAC1, VPAC1, VPAC2  
                
Abbreviations:  ATP, adenosine triphosphate; H+, protons; TRPA, transient receptor potential 
ankyrin-type channel; TRPM, transient receptor potential melastatin-type channel; TRPV, 
transient receptor potential vanilloid-type channel; TrkA, receptor tyrosine kinase A; p75NTR, 
low affinity neurotrophin receptor; CRHR1, corticotropin releasing factor receptor 1; CRHR2, 
corticotropin releasing factor receptor 2; VIP, vasoactive intestinal polypeptide; PACAP, 






Figure 1:  Potential model of possible reciprocal interactions among bladder afferent and 
efferent nerves (not shown), urothelial cells, myofibroblasts located in the suburothelium and 
detrusor smooth muscle that underlie physiological bladder reflex function as well as 
pathophysiology in bladder disease.  Receptor activation and channel stimulation on urothelial 
cells can elicit secretion of chemical mediators that can affect adjacent tissues including bladder 
nerves in the suburothelial plexus, myofibroblasts and detrusor smooth muscle.  Urothelial cells 
can also be responsive to neurotransmitters released from bladder nerves and other cell types 
including inflammatory cells.  Abbreviations: ATP, adenosine triphosphate; TRPs, transient 
receptor potential channels; TrkA, receptor tyrosine kinase A; TrkB, receptor tyrosine kinase B; 
p75NTR, low affinity neurotrophin receptor; CRHR2, corticotropin releasing factor receptor 2; 
ASIC, acid-sensing ion channel; PG, prostaglandin; NO, nitric oxide; NGF, nerve growth factor; 
NP, neuropeptides; Ach, acetylcholine; PAC1, pituitary adenylate cyclase-activating polypeptide 
(PACAP) selective receptor; VPAC2, receptor with equal and high affinity for vasoactive 
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AA   acetic acid 
ATP   adenosine triphosphate 
BOO   bladder outlet obstruction 
CGRP   calcitonin gene-related peptide 
CYP   cyclophosphamide 
DRG   dorsal root ganglia 
DSD   detrusor sphincter dyssynergia 
EFS   electric field stimulation 
hr   hours 
IC   interstitial cystitis 
ICI   intercontraction interval 
IL   interleukin 
IR   immunoreactivity 
LUT   lower urinary tract 
NGF   nerve growth factor 
NK   neurokinin 
NVCs   non-voiding contractions 
OAB   overactive bladder 
PACAP  pituitary adenylate cyclase activating polypeptide 
PBS   painful bladder syndrome 
SCI   spinal cord injury 
SP   substance P 
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VIP   vasoactive intestinal polypeptide 
VV   void volume 







Numerous neuropeptide/receptor systems including vasoactive intestinal 
polypeptide, pituitary adenylate cyclase-activating polypeptide, calcitonin gene-related 
peptide, substance P, neurokinin A, bradykinin, and endothelin-1 are expressed in the 
lower urinary tract (LUT) in both neural and non-neural (e.g., urothelium) components. 
LUT neuropeptide immunoreactivity is present in afferent and autonomic efferent 
neurons innervating the bladder and urethra and in the urothelium of the urinary bladder.   
Neuropeptides have tissue-specific distributions and functions in the LUT and exhibit 
neuroplastic changes in expression and function with LUT dysfunction following neural 
injury, inflammation and disease.  LUT dysfunction with abnormal voiding including 
urinary urgency, increased voiding frequency, nocturia, urinary incontinence and pain 
may reflect a change in the balance of neuropeptides in bladder reflex pathways.  LUT 





substance P, calcitonin gene-related peptide, vasoactive intestinal polypeptide, pituitary 
adenylate cyclase activating polypeptide, nerve growth factor
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19.1  Introduction:  Micturition Overview and Anatomy of Lower Urinary Tract  
Micturition is regulated by neural circuits in the brain and spinal cord that 
coordinate the activity of the smooth and striated muscles of the lower urinary tract 
(LUT) (Fowler et al., 2008).  These circuits act as on-off switches to shift the urinary 
tract between two modes of operation: storage and elimination.  Bladder smooth muscle 
and the urethral outlet must function reciprocally for efficient elimination of urine 
(Fowler et al., 2008).  The bladder smooth muscle must remain relaxed during storage 
mode to allow for filling, while the urethral outlet is contracted (Fowler et al., 2008).  
Elimination mode requires contraction of bladder smooth muscle and relaxation of the 
urethral outlet to allow urine flow (Andersson and Arner, 2004).  Precise coordination of 
the reciprocal functions of the urinary bladder and urethra and complex neural 
organization are required for normal function (Fowler et al., 2008).  
The LUT, consisting of the urinary bladder, urethra, internal urethral sphincter 
and external urethral sphincter, is composed of both striated and smooth muscle, and 
therefore under both voluntary (somatic) and involuntary (autonomic) influence 
(Andersson and Arner, 2004).  The bladder consists of three layers: a urothelium on the 
lumenal surface, a lamina propria just deep to the urothelium that contains a suburothelial 
plexus of nerves and vasculature, and an outer muscle layer, named the detrusor, that 
contains both longitudinal and circular smooth muscle (Andersson and Arner, 2004) (Fig. 
19.1).  The urothelium in rodents is composed of at least three layers: the basal, 
intermediate and superficial/umbrella layers.  However, in higher mammals including 
humans, there are additional intermediate layers (Wu et al., 2009).  The umbrella cells are 
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connected by tight junctions and are covered on their apical surface by crystalline 
proteins, which assemble into hexagonal plaques (for review see (Wu et al., 2009)).  
 
19.1.1 Neural control of micturition 
   The storage and periodic elimination of urine requires a complex neural 
control system that coordinates the activities of a variety of effector organs including the 
smooth muscle of the urinary bladder and the smooth and striated muscle of the urethral 
sphincters (Kuru, 1965; Klück, 1980; de Groat and Steers, 1990; Andersson and Arner, 
2004).  Three neural pathways regulate the LUT:  (1) sacral parasympathetic (pelvic) 
nerves provide excitatory input to the bladder; (2) thoracolumbar sympathetic 
(hypogastric) nerves provide an inhibitory input to the bladder and an excitatory input to 
the bladder neck and urethra; and (3) sacral somatic (pudendal) nerves which innervate 
the striated muscles of the sphincters and pelvic floor (Kuru, 1965; Klück, 1980; de Groat 
and Steers, 1990; Middleton and Keast, 2004).  Each of these sets of nerves contains 
afferent (sensory) as well as efferent (motor) axons (Morrison, 1987; Lincoln and 
Burnstock, 1993).   
   The central neural pathways controlling the LUT exhibit "all-or-none" or "switch-
like" characteristics reflecting the storage and elimination functions of the LUT (de Groat 
et al., 1993; de Groat and Kruse, 1993; de Groat, 1997).  During urine storage, somatic 
and sympathetic pathways to the sphincters and sympathetic inhibitory inputs to the 
bladder are tonically active whereas parasympathetic pathways are inactive (Kuru, 1965; 
de Groat et al., 1993; de Groat and Kruse, 1993; de Groat, 1997).  During reflex or 
voluntary micturition, the activity patterns are reversed such that parasympathetic 
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pathways are excited and somatosympathetic pathways are inhibited thereby promoting 
urine flow (Middleton and Keast, 2004). 
   The LUT reflex mechanisms, organized at the level of the lumbosacral spinal 
cord, are modulated predominantly by supraspinal controls (Kuru, 1965; de Groat, 1975; 
de Groat et al., 1993; de Groat and Kruse, 1993; de Groat, 1997; Middleton and Keast, 
2004). These mechanisms can be summarized as follows:  (1) storage reflexes 
(parasympathetic and somatic) are organized at the spinal level; (2) elimination reflexes 
(parasympathetic) are organized at a supraspinal site in the pons; and (3) spinal storage 
reflexes are modulated by inputs from the rostral pons.  
 
19.1.2 Neurochemistry and morphology of afferent and spinal pathways to the 
urogenital tract 
 Bladder afferent neurons travel in the hypogastric and pelvic nerves, and their cell 
bodies are located in dorsal root ganglia (DRG) at spinal segments T11-L2 and S2-S4 in 
humans and L1-L2 and L6-S1 in rats (Fowler et al., 2008) (Fig. 19.1).  Bladder afferent 
fibers consist of lightly myelinated Aδ fibers and unmyelinated C-fibers.  Sensation of 
bladder filling is conveyed by Aδ fibers, the most important mechanoreceptors of the 
bladder.  C-fibers are normally “silent”, but they do respond to chemical or noxious 
stimuli, including extreme bladder pressure (Fowler et al., 2008).  Aδ and C-fibers 
terminate in the urothelium, suburothelium, and smooth muscle layers of the bladder 
(Kullmann et al., 2008).  Most bladder afferent fibers project to lumbosacral spinal cord 
segments, and this is the most important region of the spinal cord relative to signaling the 
micturition reflex (Holstege, 2005) (Fig. 19.1).  Most sensory nerves in the bladder are 
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located in a dense suburothelial plexus just beneath the urothelium (Andersson and Wein, 
2004) (Fig. 19.1).   
Bladder afferent fibers in the pelvic nerve in rodents pass through the dorsal roots 
into Lissauer’s tract at the apex of the dorsal horn and then give off collateral branches 
that extend ventromedially and ventrolaterally along the superficial layers of the dorsal 
horn to the dorsal commissure and to the area of the sacral parasympathetic nucleus 
(laminae V-VII) that contains preganglionic parasympathetic neurons that project to the 
periphery (de Groat et al., 1981; Donovan et al., 1983; de Groat et al., 1986; Steers et al., 
1991a; de Groat and Kruse, 1993; de Groat et al., 1994; Nadelhaft and Vera, 1995; de 
Groat, 1997; Marson, 1997).  The most prominent pathway is located in lamina I on the 
lateral edge of the dorsal horn in a region termed the lateral collateral pathway of 
Lissauer’s tract. Afferent projections from the pudendal nerve and genital structures 
follow the medial edge of the dorsal horn into the dorsal commissure region, forming the 
medial collateral pathway (Kawatani et al., 1990).  Bladder afferent fibers contain a 
variety of neuropeptides, including: calcitonin-gene related peptide (CGRP), substance P 
(SP), neurokinin A, neurokinin B, vasoactive intestinal polypeptide (VIP), 
cholecystokinin and enkephalins (Donovan et al., 1983; de Groat et al., 1986; Keast, 
1991; de Groat et al., 1996; Vizzard, 2000d; Vizzard, 2001) (Fig. 19.1).  We have 
demonstrated (Vizzard, 2000d) that bladder afferent cells express pituitary adenylate 
cyclase-activating polypeptide (PACAP) and that expression is increased after 
cyclophosphamide (CYP)-induced cystitis in rats.  With the exception of CGRP, all of 
these substances are predominantly expressed in small (presumably C-fiber) afferents (Ek 
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et al., 1977; Donovan et al., 1983; de Groat et al., 1986; Su et al., 1986; Keast and de 
Groat, 1992; Vizzard et al., 1993a; Vizzard et al., 1993b; Vizzard et al., 1994; Vizzard et 
al., 1995; de Groat et al., 1996; Vizzard and de Groat, 1996). The administration of 
capsaicin, which acts selectively on small diameter afferent fibers to deplete 
neurotransmitter stores to induce neuronal degeneration, reduces the levels of substance 
P, neurokinin A and CGRP within the pelvic viscera but does not affect VIP or 
enkephalin expression (de Groat, 1987).  These findings are consistent with SP, related 
tachykinins and CGRP expression in afferent pathways to the pelvic viscera (de Groat, 
1987). 
Many bladder afferent fibers project to the sacral parasympathetic nucleus, 
synapsing with preganglionic parasympathetic neurons as well as interneurons (Morgan 
et al., 1981; Fowler et al., 2008).  Primary bladder afferents from the pelvic and 
hypogastric nerves also project to the dorsal commissure and superficial dorsal horn 
(Fowler et al., 2008).  The lumbosacral dorsal commissure, superficial dorsal horn, and 
parasympathetic nucleus all contain interneurons important to urinary bladder function 
(de Groat and Kruse, 1993; Fowler et al., 2008).  These interneurons project locally in the 
spinal cord or to the brain (Fowler et al., 2008).  Some bladder afferents synapse with 
ascending pathways in the spinal cord that project to neuronal populations in the brain 
involved in micturition control, including the pontine micturition center (de Groat and 




19.1.3 Neurochemical plasticity in the LUT with bladder inflammation, neural 
injury or disease 
  Neuroactive compounds, including neuropeptides, in the afferent 
pathways to the LUT exhibit either excitatory or inhibitory actions.  Non-neural sources 
of peptides in the LUT include plasma, sites of tissue inflammation or injury, detrusor 
smooth muscle cells, bladder fibroblasts and the urothelium.   Pathology, neural injury 
and target organ pathology (e.g., bladder inflammation) can alter the known balance of 
neuropeptides either in the periphery and/or central pathways conceivably shifting the 
balance to a hyper- or hypo-active reflex state.  Changes in micturition reflex function 
observed with urinary bladder inflammation (Vizzard, 2000d; Vizzard, 2000b; Vizzard, 
2001), interstitial cystitis (IC)/painful bladder syndrome (PBS), spinal cord injury (upper 
motoneuron injury) (Vizzard, 2006; de Groat and Yoshimura, 2009), overactive bladder 
(OAB) (Yoshimura et al., 2008), and detrusor overactivity secondary to bladder outlet 
obstruction (BOO) (Andersson, 1999; 2006) may reflect a change in the balance of 
neuropeptides in LUT reflex pathways.  Information presented in this review will address 
both direct and indirect effects of neuropeptides in the LUT.  Due to 
neuropeptide/receptor expression and diversity of functions in the LUT and subsequent 
regulation with neural injury, disease, and bladder inflammation, neuropeptide/receptor 
systems may be potential targets for therapeutic intervention (Fig. 19.1).   
 
 The following sections will address the distribution, function and regulation of 





19.2 PACAP/VIP and associated receptors signaling in the LUT 
 
A number of peptides have been demonstrated in the LUT and have demonstrated 
roles in regulating the micturition reflex. PACAP and VIP are members of the 
glucagon/secretin superfamily of hormones (Dickinson et al., 1999).  PACAP and VIP 
share receptor subtypes coupled to different intracellular effectors; PACAP peptides 
exhibit high affinity for the PAC1 receptor, whereas VIP and PACAP have similar high 
affinities for the VPAC1 and VPAC2 receptors (Arimura, 1998; Sherwood et al., 2000).  
Both PACAP- and VIP-immunoreactivity (IR) have been identified in urinary bladder 
(Fahrenkrug and Hannibal, 1998; Mohammed et al., 2002). Widespread PACAP-IR 
exists in nerve fibers in rat LUT with the majority of the PACAP nerve fibers being 
derived from sensory neurons (Fahrenkrug and Hannibal, 1998; Zvarova et al., 2005).  
PACAP receptors have been identified in various tissues of the micturition pathway 
including bladder detrusor smooth muscle, urothelium and major pelvic ganglia (Table 
19.1)(Braas et al., 2006; Tompkins et al., 2010).   
 
19.2.1 PACAP/receptors in micturition reflex pathways   
 Recent studies support roles for PACAP in micturition and suggest that 
inflammation-induced plasticity in PACAP expression in peripheral and central 
micturition pathways contribute to bladder dysfunction with cystitis. We have previously 
demonstrated facilitatory direct effects of PACAP on bladder smooth muscle contractility 
(Braas et al., 2006).  PACAP increased bladder smooth muscle tone and potentiated 
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electric field stimulation (EFS)-induced contractions (Braas et al., 2006).  EFS-induced 
contractions were superimposed on spontaneous muscle contractions and were 
tetrodotoxin-insensitive suggesting that the responses were direct detrusor smooth muscle 
effects (Braas et al., 2006).  Excitatory effects of PACAP on the micturition reflex 
pathway are enhanced 2-4 weeks after spinal cord injury in the rat (Yoshiyama and de 
Groat, 1997).  
 
19.2.2 PACAP expression in bladder afferent pathways and regulation by CYP-
induced cystitis   
 PACAP is expressed in LUT pathways and is regulated by CYP-induced cystitis 
(Vizzard, 2000d; Braas et al., 2006).  In control rats, PACAP-IR was expressed in fibers 
in the superficial dorsal horn at all segmental levels examined (L1, L2, and L4 –S1).  
Bladder afferent cells (40–45%) in the dorsal root ganglia (DRG; L1, L2, L6, and S1) 
from control animals also exhibited PACAP-IR (Vizzard, 2000d).  After chronic, CYP-
induced cystitis, PACAP-IR increased dramatically in spinal segments and DRG (L1, L2, 
L6, and S1) involved in micturition reflexes (Vizzard, 2000d).  The density of PACAP-IR 
was increased in the superficial laminae (I–II) of the L1, L2, L6, and S1 spinal segments 
(Vizzard, 2000d). Staining also increased dramatically in a fiber bundle extending 
ventrally from Lissauer’s tract in lamina I along the lateral edge of the dorsal horn to the 
sacral parasympathetic nucleus in the L6 –S1 spinal segments (lateral collateral pathway 
of Lissauer). After chronic cystitis, PACAP-IR in cells in the L1, L2, L6, and S1 DRG 
increased significantly, and the percentage of bladder afferent cells expressing PACAP-




19.2.3 PACAP/VIP receptor expression in LUT and modulation with cystitis 
19.2.3.1 Urinary bladder 
 With acute CYP-induced cystitis, PAC1 receptor transcript exhibited a significant 
decrease in expression in both urothelium and detrusor; however, a significant increase in 
PAC1 receptor transcript expression in urothelium and detrusor smooth muscle was 
induced by intermediate and chronic CYP-induced cystitis (Girard et al., 2008).  
19.2.3.2 Lumbosacral dorsal root ganglia (DRG) 
 CYP-induced inflammation of the urinary bladder only affected receptor transcript 
expression in L6-S1 DRG following acute (4 hr) CYP-induced cystitis.  PAC1 and 
VPAC2 receptor transcript expression significantly decreased in both L6 and S1 DRG 
with acute (4 hr) CYP-induced cystitis.  For VPAC1 receptor transcript expression, a 
significant increase in expression was demonstrated in the S1 DRG after acute CYP-
induced cystitis.  No changes in PAC1, VPAC1 or VPAC2 receptor expression in L6 or S1 
DRG were demonstrated with intermediate (48 hr) or chronic (8 day) CYP-induced 
cystitis.  PACAP transcript expression significantly increased in the urothelium with 
intermediate (48 hr) and chronic (8 days) CYP treatment whereas no changes were 
observed with acute (4 hr) CYP-induced cystitis in either urothelium or detrusor smooth 
muscle (Girard et al., 2008). Changes in PACAP transcript with CYP-induced cystitis 
mirrored those observed in the urinary bladder with acute CYP-induced cystitis 
decreasing and intermediate (48 hr) and chronic (8 day) treatments significantly 
increasing PACAP transcript expression in both the L6 and S1 DRG (Girard et al., 2008).  
In a rat CYP-induced cystitis paradigm, intrathecal or intravesical administration of PAC1 
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receptor antagonist, PACAP6-38, reduced cystitis-induced bladder hyperreflexia (Braas 
et al., 2006).  These studies demonstrate that PACAP/receptor are modulated by CYP-
induced cystitis in tissue-specific ways and that PACAP/receptor signaling plays a role in 
urinary bladder afferent pathways after urinary bladder inflammation 
 
19.2.4 PACAP in micturition reflexes and modulation after spinal cord injury (SCI) 
 SCI rostral to the lumbosacral spinal cord alters the coordination between the urinary 
bladder and external urethral sphincter in many species and results in detrusor sphincter 
dyssynergia (DSD) that interferes with efficient voiding and results in urinary retention, 
bladder hypertrophy, increased voiding pressures, increased bladder capacity, and 
numerous non-voiding contractions (NVCs) during bladder filling (Vizzard, 2006). 
PACAP is upregulated in micturition reflex pathways after SCI. These studies (Zvara et 
al., 2006) demonstrate that intrathecal (L6-S1) administration of the PAC1 receptor 
antagonist, PACAP6-38 (10 nM), significantly reduced intermicturition interval, 
threshold and micturition pressures, and number and amplitude of NVCs after SCI (Zvara 
et al., 2006). In addition, PACAP6-38 increased voiding frequency (i.e., decreased 
bladder capacity) after SCI (Zvara et al., 2006). In contrast, intravesical administration of 
PACAP6-38 was without any effect, possibly due to lack of penetration of the PAC1 
antagonist through the urothelium. The presence of PAC1 receptor transcript in the 
lumbosacral spinal cord and DRG has been demonstrated (Girard et al., 2008). Thus, 
intrathecal administration of PACAP6-38 may act at the lumbosacral spinal cord or DRG. 
The effects of PACAP6-38 after SCI are consistent with PACAP-27 facilitation of 
micturition in rats (Ishizuka et al., 1995a).   PACAP6-38 reduced the number and 
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amplitude of NVCs after SCI (Zvara et al., 2006). This may be attributed to a reduction in 
DSD or through an effect on C-fiber bladder afferents (Cheng et al., 1995). An effect of 
PACAP6-38 on urinary bladder C-fiber afferents is consistent with previous studies that 
demonstrate that capsaicin depletes PACAP-IR in the LUT (Fahrenkrug and Hannibal, 
1998) and that PACAP-IR nerve fibers in the bladder express the vanilloid receptor 
(Zvarova et al., 2005).  PACAP expression is upregulated in micturition pathways after 
SCI and the present studies demonstrated improved bladder function after intrathecal 
PACAP antagonist administration.  Additional studies addressing the role of PACAP in 
micturition reflexes suggest that after SCI, PACAP-38 activates spinal circuitry to 
facilitate the parasympathetic outflow to the urinary bladder and that the elimination of 
sympathetic pathways enhances this effect (Yoshiyama and de Groat, 2008a; 2008b). 
 
19.2.5 PACAP and VIP expression and effects on major pelvic ganglion (MPG) 
neurons 
 Tissue culture experiments modeling neuronal injury have shown PACAP 
expression regulation in the MPG, the ganglia supplying the majority of autonomic (both 
sympathetic and parasympathetic) innervation to the bladder, other urogenital organs and 
components of the lower bowl.  While PACAP expression was devoid in acute (4 hour 
(hr) cultures (Tompkins et al., 2010), both PACAP-IR and PACAP transcript levels 
increased significantly by day 3 (Girard et al., 2010a).  PACAP was preferentially 
expressed in parasympathetic neurons (Girard et al., 2010a).  Transcripts for VPAC1, 
VPAC2 and PAC1 were present by 4 hr culture (Tompkins et al., 2010), but only VPAC2 
transcript levels increased by day 3 (Girard et al., 2010a).  Local application of PACAP 
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or maxadilan, a PAC1-selective agonist, decreased after hyperpolarization and increased 
neuronal excitability in a subpopulation of neurons (Tompkins et al., 2010).  Therefore, 
PACAP receptor signaling in the MPG may represent another mechanism for 
neuropeptide-modulated bladder function.  Additionally, we have demonstrated VIP 
expression in the MPG, and local application of VIP results in a decreased after 
hyperpolarization and increased neuronal excitability in a subpopulation of neurons 
(Tompkins et al., 2010).  However, VIP expression did not increase with prolonged 
culture (3 days) (Girard et al., 2010a).   
 
19.2.6 PACAP null mice exhibit altered bladder function and somatic sensitivity 
PACAP contributions to micturition and somatic sensation were recently studied 
in PACAP knockout (PACAP-/-), littermate heterozygote (PACAP+/-) and wildtype (WT) 
mice using conscious cystometry with continuous intravesical saline or acetic acid (AA; 
0.5%) instillation, urination patterns, somatic sensitivity testing of hindpaw and pelvic 
region with calibrated von Frey filaments and morphological assessments of urinary 
bladder (May and Vizzard, 2010).  PACAP-/- mice exhibit increased bladder mass with 
fewer but larger urine spots (Fig. 19.2).  In PACAP-/- mice, the lamina propria and 
detrusor smooth muscle are significantly thicker whereas the urothelium is unchanged 
(Fig. 19.2).  PACAP-/- mice exhibit increased bladder capacity, void volume (VV) and 
longer intercontraction interval (ICI) with significantly increased detrusor contraction 
duration and large residual volume (May and Vizzard, 2010) (Fig. 19.2).  WT mice 
respond to AA (0.5%) with a reduction in VV and a decreased ICI whereas PACAP+/- and 
PACAP-/- mice do not respond.  PACAP-/- mice are less responsive to somatic 
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stimulation.  PACAP+/- also exhibit bladder dysfunction and somatic and visceral sensory 
abnormalities but to a lesser degree (May and Vizzard, 2010).  PACAP gene disruption 
contributes to changes in bladder morphology, bladder function and somatic and visceral 
hypoalgesia (May and Vizzard, 2010). 
 
19.2.7 VIP/receptors and micturition reflex pathways  
VIP exerts, species-specific, excitatory or inhibitory actions in neural pathways 
controlling micturition and these functions may be altered with neural injury, disease or 
inflammation (Erol et al., 1992; Igawa et al., 1993; Uckert et al., 2002; Hernandez et al., 
2006). A number of diverse and conflicting roles for VIP have been demonstrated in the 
urinary bladder from numerous species.  VIP has been shown to relax urinary bladder 
from human (Uckert et al., 2002) or pig (Hernandez et al., 2006), and contract or produce 
no effects on urinary bladder from the rat (Erol et al., 1992; Igawa et al., 1993).  These 
contradictory findings might be attributable to species differences (Uckert et al., 2002) 
and differential VIP receptor distribution (Table 19.1).  The majority of VIP in the LUT 
is located in postganglionic efferent neurons of the pelvic ganglia (Chapple et al., 1992; 
Smet et al., 1997; Wanigasekara et al., 2003).  Surprisingly, VIP had no apparent effects 
on either bladder tone or EFS-stimulated contractions despite VPAC2 receptor transcript 
expression in detrusor (Braas et al., 2006). However, as VIP innervation to the urinary 
bladder is minimal compared to that for PACAP (Fahrenkrug and Hannibal, 1998), these 
results may be in keeping with suggestions that PACAP and PAC1 signaling are more 
prominent regulators of rat bladder physiology (Braas et al., 2006). These VIP results are 
consistent with previous studies that demonstrated that VIP application to detrusor 
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smooth muscle had no effect on spontaneous or carbachol-induced bladder contractions 
despite facilitation of micturition when VIP was administered intrathecally or 
intraarterially close to the rat bladder (Igawa et al., 1993).  Recent studies (Studeny et al., 
2008) using VIP-/- mice reveal that VIP-/- mice exhibit increased bladder mass and fewer 
but larger urine spots on filter paper. VIP-/- mice exhibit increased void volumes and 
shorter intercontraction intervals with continuous intravesical infusion of saline (Studeny 
et al., 2008).  No differences in transepithelial resistance or water permeability were 
demonstrated between VIP-/- and WT mice (Studeny et al., 2008).  With the induction of 
bladder inflammation by acute administration of CYP, an exaggerated or prolonged 
bladder hyperreflexia was demonstrated in VIP-/- mice (Studeny et al., 2008).  The 
changes in bladder hyperreflexia may reflect increased expression of neurotrophins 
and/or or proinflammatory cytokines in the urinary bladder (Studeny et al., 2008).  
  
19.2.8 PACAP-mediated ATP release from cultured, rat urothelium  
 Earlier studies have indicated that the urothelium releases ATP in response to various 
stimuli (Birder, 2006).  In addition, it has been suggested that adenosine triphosphate 
(ATP) released from the serosal surface of the urothelium during bladder filling 
stimulates receptors on suburothelial sensory nerve fibers and contributes to bladder 
filling sensation (Cockayne et al., 2000).  ATP in the cell cytoplasm can be released 
extracellularly by several mechanisms including exocytosis of ATP-containing vesicles 
(Bodin and Burnstock, 2001; Novak, 2003).  PACAP27, PACAP38 and VIP application 
evoked ATP release from rat urothelial cell cultures; however, ATP release was greatest 
with PACAP27 treatment and significantly blocked by the PAC1 receptor selective 
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antagonist, M65 (Girard et al., 2008).  Current research supports the suggestion that 
PACAP and PAC1 signaling are regulators of bladder physiology at the level of the 
urinary bladder and specifically, the urothelium (Girard et al., 2008).  
 
19.3 Tachykinins and calcitonin-gene related peptide (CGRP) in micturition reflex 
pathways 
 A variety of neuropeptides are present in the somata and processes of urogenital 
DRG cells including urinary bladder and urethra with CGRP and Substance P (SP) being 
the most widely distributed (Keast, 1992).  Tachykinins (SP, neurokinin A, neurokinin B) 
and CRGP are present in the LUT and act on neurokinin (NK)1, NK2, NK3 or CGRP 
receptors, respectively (Andersson, 2002; Canda et al., 2006).  NK1 and NK2 receptors 
have been reported in the detrusor smooth muscle whereas NK2 receptors are present in 
the urothelium (Ishizuka et al., 1995b; Birder, 2010).  In broad terms, the sensory 
functions of the tachykinins include regulation of micturition threshold, activation of 
cardiovascular reflexes and perception of pain from the urinary bladder (Maggi et al., 
1995; Gu et al., 2000; Andersson, 2002).  Efferent functions of the tachykinins include 
regulation of local muscle cell activity, nerve excitability, plasma extravasation and blood 
flow (Andersson, 2002).  Involvement of tachykinins located in supraspinal sites on 
micturition function has also been demonstrated (Gu et al., 2000).   
 
19.3.1 Tachykinins and CGRP in micturition reflex pathways and regulation with 
inflammation, injury or disease 
 Expression of tachykinins and associated receptors in the LUT under basal conditions 
and alterations in expression has been reported in animal models of bladder inflammation 
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and in the clinical syndrome of IC/PBS.  Recent studies have demonstrated alterations in 
SP-immunoreactivity (IR) (Pang et al., 1995) and NK1 mRNA (Marchand et al., 1998) in 
bladder biopsies from patients with IC/PBS (Johansson and Fall, 1994; Ho et al., 1997; 
Johansson et al., 1997).  In addition, a study involving an acute rat model of urinary 
bladder inflammation (48 hr following intravesical mustard oil treatment) has 
demonstrated significant increases in CGRP- and SP-IR in rostral (L1, L2 DRG) and 
caudal (L6, S1 DRG) bladder afferent neurons (Callsen-Cencic and Mense, 1997).  
Furthermore, it has been demonstrated (Lecci et al., 1994) that intrathecal injection of SP 
antagonists reduce CYP-induced bladder hyperreflexia.  Although numerous studies have 
demonstrated changes in CGRP and SP expression in sensory neurons following nerve 
injury (Hokfelt et al., 1994) or peripheral inflammatory states (Kataeva et al., 1994; 
Luber-Narod et al., 1997; Traub et al., 1999; Hutchins et al., 2000), there are only a 
limited number of studies that have examined alterations in CGRP or SP expression 
following the induction of acute urinary bladder inflammation (Callsen-Cencic and 
Mense, 1997; Luber-Narod et al., 1997).  Increases in CGRP- and SP-IR in bladder 
afferent neurons in the lumbosacral DRG 48 hr following the induction of cystitis with 
intravesical mustard-oil have been demonstrated (Callsen-Cencic and Mense, 1997).   
 
19.3.2 SP and CGRP plasticity in LUT pathways with CYP-induced cystitis 
 Additional plasticity of CGRP and SP expression in LUT pathways has been 
demonstrated in the CYP model of bladder inflammation in rats (Vizzard, 2001).  In 
control rats, CGRP- or SP-IR was expressed in fibers in the superficial dorsal horn in all 
segmental levels examined (L4-S1).  Bladder afferent cells in the dorsal root ganglia 
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(DRG; L6, S1) from control animals also exhibited CGRP- (41–55%) or SP-IR (2–3%). 
Following chronic, CYP-induced cystitis, CGRP- and SP-IR were dramatically increased 
in spinal segments and DRG (L6, S1) involved in micturition reflexes.  The density of 
CGRP- and SP-IR was increased in the superficial laminae (I-II) and lateral collateral 
pathway of the L6 and S1 spinal segments.  Following chronic cystitis, CGRP- and SP-IR 
in cells in the L6 and S1 DRG significantly increased and the percentage of bladder 
afferent cells expressing CGRP- (76%) or SP-IR (11–18%) also significantly increased 
(Vizzard, 2001).  
 The functional significance of an upregulation of CGRP or SP in bladder 
pathways following CYP-induced cystitis is not known but changes in neuropeptide 
expression and presumably release at both central and/or peripheral projections of 
afferent pathways are possible.  Several reports have suggested that neuropeptide-
containing, capsaicin-sensitive bladder afferents may mediate urinary bladder 
hyperreflexia (Maggi, 1991; Giuliani et al., 1993a; Giuliani et al., 1993b; Ahluwalia et 
al., 1994; Ahluwalia et al., 1998).  It has also been shown that intrathecal SP facilitates 
normal micturition and SP antagonists delivered intrathecally depress normal micturition 
indicating that the peptide may be involved as an excitatory transmitter in several types of 
bladder reflexes in the rat (Mersdorf et al., 1992; Lecci et al., 1993).  CYP treatment in 
the rat induces cystitis that is characterized by increased frequency of voiding in awake 
rats and urinary bladder hyperreflexia in anesthetized rats (Maggi et al., 1992; Lecci et 
al., 1994; Lanteri-Minet et al., 1995).  Furthermore, it has been demonstrated (Lecci et 
al., 1994) that intrathecal injection of SP antagonists reduce CYP-induced bladder 
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hyperreflexia.  Intrathecal administration of neurokinin receptor (NK)1 antagonists (RP 
67580 and CP 96345) increase bladder capacity in normal conscious rats with no changes 
in voiding pressure whereas NK2 receptor antagonists were ineffective (Lecci et al., 
1994).  Bladder hyperreflexia induced by capsaicin was reduced by an NK2 antagonist 
(SR 48965) with no effects on normal micturition (Lecci et al., 1994).  Exogenous CGRP 
application or CRGP release from primary afferent nerves relaxes smooth muscle and 
produces relaxation with bladder effects being more prominent in guinea pig and dog 
compared to rat and human (Maggi, 1992; Andersson, 1993).  In addition to 
pharmacological demonstration of involvement of tachykinins/receptors systems in the 
LUT, studies with the preprotachykinin A (that encodes both SP and neurokinin A) null 
mouse, have demonstrated involvement of tachykinins in the response to chemical 
irritation of the LUT as well as to regulation of normal micturition activity (Kiss et al., 
2001).   
 Recent studies with cizolirtine citrate, an inhibitor of CGRP and SP release at the 
spinal cord level, showed a significant reduction in the total number of voids per 24 hr in 
patients with urinary incontinence secondary to OAB (Zat'ura et al., 2010).  Further, 
cizolirtine citrate resulted in improvement in urinary incontinence and urgency in 
symptomatic outpatients with OAB and/or urodynamic diagnosis of detrusor overactivity 
(Martinez-Garcia et al., 2008).  Therefore, it is possible that increased expression of 
CGRP- or SP-IR in bladder afferent cells and central and peripheral projections could 
contribute to this hyperreflexia.  Changes in neuropeptide expression and release at 
central terminals could further result in a remodeling of spinal cord circuitry controlling 
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micturition (Lecci et al., 1994).  This remodeling may include changes: (1) in the 
synaptic organization of spinal micturition reflexes; (2) in the neurochemical coding of 
specific neuronal elements (primary afferent neurons, interneurons) and (3) in the 
organization of ascending and descending projections to spinal reflexes.  Further, recent 
studies also demonstrate that SP released from nerve fibers or urothelial cells can act on 
urothelial receptors to release nitric oxide (Birder, 2006; Birder, 2010).  In response to 
stimulation of receptors on urothelial cells, SP and neurokinin A can be released from 
urothelial cells.  Thus, neural as well as non-neural tachykinins may contribute to LUT 
pathways.  Non-neural involvement of neuropeptides in the LUT has been recently 
addressed (Birder, 2006; Birder, 2010).     
 The exact role(s) of tachykinins in urethral physiology is not known but 
tachykinins induce urethral contraction in many species including humans (Maggi et al., 
1988; Maggi, 1992; Palea et al., 1996; Parlani et al., 1996; Canda et al., 2006; 2008).  In 
patients with genitourinary prolapse with concomitant urinary incontinence, the density 
of SP-immunoreactive nerves in the perineal muscles was significantly decreased 
compared to a continent group suggestive of a role for tachykinins in urinary continence 
mechanisms (Busacchi et al., 2004).  Additional research focused on the role of 
tachykinins in urethral physiology is necessary. 
 
19.4 Role of Neurotrophic Factors in Neuropeptide Expression in Micturition 
Pathways after CYP-induced Cystitis  
 Altered bladder neurotrophic factor content may underlie neurochemical (Vizzard 
and de Groat, 1996; Vizzard, 2000d; Vizzard, 2000c; Vizzard, 2000a; Vizzard, 2001) 
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changes in bladder afferent neurons after cystitis.  The occurrence of trophic interactions 
between nerve cells and target tissues is clearly demonstrated during embryonic and 
postnatal development (Lindsay et al., 1990; Oppenheim et al., 1991; Lapchak et al., 
1992; Vantini and Skaper, 1992).  Recent experiments have demonstrated the influence 
of interactions between target organ and neurons in adult animals (Steers and de Groat, 
1988; Steers et al., 1991a; Steers et al., 1991b; Tuttle and Steers, 1992, Tuttle et al., 1994; 
Vizzard, 2000b; Dupont et al., 2001).  NGF is expressed under normal conditions in the 
urinary bladder, and part of its function is likely maintenance of sensory afferent fibers 
(Chao and Hempstead, 1995; Chuang et al., 2001).  We have demonstrated that chronic 
CYP-induced cystitis alters NGF expression and other neurotrophic factors in the bladder 
(Vizzard, 2000b).  The role(s) of NGF in micturition reflexes and sensation have been 
evaluated using a variety of addition and subtraction techniques (Dmitrieva and 
McMahon, 1996; Clemow et al., 1998; Yoshimura et al., 2006).  Importantly, exogenous 
NGF application to the rat bladder detrusor through an osmotic pump reduced bladder 
capacity and increased expression of CGRP in the lumbosacral spinal cord (Zvara and 
Vizzard, 2007)(Fig. 19.3).  
 
 Recent studies involving a novel NGF overexpressing (OE) mouse model 
(Cheppudira et al., 2008; Schnegelsberg et al., 2010) are being used to further define 
NGF-mediated changes in LUT structure and function and effects on 
neuropeptide/receptor systems (Fig. 19.4).  The urinary bladder in NGF OE mice exhibits 
marked hyperinnervation.  To characterize the sub-populations of neurons contributing to 
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the generalized hyperinnervation observed in NGF-OE transgenic mice, we have 
performed whole-mount immunostaining of bladder urothelium using a panel of neuronal 
markers.  Using the pan-neuronal marker PGP 9.5, a marked increase in total nerve fiber 
density was seen in the urinary bladders of transgenic mice compared to WT controls 
(Fig. 19.4), consistent with the histology stains. This dense network was composed of 
CGRP-positive (Fig. 19.4) and substance P-positive (Fig. 19.4) unmyelinated C-fiber 
sensory afferents, NF 200-positive myelinated sensory afferents and TH-positive, post-
ganglionic sympathetic nerve fibers (Schnegelsberg et al., 2010).  The increased nerve 
fiber density observed in transgenic mouse urinary bladders was evident in both the neck 
and the dome region of the urinary bladder.  However, we observed a higher innervation 
density within the urinary bladder neck region compared to the dome  in both WT and 
transgenic mice.  With CGRP immunostaining, we also observed CGRP-positive ganglia 
(5-9 CGRP-positive cells per ganglia) interspersed among CGRP-positive nerve fibers 
within the suburothelial plexus in transgenic mice.  These CGRP-positive ganglia were 
not observed in whole-mount preparations of WT urinary bladder (Schnegelsberg et al., 
2010).  Studies are currently underway to examine effects of neuropeptide/receptor 
blockade on bladder function in NGF OE mice that exhibit bladder hyperreflexia with the 
presence of NVCs (Schnegelsberg et al., 2010). 
 
 Recent studies also demonstrate changes in PACAP/VIP and receptor expression in 
micturition pathways in NGF-OE mice (Girard et al., 2010b).  Results demonstrate 
upregulation of PAC1 receptor transcript and PAC1-immunoreactivity in urothelium of 
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NGF-OE mice whereas PACAP transcript and PACAP-immunoreactivity were decreased 
in urothelium of NGF-OE mice (Girard et al., 2010b).  In contrast, VPAC1 receptor 
transcript was decreased in both urothelium and detrusor smooth muscle of NGF-OE 
mice (Girard et al., 2010b). VIP transcript expression and immunostaining was not 
altered in urinary bladder of NGF-OE mice (Girard et al., 2010b).  Changes in PACAP, 
VIP and associated receptors transcripts and protein expression in micturition pathways 
resemble some, but not all, changes observed after induction of urinary bladder 
inflammation known to involve NGF production. 
 
19.5 Bradykinin/receptors system in micturition reflex pathways 
 The bradykinin/receptors system plays an important role in normal micturition 
reflexes as well as in pathology (Lecci et al., 1995; Belichard et al., 1999; Lecci et al., 
1999; Meini et al., 2000; Chopra et al., 2005; Fabiyi and Brading, 2006).  Kinins are 
small peptides (8-10 amino acids) produced in plasma or in tissues at the sites of 
inflammation or tissue damage (Bhoola et al., 1992).  Protease activation at the site of 
inflammation or tissue damage cleaves tissue/plasma kininogen precursors to release the 
nonapeptide, bradykinin (Dray and Perkins, 1993).  The biological effects of bradykinin 
are mediated by two different receptors, B1 and B2 with the bradykinin B2 receptor 
being constitutively expressed in various cell types and the B1 receptor being expressed 
de novo after inflammatory stimuli or tissue injury (Marceau et al., 1998; Lecci et al., 
1999; Chopra et al., 2005).  Recent studies (Chopra et al., 2005) have demonstrated B2 
receptor expression in the detrusor smooth muscle and urothelium (apical and basal cells) 
consistent with reported bradykinin-evoked contractility of detrusor smooth muscle.  It 
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has been recently demonstrated that bradykinin-induced facilitation of micturition 
reflexes may be due to an increase in purinergic (P2) responsiveness (Chopra et al., 
2005).  Further, stimulation of the B2 receptor in cultured rat urothelial cells resulted in 
ATP release (Chopra et al., 2005).  ATP release was reduced by the selective B2 receptor 
antagonist Hoe-140 and suggests that bradykinin may elicit bladder hyperreflexia 
indirectly through the release of ATP from the urothelium (Chopra et al., 2005).  Direct 
effects of bradykinin on pelvic afferent nerves that evoke bladder hyperreflexia have also 
been demonstrated (Lecci et al., 1995).  Thus, direct (neuronal) (Lecci et al., 1995) and 
indirect (urothelial secretion of ATP) (Chopra et al., 2005) actions of bradykinin on the 
LUT are likely to affect micturition reflexes. 
19.5.1 Bradykinin/receptors in cystitis 
 The role of the bradykinin/receptor system in the LUT varies under control or 
pathological states.  It is largely agreed that B1 receptor expression is undetectable in 
control urinary bladder (Ahluwalia and Perretti, 1999; Chopra et al., 2005).  Application 
of the selective B1 receptor agonist, des-Arg9-bradykinin exerts little or no effect on 
[Ca2+]i or ATP release from cultured rat urothelial cells consistent with no or very low 
constitutive B1 receptor expression (Chopra et al., 2005).  CYP-induced cystitis 
significantly upregulates B1 receptor expression in the detrusor smooth muscle and 
urothelium with acute (24 hr) cystitis (Chopra et al., 2005).  In cultured rat urothelial cells 
obtained from CYP (24 hr)-treated rats, the B1 receptor agonist, des-Arg9-bradykinin, 
evoked release of ATP and elevated calcium levels (Chopra et al., 2005).  B1 receptor 
expression is also upregulated in bladder biopsies from patients with IC/PBS (Ruggieri et 
al., 1997).  Cystometry performed on CYP (24 hr)-treated rats demonstrated that the B1 
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receptor antagonist, des-Arg10-Hoe-140, significantly reduced the frequency of non-
voiding bladder contractions (Chopra et al., 2005).  In contrast, the B2 receptor 
antagonist, Hoe-140, decreased voiding frequency in CYP (24 hr)-treated rats (Chopra et 
al., 2005).  It is has been suggested that one explanation for these findings is the existence 
of B1 sensitive mechanisms/or afferent pathways underlying the emergence of non-
voiding contractions and B2 sensitive mechanisms underlying voiding contractions 
(Chopra et al., 2005).  Additional studies are needed to address this possibility.  
Interestingly, chronic CYP-induced cystitis (8 days) resulted in a return to baseline of B1 
receptor expression in the detrusor smooth muscle whereas expression in the urothelium 
was similar to that observed with acute (24 hr) CYP-induced cystitis (Chopra et al., 
2005).  Bradykinin/receptors systems may exert tissue-specific and inflammatory 
duration-dependent effects on LUT reflexes. 
 
19.6 Endothelin/receptors system in LUT pathways 
 Endothelin-1 and endothelin receptors, ETA and ETB, contribute to LUT function 
under normal and pathological conditions (Ukai et al., 2006; Ogawa et al., 2008; Ukai et 
al., 2008).  In the LUT, endothelin-1 facilitates detrusor smooth muscle contraction in 
various species including rabbit, rat, dogs and humans and stimulates proliferation of the 
prostate and urinary bladder (Maggi et al., 1989; Garcia-Pascual et al., 1990; Persson et 
al., 1992; Langenstroer et al., 1997; Ogawa et al., 2004). Studies have demonstrated 
differential endothelin-1 contractile mechanisms depending on species (Persson et al., 
1992). Differential endothelin receptor density has been revealed in the LUT with the 
greatest density of ETA receptors being present in the ureter (Latifpour et al., 1995; Saenz 
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de Tejada et al., 1992; Afiatpour et al., 2003).  In humans and other animals, ETA 
expression is more dominant than ETB in the bladder dome compared to the bladder base 
or urethra, which exhibits equal ETA and ETB receptor expression (Saenz de Tejada et al., 
1992; Latifpour et al., 1995; Afiatpour et al., 2003).  Endothelin expression has been 
detected in detrusor smooth muscle, urothelium, and vascular endothelium (Saenz de 
Tejada et al., 1992; Latifpour et al., 1995; Afiatpour et al., 2003). 
 
19.6.1 Endothelin/receptor system in bladder outlet obstruction and spinal cord 
transection 
 In animal models of BOO, modulation of endothelin-1 and ETA and ETB 
expression has been demonstrated in the LUT and studies are researching the 
endothelin/receptor system as a potential therapeutic target for the treatment of bladder 
overactivity secondary to BOO (Khan et al., 1999; Ukai et al., 2008).  BOO in rabbits is 
associated with increased expression of ETA, ETB and endothelin-1 in detrusor smooth 
muscle (Khan et al., 1999; Ukai et al., 2008).  The ETA selective receptor antagonist, 
YM598, dose-dependently reduced the frequency of premicturition bladder contractions 
in BOO rats without effects on other voiding parameters (Ukai et al., 2008).  Further, 
inhibition of the endothelin-converting enzyme, which metabolizes big endothelin to 
endothelin-1, decreased bladder overactivity in BOO rats (Schroder et al., 2004).  
Additional beneficial effects of repeated administration of endothelin-converting enzyme 
inhibitor in BOO rats included normalization of:  bladder weight, micturition pressures 
and voiding durations (Schroder et al., 2004).  Suppression of ETA receptors by 
intravenous infusion of ABT-627 in rats with complete spinal cord transection (thoracic 
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8-9) significantly decreased the amplitude and number of non-voiding bladder 
contractions without changing bladder pressures, void volumes or voiding efficiency 
(Ogawa et al., 2008).  No effects on bladder function were observed when rats with spinal 
cord transection were similarly treated with an ETB receptor antagonist, A-192621 
(Ogawa et al., 2008).  Thus, endothelin and ETA receptors may be a novel therapeutic 
target to ameliorate the effects of bladder overactivity associated with BOO. 
 
Additional studies are necessary to address the mechanisms by which YM598, an 
endothelin ETA receptor antagonist, suppresses the bladder overactivity observed in 
BOO rats; potentiation of postsynaptic norepinephrine effects and endothelin-1 increase 
of interleukin-(IL) 6 have been suggested (Han et al., 2009).  Interestingly, recent studies 
have demonstrated that endothelin-converting enzyme 1 promotes the recycling and re-
sensitization of NK1 receptors and re-sensitization of the pro-inflammatory effects of SP 
(Cattaruzza et al., 2009).  Thus, reductions in bladder overactivity secondary to BOO 
observed with endothelin-converting enzyme inhibition (described above) may, in part, 
be due to amelioration of the pro-inflammatory effects of SP (Cattaruzza et al., 2009). 
19.6.2 Endothelin/receptor systems in the urethra 
 There is very limited information concerning the distribution and function of 
endothelin/receptor systems in the urethra.  ET receptors have been demonstrated in the 
urethral smooth muscle in several species (Latifpour et al., 1995; Afiatpour et al., 2003).  
ETA-mediated smooth muscle contractions of the urethra in the rabbit have been 




A large body of research supports a major role for neuropeptides in LUT function 
in health and disease thereby identifying neuropeptide/receptor systems as potential novel 
therapeutic targets for the treatment of LUT disorders (Fig. 19.1).  In animal models, 
pharmacological and/or genetic manipulation of SP, CGRP, VIP, PACAP, bradykinin or 
endothelin function affects LUT function.  Further, in animal models of LUT dysfunction 
or in clinical assessments, manipulation of neuropeptide/receptor systems improves void 
function.  Furthermore, the field has become increasingly complex, with neuronal 
plasticity exhibited in pathophysiological situations where changes in neuropeptide 
expression patterns and receptor density are regularly observed.  The study of 
neuropeptides in animal models has additionally revealed physiological and 
pathophysiological roles that in turn have led to the ongoing development of new drugs, 
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Figure 19.1:  Neuropeptide/receptor systems expression in micturition reflex 
pathways emphasizing bladder afferent and urothelium participation.  A.  
Diagram of afferent innervation of the urinary bladder.  Numerous 
neuropeptide/receptor systems have been identified in bladder afferent (i.e., 
sensory) pathways with contributions to normal lower urinary tract function as 
well as that after neural injury, disease or inflammation.  B.  Potential model of 
possible reciprocal neuropeptide/receptor interactions among bladder afferent and 
efferent nerves (not shown), urothelial cells, myofibroblasts located in the 
suburothelium and detrusor smooth muscle that underlie physiological bladder 
reflex function as well as pathophysiology in bladder disease.  Receptor activation 
and channel stimulation on urothelial cells can elicit secretion of chemical 
mediators that can affect adjacent tissues including bladder afferent nerves in the 
suburothelial plexus, myofibroblasts and detrusor smooth muscle.  Urothelial cells 
can also be responsive to neurotransmitters released from bladder nerves and 
other cell types including inflammatory cells.  Abbreviations: ATP, adenosine 
triphosphate; TrkA, receptor tyrosine kinase A; p75NTR, low affinity neurotrophin 
receptor; PG, prostaglandin; NO, nitric oxide; NGF, nerve growth factor; NP, 
neuropeptides; Ach, acetylcholine; PAC1, pituitary adenylate cyclase-activating 
polypeptide (PACAP) selective receptor; VPAC2, receptor with equal and high 
affinity for vasoactive intestinal polypeptide and PACAP; B1, bradykinin receptor 
1; B2, bradykinin receptor 2; ETA, endothelin receptor A; ETB, endothelin 
286 
 
receptor B; NK2, neurokinin receptor 2; NK1, neurokinin receptor 2; NK3, 
neurokinin receptor 3;  CGRP1, calcitonin gene-related receptor. See text for 
additional details.  Figure modified from (Arms et al., 2009). 
 
Figure 19.2:  PACAP contributions to bladder morphology and function.  A-
C.  Histological analyses of urinary bladders and bladder function among PACAP-
/-, PACAP+/- and WT mice.  Representative haematoxylin and eosin stained 
cryostat bladder sections (15 µm) from WT (A) and PACAP-/- (B) mice that 
demonstrate significantly (*, p ≤ 0.01) increased thickness of lamina propria (LP) 
and detrusor smooth muscle (SM) supported by morphometric analyses (C).  D-E. 
Summary figures of the intercontraction interval (ICI, seconds, s; D) and residual 
volume (RV, µl; E) using conscious cystometry in conscious, unrestrained WT, 
PACAP-/- and PACAP+/- mice with continuous infusion of saline or AA (0.5%).  
D.  ICI was significantly (p ≤ 0.01) longer in PACAP -/- compared to WT mice 
with instillation of saline and AA.  No changes in ICI were detected with 
intravesical instillation of AA in PACAP-/- and PACAP+/- mice compared to saline 
instillation.  ICI was significantly (p ≤ 0.01) greater in PACAP -/- and PACAP+/- 
mice with AA instillation compared to WT.  E.  RV was significantly (p ≤ 0.01) 
increased in PACAP+/- and PACAP-/- mice compared to WT.  Values represent 
mean ± S.E.M. for n = 7-10 animals in each group.  U, urothelium; WT, 
wildtype.  Calibration bar represents 120 µm in A, B.  Figure modified from (May 
and Vizzard, 2010). 
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Figure 19.3: CGRP spinal cord expression with exogenous NGF treatment.  
CGRP-IR increases in lumbosacral spinal cord with exogenous NGF treatment.  
CGRP-IR in the L6 (A-B) spinal segment in control (A) and NGF-treated (B) 
rats.  A.  Fluorescence photographs showing CGRP-IR in the L6 (A) spinal 
segment of control (saline) + bladder distention.  B.  Fluorescence photographs 
showing CGRP-IR in the L6 (B) spinal segment with NGF treatment + bladder 
distention.  Increased density of CGRP-IR was observed in the medial (MDH) to 
lateral (LDH) extent of the superficial laminae (I-II) of the dorsal horn (DH) with 
NGF treatment in L6 (C) segments.  Summary bar graph of CGRP optical density 
(O.D.) as measured in specific regions of the L6 spinal cord (C).  Calibration bar 
represents 125 µm.  SPN, sacral parasympathetic nucleus; DCM, dorsal 
commissure; LCP, lateral collateral pathway.  *, p ≤ 0.01.  Figure modified from 
(Zvara and Vizzard, 2007).  
 
Figure 19.4: Neuronal hyperinnervation in the urinary bladders of NGF-
overexpressing (OE) transgenic mice. Representative fluorescence images of 
PGP 9.5 (A, B), CGRP (C, D), SP (E, F), immunoreactivity in the bladder neck 
region in urothelial whole-mount preparations of urinary bladders from 8-10 
week-old female WT (A, C, E) and NGF-OE transgenic (B, D, F) mice from F0 
line 23 (n = 3-5). Scale bars: A-F, 50 µm. Protein Gene Product (PGP 9.5), 
Calcitonin Gene Related Protein (CGRP), Substance P (SP).  Figure modified 
from (Schnegelsberg et al., 2010). 
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